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ABSTRACT	  
Influenza	  infection	  remains	  constant	  threat	  to	  human	  health	  and	  results	  in	  huge	  financial	  loss	  
every	  year.	  Rapid	  and	  accurate	  detection	  of	  influenza	  can	  help	  governments	  and	  health	  organizations	  
monitor	  influenza	  activity	  and	  take	  measurements	  when	  necessary.	  In	  addition,	  influenza	  detection	  in	  a	  
timingly	  manner	  can	  help	  doctors	  make	  diagnosis	  and	  provide	  effective	  treatment.	  On	  the	  other	  hand,	  
novel	  inhibitors	  of	  influenza	  virus	  are	  in	  high	  demand	  because	  circulating	  strains	  have	  started	  to	  develop	  
resistance	  to	  currently	  available	  anti-­‐viral	  drugs.	  
Influenza	  virus	  has	  two	  surface	  glycoproteins:	  hemagglutinin	  (HA)	  and	  neuraminidase	  (NA),	  
which	  play	  important	  roles	  in	  the	  influenza	  infection.	  The	  binding	  of	  HA	  to	  sialic	  acid-­‐containing	  carbo-­‐
hydrates	  on	  cell	  surface	  initiates	  virus	  internalization,	  while	  cleavage	  of	  terminal	  sialic	  acid	  by	  NA	  facili-­‐
tates	  viral	  particle	  release.	  	  In	  this	  dissertation,	  we	  focus	  on	  the	  development	  of	  glycan	  microarray	  that	  
is	  comprised	  of	  a	  panel	  of	  NA	  resistant	  sialosides,	  and	  demonstrate	  the	  application	  of	  microarray	  to	  cap-­‐
ture	  influenza	  virus	  at	  ambient	  temperature	  without	  the	  addition	  of	  NA	  inhibitors.	  We	  also	  describe	  a	  
novel	  electrochemical	  biosensor	  for	  the	  detection	  of	  influenza	  virus.	  In	  addition,	  we	  have	  developed	  a	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1 INFLUENZA:	  DIAGNOSIS	  AND	  THERAPY	  
ABSTRACT	  
Influenza	  infection	  remains	  constant	  threat	  to	  human	  health	  and	  results	  in	  huge	  financial	  loss	  
every	  year.	  Rapid	  and	  accurate	  detection	  of	  influenza	  can	  help	  governments	  and	  health	  organizations	  
monitor	  influenza	  activity	  and	  take	  measurements	  when	  necessary.	  In	  addition,	  influenza	  detection	  in	  a	  
timingly	  manner	  can	  help	  doctors	  make	  diagnosis	  and	  provide	  effective	  treatment.	  On	  the	  aspect	  of	  clin-­‐
ical	  management	  of	  influenza,	  antiviral	  medications	  used	  along	  with	  vaccination.	  In	  this	  chapter,	  we	  pre-­‐
sent	  a	  thorough	  literature	  survey	  of	  salient	  features	  influenza	  virus,	  existing	  detection	  techniques	  and	  















Influenza	  virus	   is	  an	  acute	  respiratory	  pathogen	  that	  causes	  considerable	  harm	  to	  humans	  and	  
livestock.	  According	  to	  CDC	  and	  WHO,	  annual	  seasonal	  outbreak	  of	  influenza	  infection	  accounts	  for	  ap-­‐
proximately	   36,000	   deaths	   and	   200,000	   hospitalizations	   in	   the	   United	   States	   alone	   and	   250,000	   to	  
500,000	  deaths	  worldwide.	   (1,	   2)	   Pandemic	   outbreaks	   are	  more	  devastating.	   Each	  of	   the	   three	  docu-­‐
mented	   influenza	  pandemic	  outbreaks	   (1918	  Spanish	  H1N1,	  1957	  Asian	  H2N2,	  1968	  Hongkong	  H3N2)	  
caused	  more	  than	  one	  million	  deaths	  worldwide.	  (3)	  Young,	  elderly	  and	  immune	  compromised	  popula-­‐
tions	  are	  particularly	  vulnerable.(4)	  Early	  detection	  of	  influenza	  is	  essential	  to	  disease	  control	  due	  to	  the	  
fast	  spreading	  nature	  of	  influenza	  infection.(5)	  It	  could	  also	  be	  useful	  in	  administration	  of	  antiviral	  drugs.	  
The	   therapeutic	  window	  of	   antiviral	   drug	  oseltamivir	   is	  within	  48	  hours	  of	   the	   infection	  onset	   for	   im-­‐
munocompromised	   people,	   beyond	  which	   the	   efficacy	   greatly	   decreases.	   (6,	   7)	   Detection	   accuracy	   is	  
also	   important	  due	   to	   the	  unspecific	   clinical	   symptoms	  of	   influenza	   infection,	  which	  may	  be	   confused	  
with	  bacterial	  or	  other	  viral	   infection.(8)	  Addiitonally,	  new	  antiviral	  agents	  are	   in	  high	  demand	  due	   to	  
the	  emergence	  of	   resistance	   to	   currently	   available	  anti-­‐influenza	  drugs.(9)	   In	   this	   chapter,	   salient	   fea-­‐
tures	  influenza	  virus,	  existing	  detection	  techniques	  and	  anti-­‐influenza	  agents	  will	  be	  discussed.	  
1.2 Influenza	  virus	  structure	  
Influenza	   virus	   is	   an	   enveloped	   single	   stranded	   RNA	   virus,	   belonging	   to	   orthomyxoviridae	   family.	  
(10)	  There	  are	  three	  types	  of	   influenza:	  A,	  B	  and	  C,	  among	  which	  type	  A	  is	  commonly	  found	  in	  human	  
and	  associated	  with	  annual	  influenza	  epidemics.	  (11)	  Influenza	  virion	  is	  roughly	  spherical	  with	  a	  diame-­‐
ter	  of	  approximately	  100	  nm.	  	  The	  envelope	  consists	  of	  a	  lipid	  membrane,	  an	  embedded	  protein	  M2	  and	  
two	   spiked	   and	   clustered	   glycoproteins,	   hemagglutinin	   (HA)	   and	  neuraminidase	   (NA).	  M2	  protein	   is	   a	  
small	  and	  hydrophobic	  protein,	  which	  functions	  as	  an	  ion	  channel.	  HA	  and	  NA	  are	  the	  major	  viral	  anti-­‐
gens	   and	  play	   important	   roles	   in	   influenza	   infection	  of	  host	   cells.	   Serological	   antibody	   cross-­‐reactivity	  
studies	  have	   identified	  16	   types	  of	  HA	   (H1-­‐H16)	  and	  9	   types	  of	  NA	   (N1-­‐N9)	   in	  avian	  population,	  while	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only	  H1-­‐H3	  and	  N1-­‐N2	  are	  responsible	  for	  human	  influenza.	  	  Influenza	  A	  virus	  can	  be	  subtyped	  and	  ex-­‐
pressed	  as	  a	  combination	  of	  HA	  and	  NA,	  e.g.	  H1N1,	  H3N2,	  etc.	  (12-­‐15)	  Underneath	  the	  lipid	  membrane	  
is	  the	  matrix	  protein	  M1,	  which	  surrounds	  the	  core	  of	  ribonucleoprotin	  complex	  (RNP)	  and	  helps	  retain	  
the	  spherical	  structure.	  RNP	  is	  consists	  of	  a	  single	  strand	  RNA	  of	  12,000	  to	  15,000	  nucleotides,	  which	  is	  
bound	  to	  a	  single	  polymerase	  protein,	  PB1,	  PB2	  or	  PA	  and	  encapsulated	  with	  viral	  nucleoprotein	  (NP).	  
RNP	  resembles	  a	   large	   loop	  and	  forms	  a	  helix	  structure.	   Influenza	  A	  and	  B	  each	  has	  eight	  segments	  of	  
genome	  RNA	  while	  C	  has	  seven.	  	  The	  classification	  of	  influenza	  A,	  B	  and	  C	  is	  based	  on	  the	  antigenicity	  of	  
abundant	  M1	  and	  NP.	  An	  illustration	  of	  influenza	  virus	  structure	  is	  shown	  in	  figure	  1.1.	  
	  
Figure	  1.1	  Structure	  of	  influenza	  virus	  
1.3 Antigenic	  shift	  and	  drift	  
One	  feature	  of	  influenza	  virus	  is	  the	  high	  mutation	  rate,	  (16,	  17)	  which	  enables	  the	  mutant	  virus	  to	  
escape	  immune	  surveillance	  and	  results	  in	  antigenic	  drift.	  For	  instance,	  as	  many	  as	  35%	  of	  the	  substitu-­‐
tions	  have	  been	  reported	  to	  occur	  at	  only	  18	  of	  the	  329	  codons	  of	  the	  A	  (H3)	  virus.	  (18) The	  structural	  
basis	  is	  that	  viral	  RNA	  polymerase	  prone	  to	  tolerate	  a	  high	  error	  rate.	  When	  the	  mutation	  occurs	  at	  the	  
antigenic	  region	  of	  viral	  surface	  protein	  HA,	  NA	  or	  both,	  the	  antigenic	  drift	  arises.	  The	  process	  of	  anti-­‐
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genic	  drift	   is	  rather	  subtle,	  as	  point	  mutations	  occur	  potentially	  each	  time	  the	  virus	  replicates	  in	  a	  way	  
that	   they	  do	  not	  change	  the	  conformation	  of	   the	  proteins.	  However,	  some	  mutations	  can	  significantly	  
affect	   the	   conformation	   of	   the	   antigenicity	   site	   that	   results	   in	   loss	   of	   inhibition	   effect	   of	   antibodies	  
raised	  to	  previously	  circulating	  strains.	  Antigenic	  drift	  is	  observed	  in	  all	  strains	  of	  influenza	  A	  and	  B	  with	  
various	  patterns	  depending	  on	  the	  strain.	  Co-­‐circulation	  of	  various	  drifted	  strains	  is	  observed	  in	  influen-­‐
za	  B	  and	  A	  (H1),	  which	  allows	  re-­‐emergence	  of	  old	  strains.	  While	  the	  influenza	  A	  (H3)	  strains	  are	  more	  
prone	  to	  antigenic	  drift	  and	  complete	  replacement	  of	  old	  strains	  by	  new	  ones	  is	  more	  common.	  	  
Compared	  to	  the	  average	  2	  to	  8	  years	  occurrence	  rate	  of	  antigenic	  drift,	  antigenic	  shift	  is	  rather	  rare,	  
estimated	  to	  happen	  three	  times	  every	  100	  years.	  However,	  once	  an	  antigenic	  shift	  occurs,	  it	  might	  re-­‐
sult	  in	  pandemic	  or	  world	  wide	  epidemic	  outbreaks	  and	  lead	  to	  huge	  numbers	  of	  morbidity	  and	  mortali-­‐
ty.	  The	  three	  major	  influenza	  pandemic	  outbreaks	  in	  20th	  century	  are	  believed	  to	  associate	  with	  antigen-­‐
ic	  shift.	  (14,	  19)	  
Antigenic	  shift	  is	  referred	  to	  replacement	  of	  influenza	  A	  subtypes	  by	  novel	  ones.The	  cause	  is	  genetic	  
reassortment,	  referring	  to	  the	  genetic	  material	  mixing	  between	  different	  viral	  subtypes	  that	  co-­‐circulate.	  
Genetic	   reassortment	  can	  also	  occur	  between	  co-­‐infecting	  viral	   strains	   from	  different	   species,	   such	  as	  
human	  and	  avian.	  As	  a	  result,	  virulent	  strain	  may	  be	  produced.	  Antigenicly	  drifted	  strains	  remain	  as	  sus-­‐
ceptible	  to	  antigenic	  shift	  as	  any	  influenza	  virus.	  (20)	   	  
1.4 Influenza	  life	  cycle	  	  
Infection	   of	   influenza	   to	   host	   cell	   is	   initiated	   by	   the	   binding	   of	   HA	   to	   a	   cellular	   receptor:	   N-­‐
acetylneuraminic	  acid	  or	  sialic	  acid,	  a	  terminal	  residue	  on	  glycolipids	  or	  glycoproteins	  on	  the	  cell	  surface.	  
The	  binding	  promotes	  the	  fusion	  of	  viral	  membrane	  to	  the	  host	  plasma	  membrane.	  The	  virion	  particle	  is	  
incorporated	  into	  endosome	  via	  endocytosis.	  	  Inside	  the	  low	  pH	  environment	  of	  the	  endosome,	  proton	  
influx	  is	  triggered	  and	  pumped	  into	  virion	  through	  M2	  ion	  channel,	  resulting	  in	  conformational	  change	  of	  
HA	  protein	  and	  fusion	  of	  the	  viral	  membrane	  and	  endosome	  membrane.	  The	  low	  pH	  also	  promotes	  dis-­‐
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association	  of	  viral	  RNP	  from	  matrix	  protein	  M1,	  which	  facilitate	  the	  RNP	  release	  through	  M2	  ion	  chan-­‐
nel	  into	  the	  cytoplasm.	  RNPs	  	  are	  transported	  into	  cell	  nucleus,	  where	  the	  viral	  RNAs	  are	  transcribed	  and	  
replicated	  by	  trimeric	  viral	  RNA	  polymerase	  (PB1,	  PB2	  and	  PA).	  Viral	  mRNAs	  are	  also	  synthesized	  utilizing	  
host	  cell	  nucleus	  machinery.	  Viral	  proteins	  are	  translated	  in	  cytoplasm	  and	  assembled	  together	  with	  the	  
newly	  synthesized	  RNPs	  to	  form	  virions	  at	  the	  apical	  surface	  of	  the	  cell	  membrane.	  NA	  of	  the	  progeny	  
virus	  cleaves	  off	  the	  glycosidic	  bond	  between	  terminal	  sialic	  acid	  and	  galactose	  to	  facilitate	  budding	  viri-­‐
on	  escape	  from	  cell	  membrane	  and	  seek	  for	  new	  hosts.	  Influenza	  life	  cycle	  is	  briefly	  illustrated	  in	  figure	  
1.2.	  
	  
Figure	  1.2	  Illustration	  of	  influenza	  virus	  life	  cycle	  
1.5 Detection	  of	  influenza:	  Current	  methods	  
1.5.1 Viral	  culture	  














mary	  clinical	  specimens	  may	  have	   low	  virus	  titers	  and	  therefore,	  amplification	   is	  required	  for	  accurate	  
detection.	  Cell	  lines	  such	  as	  primary	  epithelial	  cells	  of	  human	  adenoid,	  Vero	  cells,	  MRC-­‐5,	  primary	  mon-­‐
key	  kidney	  cells	  and	  Madin–Darby	  canine	  kidney	  (MDCK)	  cells	  have	  been	  used	  for	  isolation	  and	  propaga-­‐
tion	   of	   influenza	   virus.	   (21)MDCK	   cells	   are	   the	  most	   commonly	   used	   cell	   line	   because	   it	   supports	   the	  
growth	  of	  both	  influenza	  A	  and	  B.	  The	  traditional	  way	  of	  reading	  the	  result	  is	  observing	  cytopathic	  effect	  
(CPE).	  Since	  the	  concentration	  of	  virus	  is	  unknown,	  multiple	  passages	  might	  be	  required	  before	  CPE	  can	  
be	  observed.	  A	  minimum	  of	   two	  passages	   is	   required	  before	  considering	  a	  sample	  negative,	  which	   in-­‐
creases	  	  the	  processing	  time,	  varying	  from	  4	  to	  10	  days.	  (22)	  Using	  MDCK	  shell	  vials	  (a	  commercial	  cell	  
culture	  kit	  with	  enhanced	  centrifugation	  feature)	  can	  significantly	  shorten	  the	  processing	  time	  to	  48	  to	  
72h.	  (23)	  This	  technique	  allows	  cell	  monolayers	  to	  grow	  on	  coverslips	  contained	  in	  flat-­‐bottomed	  shell	  
vials.	  After	  centrifugation	  of	  the	  cultures	  after	  inoculation,	  enhanced	  viral	  infection	  of	  the	  cells,	  and	  in-­‐
creased	   sensitivity	   to	   virus	   isolation	   is	   obtained.	   Prior	   to	   the	   development	   of	   CPE,	   the	   viral	   antigens	  
could	  be	  identified.	  However,	  a	  negative	  result	  does	  not	  rule	  out	  the	  viral	  etiology.	  Beside	  cell	  lines,	  em-­‐
bryonated	  chicken	  eggs	  can	  also	  be	  used.	  Following	   the	  viral	  culture,	   rapid	   immunoassays	  such	  as	   im-­‐
munofluorescent	   assay	  or	  membrane	  enzyme-­‐linked	   immunosorbent	   assay(ELISA)	   are	  used	   to	   charac-­‐
terize	  the	  virus.	  (22)	  
1.5.2 Polymerase	  Chain	  Reaction	  (PCR)	  
In	  recent	  years,	  PCR	  has	  been	  accepted	  widely	  as	  new	  “gold	  standard”	  for	  influenza	  virus	  detec-­‐
tion	  	  as	  PCR	  detects	  viruses	  and	  provides	  	  type	  and	  subtype	  information.	  (24)	  Briefly,	  viral	  nucleic	  acids	  
extracted	   from	  clinical	   specimens	   are	  used	  as	   a	   template	   for	   cDNA	   synthesis	   by	   in	   vitro	   reverse	   tran-­‐
scription.	  The	  RNA	  primers	  are	  either	  specific	  synthetic	  oligonucleotides	   that	  match	  known	  nucleotide	  
sequences	  on	  the	  viral	  genes	  or	  random	  hexamers.	  The	  cDNA	  then	  is	  amplified	  with	  specific	  primers	  and	  
DNA	  polymerase	  and	  monitored	  on	  real	  time	  by	  fluorescence	  and	  luminescence.	  The	  processing	  time	  is	  
much	  shorter	  compared	  to	  viral	  culture	  and	  sensitivity	  is	  very	  high,	  usually	  5-­‐100	  TCID50	  (tissue	  culture	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infection	  dose	  at	  50%	  end	  point)	  is	  sufficient.	  While	  viral	  culture	  requires	  104	  TCID50	  and	  ELISA	  requires	  
a	  minimum	  of	  105	  TCID50.	  (25)	  While	  highly	  precise,	  PCR	  generally	  is	  not	  preferred	  in	  point	  of	  care	  diag-­‐
nosis	  because	  of	   it’s	  high	  cost,	   lack	  of	  primers	   for	  emerging	  strains	  and	   it	   requires	  specialized	  training	  
and	  equipment.	  (26,	  27)	  
1.5.3 Immuno-­‐based	  rapid	  influenza	  diagnostic	  test	  (RIDT)	  
In	  low	  resource	  settings,	  and/or	  during	  an	  influenza	  season,	  hospitals	  usually	  lack	  the	  facility	  to	  
run	   standard	   flu	   test	  on	  hundreds	  or	   thousands	   	  of	  patient	   samples.	  Under	   such	  circumstances,	   rapid	  
influenza	   diagnostic	   tests	   (RIDTs)	  may	  be	   used	   to	   guide	   diagnosis	   and	   treatment	   decisions.	   Currently,	  
there	  are	  several	  FDA	  approved	  RIDTs	  in	  the	  marketplace,	  which	  are	  immuno-­‐based	  assays	  targeting	  at	  
influenza	  A	  and	  B	  nucleoprotein	  from	  respiratory	  specimens,	  with	  various	  readout	  methods	  such	  as	  fluo-­‐
rescent,	   direct	   color,	   etc.	   These	   RIDTs	   can	   yield	   results	   within	   a	   short	   time	   frame,	   usually	   10	   to	   15	  
minutes,	  with	  relatively	  simple	  instructions.	  Some	  of	  the	  RIDTs	  are	  approved	  for	  office/bedside	  use.	  	  The	  
3MTM	  Rapid	  Detection	  Flu	  A+B	  test	  as	  an	  example,	  it	  is	  a	  new	  immunochromatography	  (IC)	  assay	  that	  is	  
designed	  to	  detect	  and	  differentiate	  between	  influenza	  A	  and	  B	  nucleoprotein	  in	  nasal	  swab,	  aspirates, 
and	  nasopharyngeal	  swab	  specimens.	  The	  format	  of	  this	  assay	  is	  a	  self-­‐contained	  cartridge	  and	  only	  sin-­‐
gle	  specimens	  are	  required	  without	  the	  need	  of	  test	  batching.	  The	  assay	  can	  be	  completed	  in	  15	  min	  and	  
a	   reader	   detects	   the	   fluorescent	   signal.	   (28)However,	   interpreting	   the	   RIDT	   test	   result	   is	   not	   always	  
straightforward.	  Several	  factors	  including	  clinical	  symptoms,	  types	  and	  collecting	  time	  of	  specimens,	  dis-­‐
ease	  prevalence	  must	  also	  be	  considered.	  (29)This	  is	  due	  to	  possible	  false	  negative	  results	  caused	  by	  the	  
relatively	   lower	  sensitivity	  of	  RIDTs	  compared	   to	   the	  “golden	  standard”	  viral	   culture	  or	  RT-­‐PCR.	  A	  sys-­‐
tematic	  study	  analyzing	  most	  commercial	  available	  RIDTs	  shows	  that	  the	  sensitivity	  to	  detect	  different	  




RIDT	  Names	   Influenza	  
virus	  
types	  	  
Specimens	   Ability	  to	  
distinguish	  
A	  and	  B	  
3M™	  Rapid	  Detection	  Flu	  A+B	  
Test	  
A	  and	  B	   NP	  swab/aspirate,	  Nasal	  
wash/aspirate	  
Yes	  
Alere	  Influenza	  A	  &	  B	   A	  and	  B	   Nasal	  swab	   Yes	  
BD	  Veritor	  System	  for	  Rapid	  
Detection	  of	  Flu	  A+B	  
A	  and	  B	   NP	  swab/nasal	  swab	   Yes	  
BinaxNOW®	  Influenza	  A&B	   A	  and	  B	   NP	  swab,Nasal	  
wash/aspirate/swab	  
Yes	  
BioSign®	  Flu	  A+B	   A	  and	  B	   NP	  swab/aspirate/wash,	  nasal	  
swab	  
Yes	  
Directigen™	  EZ	  Flu	  A+B	   A	  and	  B	   NP	  wash/aspirate/swab,	  Throat	  
swab	  
Yes	  
OSOM®	  Influenza	  A&B	   A	  and	  B	   Nasal	  swab	   Yes	  
QuickVue®	  Influenza	  Test	   A	  or	  B	   Nasal	  wash/aspirate/swab	   Yes	  
QuickVue®	  Influenza	  A+B	  Test	   A	  and	  B	   NP	  swab,	  Nasal	  
wash/aspirate/swab	  
No	  
SAS™	  FluAlert	  A&B	   A	  and	  B	   Nasal	  wash/aspirate	   Yes	  
SAS™	  FluAlert	  A	   A	  only	   Nasal	  wash/aspirate	   N/A	  
SAS™	  FluAlert	  B	   B	  only	   Nasal	  wash/aspirate	   N/A	  
Sofia	  Influenza	  A+B	  	   A	  and	  B	   NP	  aspirate/swab/wash,	  Nasal	  
wash	  
Yes	  
TRU	  FLU®	   A	  and	  B	   NP	  aspirate/swab,Nasal	  wash	   Yes	  
XPECT™	  Flu	  A&B	   A	  and	  B	   Nasal	  wash/swab,	  Throat	  swab	   Yes	  
	  
Table	  1.1	  Commercial	  influenza	  RIDTs	  and	  characteristics	  
1.5.4 Glycan-­‐based	  detection	  method	  for	  influenza	  virus	  
Another	  method	   of	   detection	   of	   influenza	   is	   the	   use	   of	   small	  molecules.	   Since	   sialylated	   gly-­‐
coconjugates	  have	  been	  found	  to	  be	  essential	  in	  cell	  entry	  of	  influenza	  viruses,	  sialosidescan	  be	  used	  as	  	  
probes	   for	   the	   detection	   of	   influenza	   viruses.	   	   In	   general,	   oligosaccharides/glycoconjugates	   represent	  
the	  most	  abundant	  class	  of	  organic	  molecules	  with	   the	  capacity	  of	   structural	  diversity	   far	  exceed	  pro-­‐
teins	  and	  nucleic	  acids.	  The	  structural	  diversity	  enables	  them	  to	  play	  a	  variety	  of	  roles	  in	  cell	  biological	  
processes	  such	  as	  cellular	  communication,	  cell	  signaling,	  differentiation,	  etc.	  95%	  of	  the	  mammalian	  cell	  
surface	  is	  covered	  with	  glycans	  in	  the	  form	  of	  glycoproteins	  or	  glycolipids,	  which	  are	  in	  the	  front	  line	  for	  
pathogen	   recognition.(31)	   Therefore,	   using	   glycans	   as	  probes	   for	   the	  detection	  of	  pathogens	  have	  at-­‐
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tracted	  much	  attention.	  Since	  glycans	  typically	  bind	  through	  a	  multivalent	  effect,	  we	  discuss	  multivalen-­‐
cy	  below.	  	  
1.5.4.1 Multivalency	  effect	  
Multivalency	  effect	   is	  observed	  widely	   in	  receptor-­‐ligand	  binding	  process	   in	  the	  form	  of	  higher	  
apparent	  affinity	  of	  multivalent	  ligand	  to	  receptor	  compared	  to	  monovalent	  ligand.	  The	  receptor-­‐ligand	  
binding	  process	   can	  be	   summarized	   into	   four	   categories	   and	   the	  proposed	  mechanisms	   are	   shown	   in	  
Figure	  1.2.	  The	  first	  widely	  observed	  type	  of	  interaction	  is	  the	  binding	  of	  multivalent	  ligand	  to	  oligomeric	  
receptors.	  In	  this	  case,	  the	  translational	  entropy	  is	  paid	  only	  for	  the	  initial	  contact	  of	  receptor	  and	  multi-­‐
valent	  ligand	  but	  not	  the	  subsequent	  binding	  interactions,	  thus	  the	  total	  entropy	  cost	  is	  much	  lower.	  The	  
second	  type	  is	  the	  binding	  of	  multivalent	  ligand	  to	  multiple	  monomeric	  receptors.	  Binding	  of	  the	  ligand	  
to	  the	  first	  receptor	  “recruit”	  other	  receptors	  in	  the	  fluid	  bilayer	  by	  the	  two-­‐dimensional	  diffusion.	  The	  
third	  type	  is	  the	  binding	  of	  one	  multivalent	  ligand	  to	  one	  monomeric	  receptor,	  which	  possesses	  binding	  
subsites	   in	  addition	  to	  the	  primary	  binding	  site.	   In	  the	  case	  of	  binding	  to	  monomeric	  receptor	  without	  
diffusion,	  multivalent	  ligands	  still	  possesses	  higher	  functional	  affinities	  due	  to	  higher	  local	  concentration	  
of	  binding	  element.	  (32)	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Figure	  1.3	  Mechanism	  of	  multivalent	  ligand	  interaction	  with	  cellular	  receptors:	  (A)	  Multivalent	  
ligands	  bind	  to	  receptors	  with	  multiple	  binding	  sites.	  (B)	  Multivalent	  ligands	  occupy	  both	  primary	  and	  
secondary	  binding	  sites	  of	  receptors.	  (C)	  Multivalent	  ligands	  binding	  cause	  receptors	  to	  cluster.	  (D)	  Mul-­‐
tivalent	  ligands	  display	  high	  local	  concentration	  and	  result	  in	  high	  apparent	  binding	  affinity.	  1.5.4.2 Glycan	  microarray	  
Since	  multivalency	  is	  a	  requirement	  for	  glycan	  based	  diagnosis	  	  of	  influenza,	  clustering	  of	  glycans	  
can	  be	  achieved	  by	  attaching	  the	  same	  glycan	  to	  a	  surface.	  When	  multiple	  glycans	  are	  printed	  at	  differ-­‐
ent	  regions	  of	  a	  glass	  slide,	  it	  gives	  rise	  to	  a	  glycan	  microarray,	  which	  can	  be	  used	  to	  detect	  influenza	  
virus.	  	  
Binding	  affinity	  of	  a	   single	   carbohydrate	  molecule	   to	  proteins	  are	  usually	  weaker	   (dissociation	  
constant	  KD:	  10-­‐3	   to	  10-­‐6M)	  compared	   to	  antigen-­‐antibody	   interactions	   (10-­‐8	   to	  10-­‐12	  M).(33)Due	   to	   the	  
structural	  complexity	  of	  carbohydrates	  and	  difficulties	  in	  synthesis,	  obtaining	  structure-­‐defined	  oligo-­‐	  or	  
polysaccharides	  in	  large	  quantties	  is	  very	  challenging.	  A	  method	  that	  can	  analyze	  carbohydrate-­‐protein	  
interactions	  with	  high	  sensitivity	   is	   in	  high	  demand.	  Taking	   the	  multivalent	  effect	   into	  account	  and	   in-­‐
spired	  by	  the	  success	  of	  high-­‐throughput	  DNA	  and	  protein	  microarray	  technique,	  glycan	  microarray	  was	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first	  introduced	  in	  2002	  by	  several	  independent	  groups.(34-­‐36)Glycan	  microarrays	  are	  composed	  of	  var-­‐
ious	   oligo-­‐	   or	   polysaccharides,	   which	   are	   immobilized	   on	   a	   chip-­‐like	   surface	   in	   a	   spatially	   defined	   ar-­‐
rangement.	   Before	   the	   introduction	   of	   microarray,	   glycan	   arrays	   on	   different	   surfaces,	   such	   as	   silica	  
plates,	  beads	  or	  ELISA	  wells	  have	  been	  around	  for	  many	  years.(37-­‐39)Only	  after	  the	  invention	  of	  robotic	  
arraying	   and	   high-­‐resolution	   scanning	   technique,	   a	  miniature	   form	  of	   glycan	   array	   on	   a	   standard	   size	  
microscope	   slide	  was	   realized.	   Hundreds	   of	   glycans	   can	   be	   spotted	   on	   a	   single	  microscope	   slide	   and	  
screened	  with	  various	  target	  proteins.(40)	   In	  the	  past	  decade,	  progress	   in	  development	  of	   immobiliza-­‐
tion	  chemistry	  of	   carbohydrate	  has	  been	  made	  and	   the	  application	  of	  glycan	  microarray	  has	  been	  ex-­‐
panded,	  which	  will	  be	  discussed	  in	  the	  following	  paragraphs.	  
The	  first	  generation	  of	  glycan	  microarray	  was	  fabricated	  using	  non-­‐covalent	  method	  to	  immobi-­‐
lize	  polysaccharides,	  proteoglycans	  and	  neoglycoproteins	  on	  nitrocellulose(41)	  or	  oxidized	  polystyrene	  
surface(42)	  through	  adsorption	  or	  electrostatic	  interactions.	  This	  method	  does	  not	  require	  any	  modifica-­‐
tion	  of	  carbohydrates,	  however,	  the	  application	  scope	  was	  limited	  to	  carbohydrates	  with	  large	  molecu-­‐
lar	  weight.	  	  
For	  the	  immobilization	  of	  low	  molecular	  weight	  oligosaccharides,	  structural	  modification	  is	  re-­‐
quired.	  Generally,	  linkers	  with	  various	  properties	  or	  different	  functional	  groups	  are	  chemically	  attached	  
to	  oligosaccharides.	  For	  instance,	  oligosaccharides	  with	  long	  alkyl	  linker	  can	  be	  arrayed	  on	  polystyrene	  
surface	  by	  hydrophobic	  adsorption(43,	  44).	  Similarly,	  oligosaccharides	  with	  fluorous	  tag	  (C8F17)	  showed	  
high	  affinity	  to	  a	  surface	  coated	  with	  the	  same	  chains	  (C8F17).	  (45)Other	  tightly	  binding	  pairs	  such	  as	  bio-­‐
tinylated	  glycan-­‐streptavidin	  coated	  slide,(46,	  47)	  or	  oligosaccharides	  with	  complementary	  DNA	  se-­‐
quence	  have	  also	  been	  applied.	  (48)	  
The	  strategy	  of	  attaching	  linkers	  with	  certain	  functional	  group	  into	  glycans	  is	  also	  well	  devel-­‐
oped.	  Thiol	  and	  primary	  amine	  are	  two	  widely	  used	  functional	  groups	  that	  serve	  the	  purpose	  of	  cova-­‐
lently	  immobilizing	  glycans	  onto	  solid	  surface.	  Thiol	  group	  is	  reactive	  to	  maleimide	  (49)while	  primary	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amine	  can	  be	  coupled	  with	  cyanuric	  chloride,	  (50)NHS	  ester(51,	  52)	  or	  epoxide.(53)	  “Click”	  reaction	  is	  
also	  used	  in	  the	  fabrication	  of	  glycan	  microarray.	  Generally,	  glycans	  are	  functionalized	  with	  azide	  and	  
reacted	  with	  alkyne	  functionalized	  surface	  with	  Copper(I)	  as	  catalyst,	  resulting	  in	  the	  formation	  of	  tria-­‐




































Figure	  1.4	  Typical	  coupling	  reactions	  of	  thiol,	  primary	  amine	  and	  "click"	  chemistry	  
	  
Direct	  immobilization	  or	  modification	  of	  free	  reducing	  glycans	  through	  reductive	  amination(55,	  
56),	  glycosylamine	  formation	  and	  trapping(53),	  hydrazine	  chemistry(57),	  condensation	  of	  oxy-­‐
amines(58)/N-­‐alkyl	  oxyamines(59)	  with	  aldehydes	  have	  also	  been	  reported.	  This	  strategy	  shows	  its	  merit	  
in	  modifying	  naturally	  derived	  glycans	  since	  complex	  protection/deprotection	  synthetic	  strategy	  is	  not	  










































Figure	  1.5	  Direct	  conjugation	  of	  reducing	  glycans	  
	  
To	  summarize,	  three	  major	  types	  of	  conjugation	  can	  be	  used	  to	  immobilize	  glycans,	  including	  
non-­‐covalent,	  covalent	  and	  direct	  conjugation	  at	  the	  reducing	  end.	  The	  progress	  in	  the	  development	  of	  
the	  immobilization	  methodology	  has	  greatly	  advanced	  the	  glycan	  microarray	  technique.	  Different	  types	  
of	  glycan	  conjugation	  are	  summarized	  in	  table	  1.2.	  
Type	  of	  conju-­‐
gation	  
Type	  of	  immobilization	  interaction	  or	  chemis-­‐
try	  
Application	  
Noncovalent	  	   Mix	  of	  hydrophilic	  and	  hydrophobic	   Polysaccharides,	  proteogly-­‐
can,	  Neoglycoprotein	  on	  ni-­‐
trocellulose	  or	  oxidazed	  poly-­‐
styrene	  surface	  	  
Hydrophobic	   Neoglycolipid	  on	  nitrocellu-­‐
lose	  surface	  
Fluorophilic	   Glycans	  with	  fluorous	  linker	  
on	  fluorous	  surface	  
Electrostatic	   Sulfated	  GAG	  on	  poly-­‐lysine	  
surface	  
Small	  molecule/protein	  interaction	   Biotinylated	  glycan	  on	  strep-­‐
tavidin	  coated	  surface	  
Complimentary	  hybridization	   Single-­‐stranded	  DNA	  conju-­‐







Amine	  chemistry	   Primary	  amine	  with	  NHS	  ester	  
slide	  
Primary	  amine	  with	  epoxide	  
slide	  
Primary	  amine	  with	  cyanuric	  
chloride	  coated	  surface	  
Thiol	  chemistry	   Thiolated	  glycans	  with	  ma-­‐
leimide	  surface	  or	  vice	  versa	  	  
"Click"	  chemistry	   Azide	  functionalized	  glycans	  





Reductive	  amination	   Conjugate	  glycans	  with	  linkers	  
(with	  reducing	  end	  monosac-­‐
charides	  in	  ring-­‐open	  form)	  
Glycosamine	  formation	  and	  trapping	   First	  react	  with	  acid	  chloride	  
then	  with	  linker	  (with	  reduc-­‐
ing	  end	  monosaccharides	  in	  
ring-­‐closed	  form)	  
Hydrazine	  chemistry	   Directly	  immobilize	  glycan	  on	  
hydrozine	  modified	  surface	  
(with	  reducing	  end	  monosac-­‐
charides	  predominantly	  in	  
ring-­‐closed	  form)	  
Oxyamine	  condensation	   Generate	  neoglycolipid	  for	  
noncovalent	  immobilization	  
(with	  reducing	  end	  monosac-­‐
charides	  partially	  in	  ring-­‐
closed	  form)	  
	  N-­‐alkyl	  oxyamine	  condensation	   Incorporate	  bifunctional	  link-­‐
er	  for	  glycan	  immobilization	  
(with	  reducing	  end	  monosac-­‐
charides	  in	  ring-­‐closed	  form)	  
	  
Table	  1.2	  Summary	  of	  different	  types	  of	  glycan	  conjugation	  
	  
Progress	  made	  in	  chemical,	  enzymatic,	  chemoenzymatic	  synthesis	  of	  glycans	  has	  enormously	  
enlarged	  the	  library	  of	  structure-­‐defined	  carbohydrates.	  Combining	  with	  various	  immobilization	  tech-­‐
niques,	  glycan	  microarrays	  with	  different	  composition	  have	  been	  applied	  broadly	  to	  analyze	  the	  binding	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properties	  of	  several	  classes	  of	  proteins	  such	  as	  lectins	  from	  plants,	  animals,	  virus	  and	  bacteria,	  antibod-­‐
ies,	  cytokines	  and	  growth	  factors,	  etc.	  In	  addition,	  studies	  that	  determine	  the	  binding	  profiles	  of	  larger	  
and	  more	  complex	  targets	  such	  as	  cells	  and	  pathogens	  including	  bacteria	  on	  glycan	  microarray	  platforms	  
have	  also	  been	  reported.	  	  
Glycan	  microarrays	  have	  revealed	  a	  lot	  of	  biological	  secrets.	  A	  comprehensive	  dataset	  of	  hun-­‐
dreds	  of	  examples	  of	  the	  application	  of	  glycan	  microarrays	  can	  be	  found	  at	  the	  Consortium	  for	  Function-­‐
al Glycomics	  website:	  http://www.functionalglycomics.org/.We	  describe	  briefly,	  a	  few	  examples	  that	  
demonstrate	  the	  power	  of	  glycan	  microarrays.	  	  
1.5.4.3 Glycan-­‐protein	  interactions	  using	  glycan	  microarrays	  
Lectins	  are	  proteins	  that	  bind	  to	  carbohydrate	  with	  high	  specificities,	  which	  are	  commonly	  used	  
to	  probe	  glycans	  and	  characterize	  glycan	  microarrays.	  A	  comprehensive	  understanding	  of	  the	  binding	  
profile	  of	  lectins	  to	  carbohydrate	  can	  expand	  their	  applications.	  For	  instance,	  a	  screening	  of	  plant	  lectins	  
ConA	  Concanavalin	  A	  (ConA)	  and	  Erythrina	  cristagalli	  lectin	  ECA	  binding	  profile	  by	  Consortium	  for	  Func-­‐
tional Glycomics	  (CFG)	  confirmed	  that	  ConA	  specifically	  bound	  to	  glycans	  with	  at	  least	  one	  a-­‐D-­‐mannose	  
residue;	  while	  ECA	  bound	  exclusively	  to	  various	  terminal	  N-­‐acetyllactose	  amine	  structure.	  (52)Another	  
example	  was	  demonstrated	  by	  Feizi	  laboratory.	  A	  membrane-­‐anchored	  ER	  protein	  malectin	  that	  is	  highly	  
conservative	  in	  animals	  was	  found	  to	  recognize	  glucose	  oligomers	  by	  NMR	  studies,	  however,	  the	  exact	  
structure	  of	  ligand	  was	  not	  clear.	  (60)The	  profiling	  study	  on	  glycan	  microarrays	  revealed	  that	  malectin	  
selectively	  bound	  to	  diglucosylated	  high	  mannose-­‐N-­‐glycan	  structure.	  The	  binding	  profiles	  of	  some	  novel	  
lectins	  such	  as	  galectin	  8,	  human	  ficolin	  and	  Candida	  glabrata	  have	  also	  been	  determined	  using	  glycan	  
microarrays	  by	  different	  groups.	  (61-­‐63)	  
Array	  of	  synthetic	  glycan	  fragments	  of	  large	  natural	  polysaccharides	  such	  as	  glycosamineglycans	  
can	  be	  used	  to	  elucidate	  the	  structure-­‐binding	  correlation	  of	  such	  macromolecules	  to	  their	  receptors.	  
Seeberger	  group	  has	  constructed	  glycan	  microarrays	  using	  synthetic	  heparin	  oligosaccharides	  and	  eval-­‐
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uated	  the	  heparin-­‐like	  glycosaminoglycan	  (GAG)-­‐fibroblast	  growth	  factors	  (FGF-­‐1	  and	  FGF-­‐2)	  interation.	  
They	  found	  that	  FGF-­‐2	  bound	  best	  to	  the	  hexamer	  and	  tetramer	  of	  heparin	  oligosaccharides	  but	  not	  
with	  the	  unusual	  2,4-­‐O-­‐sulfated	  monomer.	  In	  the	  contrary,	  FGF-­‐1	  showed	  comparable	  binding	  to	  all	  of	  
the	  monomer,	  tetramer	  and	  hexamer.	  This	  finding	  may	  facilitate	  the	  inhibitor	  design	  of	  FGF.(64)Hsieh-­‐
Wilson	  group	  reported	  the	  first	  example	  of	  using	  chondroitin	  sulfate	  microarray	  with	  distinct	  sulfation	  
sequence	  to	  probe	  GAG-­‐cytokine	  interactions.	  They	  studied	  both	  TNF-­‐α as	  well	  as	  midkine-­‐derived	  and	  
brain-­‐derived	  neurotrophic	  factor.	  They	  observed	  selective	  binding	  of	  these	  growth	  factors	  to	  CS-­‐E	  but	  
not	  CS-­‐A	  or	  CS-­‐C	  tetrasaccharide.	  (65)Followed-­‐up	  experiments	  have	  proven	  the	  merit	  of	  the	  binding	  
studies.	  A	  brain	  neuron	  growth	  experiment	  confirmed	  that	  the	  CS-­‐E	  motif	  stimulated	  neurite	  outgrowth	  
by	  about	  50%.(66)	  
Quantitative	  study	  of	  carbohydrate-­‐mediated	  cell	  adhesion	  to	  glycan	  array	  was	  reported	  by	  
Nimrichter	  et	  al.	  They	  used	  a	  microarray	  comprised	  of	  45	  glycans	  to	  screen	  the	  binding	  profile	  of	  fluo-­‐
rescent-­‐labeled	  primary	  chicken	  hepatocytes	  and	  CD4+	  human	  T-­‐cells	  and	  found	  that	  chicken	  hepato-­‐
cytes	  bound	  to	  nonreducing	  terminal	  GlcNAc	  residues	  in	  different	  linkages	  and	  orientations	  but	  not	  to	  
galactose	  or	  N-­‐acetylgalactosamine	  residues,	  while	  CD4+	  human	  T-­‐cells	  specifically	  adhered	  to	  the	  sialyl	  
Lewis	  x	  structure.(67)Seeberger	  et	  al.	  used	  a	  microarray	  containing	  five	  monosaccharides:	  mannose,	  
glucose,	  N-­‐acetyl	  glucose,	  galactose	  and	  fucose	  to	  determine	  the	  binding	  specificity	  of	  E.	  coli.	  They	  
demonstrated	  that	  E.	  coli	  strain	  of	  ORN178	  cells	  specifically	  bound	  to	  mannose	  but	  no	  the	  rest	  of	  mono-­‐
saccharides.	  In	  comparison,	  a	  mutant	  strain	  ORN209	  showed	  much	  lower	  binding	  to	  mannose.	  (68)	  In	  
addition,	  the	  binding	  properties	  of	  Helicobacter	  pylori	  has	  been	  determined	  by	  Walz	  et	  al.	  They	  found	  
that	  the	  binding	  profile	  of	  different	  H.	  pylori	  strains	  was	  highly	  dependent	  on	  the	  expression	  level	  of	  two	  
adhesins:	  SabA	  (sialic	  acid	  binding	  adhesin)	  and	  BabA	  (Leb-­‐binding	  adhesin).(69)	  
Pathogens	  usually	  possess	  unique	  polysaccharides	  on	  the	  surface,	  which	  play	  important	  roles	  in	  
interaction	  with	  host	  cells	  and	  can	  trigger	  immune	  response	  in	  infected	  human	  bodies.	  Microarrays	  that	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are	  comprised	  of	  these	  pathogenic	  polysaccharides	  or	  their	  fragments	  are	  valuable	  tools	  in	  analyzing	  
patient	  serum	  samples	  and	  evaluating	  the	  reactivity	  of	  antibodies,	  which	  can	  shed	  light	  to	  the	  produc-­‐
tion	  of	  vaccines.	  (70)A	  study	  aimed	  at	  the	  development	  of	  HIV	  vaccine	  incorporated	  the	  utilization	  of	  
glycan	  microarray.	  Human	  antibody	  2G12,	  which	  shows	  broad	  neutralization	  range	  to	  HIV-­‐1	  isolates,	  
recognizes	  a	  highly	  conservative	  oligomannose	  cluster	  on	  HIV-­‐1	  envelope	  glycoprotein	  gp120.	  Based	  on	  
this	  finding,	  oligomannose	  derivatives	  can	  be	  potentially	  used	  as	  HIV	  vaccines.	  However,	  the	  key	  struc-­‐
ture	  was	  not	  clear.	  A	  serial	  of	  oligomannose	  derivatives	  with	  different	  length	  and	  branching	  patterns	  
(Man4	  to	  Man8)	  were	  synthesized	  and	  arrayed	  by	  Chi-­‐Huey	  Wong	  and	  Ian	  A.	  Wilson	  groups.	  They	  found	  
that	  a	  minimum	  element	  of	  Man4	  was	  required	  in	  binding,	  and	  Man4	  bound	  as	  effective	  to	  2G12	  as	  the	  
Man9GlcNAc2-­‐high	  mannose	  core.(71)	  The	  inhibition	  study	  using	  these	  oligomannose	  was	  also	  in	  
agreement	  with	  the	  binding	  study.	  (72)These	  results	  have	  great	  impact	  in	  guiding	  the	  design	  of	  immu-­‐
nogens	  to	  elicit	  2G12-­‐like	  neutralizing	  antibodies	  as	  a	  component	  of	  an	  HIV	  vaccine.	  Seeberger	  group	  
demonstrated	  another	  example	  that	  targeted	  at	  malaria	  parasites.	  They	  arrayed	  analogues	  of	  malaria	  
parasite	  glycosylphosphatidylinositol	  (GPI)	  toxin	  with	  different	  mannoside	  units	  and	  analyzed	  serum	  
samples	  from	  African	  donors	  living	  in	  a	  malaria	  endemic	  area	  and	  European	  donors.	  They	  were	  able	  to	  
show	  correlation	  of	  anti-­‐GPI	  antibody	  levels	  and	  protection	  from	  severe	  malaria	  using	  the	  synthetic	  GPI	  
glycan	  array.	  (73)	  
Glycan	  microarrays	  have	  also	  been	  applied	  in	  cancer-­‐induced	  antibody	  recognition,	  since	  cancer	  
cells	  usually	  possess	  aberrant	  glycosylation	  pattern.	  Globo	  H	  hexasaccharide,	  a	  cancer	  marker	  epitope	  
that	  is	  found	  on	  the	  surface	  of	  breast,	  prostate	  and	  ovarian	  cancer	  cells,	  and	  its	  truncated	  sequences	  
were	  arrayed	  to	  analyze	  two	  monoclonal	  antibodies	  (MBr1	  and	  VK-­‐9)	  and	  serum	  samples	  from	  breast	  
cancer	  patients.	  The	  terminal	  tetrasacchride	  with	  fucose	  residue	  was	  identified	  as	  the	  key	  element	  for	  
effective	  binding	  to	  monoclonal	  antibodies.	  This	  study	  opened	  a	  door	  of	  using	  glycan	  microarray	  to	  mon-­‐
itor	  immune	  response	  to	  carbohydrate	  epitopes	  at	  different	  stages	  during	  differentiation,	  metastasis,	  or	  
18 
treatment.(74)	  Another	  study	  used	  an	  array	  containing	  37	  carbohydrates	  to	  compare	  the	  serum	  anti-­‐
body	  (IgG	  and	  IgM)	  levels	  of	  classical	  Hodgkin’s	  lymphoma	  (cHL)	  patients	  and	  age/sex-­‐matched	  healthy	  
controls.	  The	  two	  groups	  of	  samples	  showed	  remarkable	  deviation	  in	  glycan-­‐binding	  specificity.	  (75)	  All	  
of	  these	  examples	  demonstrate	  the	  importance	  of	  glycan	  microarrays	  to	  further	  our	  knowledge	  on	  the	  
fundamental	  understanding	  of	  protein-­‐glycan	  interactions.	  	  
Another	  important	  application	  of	  glycan	  microarray,	  which	  is	  highly	  relevant	  to	  our	  research	  fo-­‐
cus,	  is	  analyzing	  the	  binding	  properties	  of	  viral	  proteins	  and	  intact	  viruses.	  The	  carbohydrate	  binding	  
profiling	  of	  influenza	  viruses	  and	  envelope	  glycoprotein	  HAs	  has	  attracted	  much	  research	  interest,	  most-­‐
ly	  due	  to	  the	  well	  recognized	  binding	  specificity	  of	  HAs	  to	  sialosides.	  In	  addition,	  mutations	  of	  HAs	  occur	  
frequently	  which	  have	  impact	  on	  the	  binding	  profiling.	  Sialoside	  microarray	  can	  also	  be	  used	  to	  gain	  bet-­‐
ter	  understanding	  of	  the	  species	  barrier	  of	  influenza	  virus	  transmission	  (avian	  vs	  human).	  	  This	  point	  is	  
described	  in	  detail	  below.	  
1.5.4.4 Elucidating	  HA-­‐glycan	  interactions	  using	  focused	  sialoside	  microarrays	  
HA	  is	  a	  trimeric	  glycoprotein	  with	  each	  monomer	  comprised	  of	  two	  disulfide-­‐linked	  subunits	  
HA1	  and	  HA2.	  The	  tip	  of	  the	  HA	  spike	  is	  formed	  from	  globular	  regions	  of	  HA1,	  and	  the	  transmembrane	  
stem	  region	  is	  formed	  from	  portions	  of	  both	  HA1	  and	  HA2.	  The	  receptor	  binding	  domain,	  vestigial	  ester-­‐
ase	  domain	  and	  most	  of	  the	  epitopes	  for	  antibody	  recognition	  locate	  at	  the	  HA1	  globular	  cap.	  The	  
transmembrane	  region	  located	  close	  to	  the	  C	  terminus	  of	  HA2	  anchors	  HA	  in	  the	  viral	  membrane.	  The	  
region	  near	  the	  N	  terminus	  of	  HA2	  contains	  the	  fusion	  peptide	  sequence,	  which	  undergoes	  conforma-­‐
tional	  change	  at	  lower	  pH	  and	  induces	  membrane	  fusion	  of	  virus	  and	  host	  cell.	  The	  structure	  of	  the	  tri-­‐
meric	  HA	  is	  shown	  in	  figure	  1.5.	  Superimposition	  of	  Viet04	  HA	  monomer	  with	  another	  H5	  HA	  and	  1918	  
pandemic	  virus	  HA	  reveals	  more	  similarity	  of	  this	  avian	  HA	  to	  human	  H1	  HA	  than	  a	  more	  sequence-­‐
related	  H5	  HA.	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Figure	  1.6	  Structure	  of	  HA:	  (A)	  Overview	  structure	  of	  of	  the	  H5N1	  Viet04	  trimer.	  Each	  monomer	  
has	  been	  colored	  differently.	  Carbohydrates	  observed	  in	  the	  electron-­‐density	  maps	  are	  colored	  orange.	  
(B)	  Structural	  comparison	  of	  the	  Viet04	  monomer	  (olive)	  with	  duck	  H5	  (orange)	  and	  1918	  H1	  (red)	  HAs.	  
(Figure	  1.6	  is	  adapted	  from	  (76)with	  permission)	  
	  
Influenza	  A	  virus	  specificity	  for	  the	  host	  is	  mediated	  by	  HA.	  HA	  binds	  to	  receptors	  containing	  gly-­‐
cans	  with	  terminal	  sialic	  acids,	  where	  their	  precise	  linkage	  determines	  species	  preference.	  Avian	  viral	  HA	  
preferentially	  binds	  to	  sialic	  acids	  connected	  to	  galactose	  in	  α-­‐2,3-­‐linkages,	  which	  are	  commonly	  found	  
on	  receptors	  of	  avian	  intestinal	  epithelial	  cells,	  whereas	  human	  viral	  HA	  prefers	  the	  α-­‐2,	  6	  linkage,	  the	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dominant	  form	  on	  epithelial	  cells	  of	  the	  lungs	  and	  upper	  respiratory	  tract.	  A	  switch	  in	  receptor	  specifici-­‐
ty	  is	  a	  major	  obstacle	  for	  influenza	  A	  viruses	  to	  cross	  the	  species	  barrier	  and	  to	  adapt	  to	  a	  new	  host.	  The	  
structures	  of	  sialosides	  with	  different	  connections	  to	  galactose	  and	  their	  configurations	  adopted	  in	  the	  
HA	  binding	  site	  with	  electron	  density	  maps	  are	  shown	  in	  figure	  1.7.	  The	  α-­‐2,	  6-­‐linked	  human	  receptor	  
analog	  6’-­‐SLN	  adopt	  a	  compact,	  folded	  configuration	  in	  the	  receptor-­‐binding	  site	  of	  HA	  (Figure	  1.7C);	  
while	  α-­‐2,	  3-­‐linked	  avian	  receptor	  analog	  3’-­‐SLN	  is	  linear	  (Figure	  1.7D).	  	  	  
	  
Figure	  1.7	  Structures	  and	  configuration	  of	  human	  and	  avian	  receptor	  analogues:	  (A)	  Structure	  of	  
α-­‐2,	  6-­‐sialosides.	  (B)	  Structure	  of	  α-­‐2,	  3-­‐sialosides.	  (C)	  Electron	  density	  map	  of	  6’-­‐SLN.	  (D)	  Electron	  densi-­‐
ty	  map	  of	  3’-­‐SLN.	  (C	  and	  D	  are	  adapted	  from	  (77)	  with	  permission)	  
	  
A	  study	  of	  the	  crystal	  structures	  of	  HA	  from	  the	  2009	  H1N1	  pandemic	  viruses	  bound	  to	  
sialodes(77)	  with	  different	  length	  and	  linkages	  demonstrates	  s	  that	  the	  H1	  HA	  preferentially	  recognizes	  
α-­‐2,	  6-­‐sialylated	  receptors,	  which	  is	  achieved	  by	  hydrogen	  bonds	  between	  the	  glycan	  and	  HA	  mediated	  
mainly	  by	  Asp190	  and	  Asp225.	  Asp190	  interacts	  with	  GlcNAc-­‐3	  while	  Asp225	  contacts	  Gal-­‐2	  of	  α-­‐2,	  6-­‐
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sialylated	  receptors	  (human	  like).	  However,	  no	  significant	  interaction	  is	  observed	  with	  α-­‐2,	  3-­‐sialylated	  
receptors	  (Avian	  like)	  due	  to	  differences	  in	  the	  overall	  configurations	  of	  α−2,	  6-­‐	  versus	  α−2-­‐3-­‐linked	  si-­‐
alylated	  glycans,	  which	  explains	  the	  considerably	  weaker	  HA	  avidity	  to	  avian-­‐like	  receptor	  analogs.	  An-­‐
other	  observation	  is	  that	  the	  trisaccharide	  and	  pentasaccharide	  adopt	  similar	  configuration	  at	  the	  bind-­‐
ing	  site	  and	  only	  the	  three	  terminal	  glycans	  interact	  with	  the	  binding	  pocket.	  (Figure	  1.7)	  Although	  dif-­‐
ferences	  in	  individual	  HA/glycan	  affinity	  are	  small,	  when	  amplified	  by	  multivalent	  binding,	  the	  property	  
becomes	  distinguishable(78,	  79).	  The	  microarray	  binding	  study	  also	  shows	  the	  binding	  preferences	  of	  
2009	  H1	  HA	  to	  α-­‐2,	  6-­‐sialylated	  receptors.	  These	  corresponding	  results	  demonstrate	  that	  sialoside	  mi-­‐
croarray	  is	  a	  powerful	  tool	  in	  studying	  influenza	  binding	  profile.	  
	  
Figure	  1.8	  Receptor-­‐binding	  specificity	  of	  CA04	  HA	  to	  pentasaccharide	  or	  trisaccharide	  receptor	  
analogs	  in	  the	  CA04	  receptor	  binding	  site	  (green).	  The	  trisaccharide	  receptor	  analogs	  are	  shown	  in	  yel-­‐
low	  the	  pentasaccharide	  analogs	  	  in	  gray.	  (A)	  α-­‐2,	  6-­‐linked	  glycans;	  (B)	  α-­‐2,	  3-­‐linked	  glycans.	  (Figure	  1.7	  
is	  adapted	  from	  (77)	  with	  permission)	  
	  
The	  diversity	  of	  sialoside	  microarray	  has	  been	  greatly	  increased	  resulted	  from	  the	  development	  
of	  synthetic	  methodologies	  and	  increase	  interest	  of	  using	  microarray	  technique	  to	  profile	  the	  binding	  
properties	  of	  newly	  emerged	  influenza	  or	  to	  differentiate	  different	  strains	  of	  viruses.	  Chi-­‐Huey	  Wong	  
group	  reported	  the	  preparation	  of	  a	  microarray	  composed	  of	  30	  synthetic	  sialosides	  of	  different	  length,	  
branching	  sulfation	  pattern	  with	  either	  2,3-­‐	  or	  2,6-­‐linkage.(80)	  They	  used	  the	  sialoside	  microarray	  to	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screen	  binding	  profiles	  of	  HAs	  as	  well	  as	  intact	  viruses.	  They	  observed	  that	  human	  influenza	  HA	  had	  
higher	  binding	  to	  longer	  sialoside(a	  linear	  heptasaccharide	  shows	  maximum	  binding	  to	  almost	  all	  human	  
HAs	  that	  were	  tested).	  
1.6 Inhibitors	  of	  influenza	  virus	  
Two	  major	  tools	  of	  combating	  influenza	  are	  vaccine	  and	  anti-­‐influenza	  drugs.	  Vaccination	  is	  the	  
prevention	  and	  control	  strategy,	  which	  has	  been	  proven	  to	  provide	  adults	  (aged	  18-­‐65	  years)	  moderate	  
protection	  against	  virologically	  confirmed	  influenza.	  However,	  vaccine	  efficacy	  varies	  for	  seasonal	  flu,	  
even	  absent	  in	  some	  seasons.	  As	  mentioned	  before,	  influenza	  vaccines	  are	  usually	  produced	  several	  
months	  in	  advance	  base	  on	  the	  prediction	  of	  circulating	  strains	  of	  the	  upcoming	  season	  and	  in	  case	  of	  
pandemic	  outbreaks,	  production	  of	  effective	  vaccines	  might	  lag	  behind	  virus	  rapid	  spread.	  Finally,	  if	  is	  
virtually	  impossible	  to	  vaccinate	  everybody	  against	  influenza	  virus	  every	  single	  year.	  Taken	  together	  ,	  
relying	  solely	  on	  vaccination	  is	  not	  a	  realistic	  strategy	  for	  fighting	  against	  influenza	  infection.	  	  
Antiviral	  medications	  provide	  alternative	  options	  to	  treat	  and	  control	  influenza	  infection.	  When	  
administrated	  within	  the	  therapeutic	  window,	  antiviral	  drugs	  can	  significantly	  shorten	  illness	  onset	  and	  
prevent	  serious	  flu	  complications	  such	  as	  pneumonia.	  (81)	  FDA	  has	  approved	  four	  antiviral	  drugs	  in	  
treating	  influenza	  infection,	  including	  two	  NA	  inhibitors,	  oseltamivir	  (Tamiflu®)	  and	  zanamivir	  (Re-­‐
lenza®),	  two M2	  channel	  blockers,	  amantadine	  (Symmetrel®)	  and	  rimantadine (Flumadine®).	  As	  circulat-­‐
ing	  strains	  of	  influenza	  viruses	  have	  started	  to	  develop	  resistance	  to	  these	  drugs,	  new	  drug	  candidates	  
are	  in	  high	  demand	  (82).	  
The	  clear	  illustration	  of	  influenza	  life	  cycle	  provides	  a	  number	  of	  targets	  for	  antiviral	  drug	  design.	  
In	  fact,	  almost	  all	  viral	  proteins	  are	  becoming	  potential	  therapeutic	  targets.	  These	  target	  proteins,	  inhibi-­‐
tors	  and	  inhibition	  mechanisms	  are	  summarized	  in	  Table	  1.3.	  Inhibitors	  targeting	  different	  sites	  are	  dis-­‐
cussed	  in	  detail	  in	  the	  following	  section.	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Viral	  proteins	   Inhibitors	  	   Inhibition	  mechanisms	  
M2	   Amantadine;	  Rimitadine	   Inhibit	  endosomal	  acidification	  and	  uncoating	  of	  endo-­‐
some-­‐entrapped	  virus;	  disable	  the	  dissociation	  of	  RNPs	  
from	  M1	  matrix	  
HA	   Neu5Ac;	  TBHQ	   Inhibit	  HA	  binding	  to	  sialic	  acid	  on	  cell	  surface	  and	  vi-­‐
rus	  entry	  
NA	   Oseltamivir;	  zanamivir;	  
peramivir;	  laninamivir	  	  
Inhibit	  virus	  release	  
Polymerase	   marchantin	  E;	  Ribavirin;	  
viramidine;	  favipiravir	  
Inhibit	  viral	  replication	  
NP	   Nucleozin	   Inhibit	  RNP	  formation	  
	  
Table	  1.3	  Inhibitors	  and	  inhibition	  mechanisms	  of	  influenza	  proteins	  (Table	  1.3	  is	  adapted	  from	  
(83)	  
1.6.1 Small	  molecules	  target	  at	  HA	  
HA	  binds	  to	  sialylated	  glycoproteins	  or	  glycolipids	  on	  cell	  surface	  and	  initiates	  virus	  entry.	  Also,	  
HA	  undergoes	  conformational	  change	  inside	  endosome	  at	  low	  pH	  and	  promotes	  RNP	  release.	  Designing	  
inhibitors	  that	  block	  the	  binding	  function	  of	  HA	  have	  proven	  to	  be	  challenging	  because	  of	  the	  shallow	  
binding	  pocket	  of	  HA.	  The	  structure	  of	  HA	  inhibitors	  are	  shown	  in	  figure	  1.9.	  Most	  drug	  designs	  use	  
Neu5Ac	  as	  template	  but	  the	  binding	  affinity	  of	  the	  Neu5Ac	  derivatives	  to	  HA	  is	  not	  very	  high.	  For	  in-­‐
stance,	  the	  dissociation	  constant	  KD	  of	  Neu5Ac2Me	  (Compound	  1)	  is	  in	  the	  milimolar	  range.	  
(78)Introducing	  hydrophobic	  substituents	  at	  the	  anomeric	  carbon	  of	  Neu5Ac	  increases	  binding	  affinity	  to	  
a	  certain	  extend.	  E.g.	  Ki	  of	  compound	  2	  to	  is	  40	  uM	  against	  influenza	  virus	  X-­‐31.	  (84)	  Another	  strategy	  of	  
increasing	  the	  binding	  affinity	  of	  Neu5Ac	  derivatives	  to	  HA	  is	  increasing	  valency.	  	  Compound	  3	  has	  been	  
reported	  to	  inhibit	  hemagglutination	  with	  an	  IC50	  of	  3	  uM	  against	  a	  recombinant	  influenza	  virus	  X-­‐31	  














































Figure	  1.9	  Influenza	  HA	  inhibitors	  targeting	  at	  sialic	  acid	  binding	  site	  (1-­‐3)	  or	  inhibit	  membrane	  
fusion	  (TBHQ	  and	  4)	  
	  
Progress	  has	  been	  reported	  in	  the	  discovery	  of	  HA	  inhibitors	  that	  interfere	  with	  membrane	  fu-­‐
sion.	  One	  lead	  compound	  is	  tert-­‐butylhydroquinone	  (TBHQ).	  The	  binding	  site	  has	  been	  identified	  in	  two	  
group-­‐2	  HAs	  (H14	  and	  H3)	  at	  the	  prefusion	  trimeric	  interface	  of	  the	  stem	  region.	  The	  TBHQ	  binding	  sta-­‐
bilizes	  the	  prefusion	  trimer	  conformation	  and	  prevent	  HA1	  undergo	  conformational	  change	  at	  low	  pH,	  
which	  is	  essential	  for	  membrane	  fusion.	  (86)	  However,	  the	  inhibition	  is	  not	  observed	  with	  group-­‐1	  HAs	  
because	  the	  binding	  site	  is	  blocked.	  Fusion	  inhibitors	  designed	  for	  group-­‐1	  HAs	  bind	  to	  a	  neighboring	  
site.	  Compound	  4	  was	  found	  to	  be	  potent	  in	  inhibiting	  group-­‐1	  HAs.	  The	  crystal	  structure	  of	  H14	  HA	  
bound	  to	  TBHQ	  is	  shown	  in	  figure	  1.10.	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Figure	  1.10	  TBHQ	  binding	  to	  fusion	  peptide	  on	  H2	  subunit	  of	  a	  group-­‐2	  HA	  (H14).	  (A)	  H14	  HA	  
trimer:	  3	  H1	  subunits	  are	  colored	  in	  blue	  and	  3	  H2	  subunits	  are	  colored	  in	  yellow,	  green	  or	  grey.	  The	  lo-­‐
cations	  of	  TBHQ	  and	  fusion	  peptide	  are	  highlighted.	  (B)	  View	  down	  the	  3-­‐fold	  axis	  of	  H14	  HA	  to	  show	  the	  
3	  TBHQ	  binding	  sites.	  (C)	  Close-­‐up	  view	  of	  a	  single	  TBHQ	  binding	  site.	  Selected	  residues	  are	  shown	  as	  
sticks,	  and	  potential	  hydrogen	  bonds	  are	  shown	  as	  dotted	  lines.	  (Figure	  1.10	  is	  adapted	  from	  (86))	  
	  
The	  strategy	  of	  inhibiting	  membrane	  fusion	  has	  been	  adopted	  to	  guide	  vaccine	  production.	  Sea-­‐
sonal	  flu	  vaccines	  are	  neutralizing	  antibodies	  that	  recognize	  epitopes	  on	  the	  surface	  of	  HA	  head	  region,	  
which	  is	  highly	  variable.	  For	  this	  reason,	  the	  vaccines	  have	  to	  be	  changed	  every	  year	  based	  on	  prediction	  
of	  circulating	  strains.	  Innovate	  antibodies	  that	  target	  at	  the	  highly	  conservative	  stem	  region	  instead	  of	  
the	  globular	  cap	  have	  been	  discovered.	  (12,	  87,	  88)This	  type	  of	  antibodies	  can	  provide	  broad	  neutraliza-­‐
tion	  to	  different	  strains	  of	  influenza	  viruses	  and	  have	  higher	  tolerance	  to	  virus	  mutation	  because	  the	  
change	  at	  the	  distal	  globular	  head	  has	  minimal	  impact	  on	  the	  stem	  region.	  The	  same	  concept	  was	  also	  
used	  in	  designing	  proteins	  that	  bind	  to	  the	  stem	  region	  of	  HAs	  and	  inhibit	  conformational	  change.	  (89) 
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1.6.2 Ion	  channel	  M2	  blocker	  
The	  M2	  protein	  is	  a	  small	  integral	  membrane	  protein	  of	  97	  amino	  acid	  residues.	  The	  intracellular	  
cytoplasmic	  domain	  has	  54	  residues	  at	  the	  C-­‐terminal;	  24	  residues	  at	  the	  N-­‐terminal	  comprise	  the	  extra-­‐
cellular	  domain	  and	  the	  rest	  of	  19	  residues	  are	  the	  transmembrane	  domain.	  (90)	  M2	  proteins	  exist	  in	  the	  
form	  of	  oligomers,	  minimally	  a	  tetramer.	  Disulfide	  bonds	  between	  subunits	  help	  retain	  the	  oligomer	  
structure.	  (91)	  Although	  M2	  protein	  is	  present	  in	  low	  abundance	  in	  the	  viral	  membrane,	  it	  plays	  im-­‐
portant	  roles	  in	  influenza	  virus	  life	  cycle	  since	  low	  pH	  environment	  is	  essential	  for	  the	  conformational	  
change	  of	  HA,	  which	  leads	  to	  viral-­‐endosomal	  membrane	  fusion.	  On	  the	  other	  hand,	  the	  RNPs	  can	  only	  
dissociate	  with	  matrix	  protein	  M1	  at	  low	  pH	  and	  being	  released	  into	  the	  cytoplasm.	  Blockade	  of	  M2	  ion	  
channel	  results	  in	  accumulation	  of	  M1-­‐associated	  RNPs	  in	  cytoplasm,	  which	  are	  unable	  to	  penetrate	  the	  
nucleus.	  (92,	  93)	  
M2	  ion	  channel	  inhibitor	  amantadine	  and	  rimitadine	  are	  the	  first	  two	  FDA	  approved	  antiviral	  
drugs	  for	  influenza	  infection	  and	  have	  demonstrated	  efficacy	  in	  clinical	  settings.	  Amantadine	  is	  believed	  
to	  bind	  to	  the	  channel	  pore	  near	  Ser31	  of	  the	  M2	  protein,	  at	  which	  site	  mutations	  occur	  and	  results	  in	  
resistance.(94,	  95)	  Rimitadine	  is	  a	  derivative	  of	  amantadine	  and	  shows	  efficacy	  against	  some	  aman-­‐
tadine	  resistant	  strains,	  however,	  resistance	  to	  rimitadine	  has	  occurred	  in	  high	  incidence	  in	  recent	  years.	  	  
Amantadine	  and	  rimitadine	  also	  show	  side	  effect	  on	  central	  nervous	  system,	  thus	  are	  not	  used	  wildly.	  	  
The	  most	  common	  mutation	  of	  amantadine	  binding	  site	  of	  M2	  protein	  is	  S31N	  while	  V27A	  and	  
L26F	  have	  also	  been	  observed.	  New	  drug	  designs	  based	  on	  amantadine	  structure	  target	  at	  these	  mu-­‐
tants.	  	  Structures	  of	  these	  compounds	  are	  shown	  below.	  Compound	  5	  shows	  inhibition	  to	  V27A	  and	  
L26F	  mutants	  but	  not	  S31N	  mutant.	  (96-­‐99)	  Actually,	  no	  effective	  inhibitor	  against	  the	  most	  common	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Figure	  1.11	  Structures	  of	  M2	  ion	  channel	  blockers	  
1.6.3 NA	  inhibitor	  
NA	  inhibitors	  represent	  the	  most	  successful	  effort	  of	  structure-­‐based	  anti-­‐influenza	  drug	  discov-­‐
ery.	  The	  inhibition	  mechanism	  is	  that	  the	  inhibitors	  block	  the	  active	  site	  of	  NA,	  thereby	  NA	  is	  unable	  to	  
cleave	  off	  sialic	  acid	  from	  cell	  membrane	  glycoproteins	  and	  hinders	  progeny	  virions	  release.	  The	  two	  
most	  commonly	  used	  antiviral	  drugs	  oseltamivir	  and	  zanamivir	  NA	  inhibitors.	  Other	  NA	  inhibitors	  are	  
also	  being	  developed	  such	  as	  peramivir	  and	  laninamivir.	  The	  reason	  for	  success	  is	  that	  the	  deep	  binding	  
pocket	  of	  NA	  is	  highly	  conservative	  and	  well	  defined.	  (Figure	  1.6)	  In	  the	  active	  site	  of	  NA,	  substrate	  α-­‐N-­‐
acetylneuraminic	  acid	  adopts	  a	  boat	  like	  conformation	  and	  in	  direct	  contact	  with	  eight	  highly	  conserva-­‐
tive	  amino	  acid	  residues,	  forming	  hydrogen	  bond	  with	  these	  charged	  residues.	  (100)	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Figure	  1.12	  Interaction	  of	  a-­‐N-­‐acetylneuraminic	  acid(a-­‐Neu5Ac)	  	  inside	  NA	  active	  site.	  (a)	  a-­‐
Neu5Ac	  bound	  in	  a	  boat-­‐like	  conformation.	  (b)	  Zoom	  view	  of	  the	  NA	  active	  site.with	  a-­‐Neu5Ac.	  (c)	  Eight	  




The	  nine	  NA	  subtypes	  are	  phylogenetically	  divided	  into	  to	  groups:	  N1,	  N4,	  N5	  and	  N8	  belong	  to	  
group	  1;	  N2,	  N3,	  N6,	  N7	  and	  N9	  compose	  group	  2.	  The	  grouping	  is	  highly	  relevant	  to	  the	  active	  site	  
structure.	  Superposition	  of	  group-­‐1	  NAs	  N1,	  N4	  and	  N8	  reveals	  identical	  active	  site,	  however,	  a	  large	  
cavity	  adjacent	  to	  the	  active	  site	  in	  group-­‐1	  NAs	  is	  absent	  in	  group-­‐2	  NAs	  (Figure	  1.13)	  (101)	  
	  
Figure	  1.13	  Active	  site	  structure	  comparisons	  of	  group-­‐1	  and	  group-­‐2	  NAs.	  (A)	  N1	  active	  site	  with	  
oseltamivir.	  (B)	  N9	  active	  site	  with	  oseltamivir.	  (C)	  Superposition	  of	  the	  active	  sites	  of	  apo-­‐N1	  (green)	  
and	  N1	  complexed	  with	  oseltamivir	  (blue).	  (D)	  Superposition	  of	  the	  active	  site	  of	  N1	  (green)	  and	  N9	  (yel-­‐
low).	  (Figure	  1.13	  is	  adapted	  from	  (101)	  with	  permission)	  
	  
2-­‐Deoxy-­‐2,3	  -­‐didehydro-­‐N-­‐acetylneuraminic	  acid	  (DANA)	  was	  developed	  by	  Meidle	  et	  al.	  in	  1974	  
as	  NA	  inhibitor.	  The	  double	  bond	  structure	  mimics	  the	  transition	  state	  of	  the	  sialosyl	  cation.	  Replace-­‐
ment	  of	  C4	  hydroxyl	  group	  with	  positively	  charged	  amino	  group	  increases	  the	  inhibitory	  effect	  by	  100	  
fold.	  The	  reason	  is	  that	  a	  negatively	  charged	  amino	  acid	  residue	  Glu119	  at	  the	  binding	  pocket	  is	  aligned	  
with	  the	  C4	  position,	  and	  the	  amino	  group	  can	  form	  a	  salt	  bridge	  with	  Glu119	  to	  further	  stabilize	  the	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interaction	  with	  the	  active	  site.	  Following	  this	  lead,	  introduction	  of	  a	  highly	  positively	  charged	  guanidinyl	  
group	  at	  the	  C4	  position	  brings	  the	  inhibition	  IC50	  to	  nanomolar	  range.	  The	  guanidinyl	  group	  of	  zanamivir	  
shows	  interaction	  with	  both	  Glu227	  and	  Glu119	  of	  the	  NA	  active	  site.	  (100,	  102,	  103)Due	  to	  the	  high	  
positive	  charge	  nature	  of	  zanamivir,	  oral	  administration	  is	  not	  suitable.	  Instead,	  it	  is	  administered	  as	  an	  
inhaler.	  	  This	  is	  also	  the	  major	  drawback	  of	  zanamivir	  because	  inhalation	  may	  increase	  the	  risk	  of	  bron-­‐
chospasms	  in	  patients	  with	  respiratory	  diseases.	  (104)Laninamivir	  is	  a	  pro-­‐drug	  of	  zanamivir.	  With	  a	  me-­‐
thyl	  ether	  group,	  a	  prolonged	  duration	  of	  antiviral	  activity	  in	  animal	  models	  was	  observed	  as	  well	  as	  a	  
prolonged	  presence	  in	  human.	  Laninamivir	  is	  also	  administrated	  through	  inhalation	  and	  shows	  similar	  
antiviral	  spectrum	  as	  zanamivir.	  	  
Oseltamivir	  is	  a	  pro-­‐drug	  with	  an	  ethyl	  ester	  group,	  which	  can	  be	  cleaved	  off	  in	  liver	  after	  inges-­‐
tion	  by	  human	  carboxylesterase	  1	  and	  form	  the	  active	  compound	  oseltamivir	  carboxylate.	  Compare	  to	  
DANA	  and	  its	  derivatives,	  oseltamivir	  is	  derived	  from	  non-­‐carbohydrate	  template	  shikimic	  acid	  with	  a	  
lipophilic	  pentane	  3-­‐oyl	  group	  instead	  of	  the	  glycerol	  group	  with	  C8	  and	  C9	  hydroxyl	  groups,	  which	  in-­‐
side	  the	  NA	  catalytic	  site	  can	  induce	  a	  conformational	  change	  in	  Glu276	  to	  interact	  with	  Arg244	  through	  
charge-­‐charge	  interaction.	  The	  induced	  fit	  of	  oseltamivir	  carboxylate	  into	  active	  site	  is	  essential	  for	  the	  
achievement	  of	  potent	  antiviral	  activity.	  A	  neighboring	  amino	  acid	  residue	  His274	  helps	  in	  the	  conforma-­‐
tional	  change.	  The	  induced	  fit	  model	  explains	  the	  drug	  resistance	  against	  oseltamivir	  when	  point	  muta-­‐
tion	  H274Y	  occurs.(105-­‐108)	  (Figure	  1.14)	  Different	  from	  zanamivir,	  oseltamivir	  is	  usually	  administrated	  
orally	  thus	  used	  more	  commonly.	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Figure	  1.14	  Structure	  of	  oseltamivir	  N1	  neuraminidase	  complexes	  (A)	  His274Tyr	  in	  complex	  with	  
oseltamivir.	  (B)	  Asn294Ser	  in	  complex	  with	  oseltamivir.	  (Figure	  1.8	  is	  adapted	  from	  (108)with	  permis-­‐
sion).	  
	  
As	  more	  and	  more	  resistance	  to	  oseltamivir	  has	  been	  reported,	  new	  NA	  inhibitors	  are	  in	  great	  
need.	  Peramivir	  and	  its	  analogue	  A315675	  retain	  inhibition	  activity	  against	  oseltamivir	  and	  zanamivir	  
resistant	  strains	  of	  influenza	  A	  and	  B	  viruses.	  A	  prolonged	  half-­‐life	  of	  peramivir	  from	  N9	  was	  also	  ob-­‐
served	  (1	  day	  vs	  1.25	  h	  of	  oseltamivir	  and	  zanamivir).	  (109)The	  design	  of	  peramivir	  follows	  similar	  con-­‐
cept	  as	  oseltamivir,	  which	  is	  replacing	  the	  carbohydrate	  core	  structure	  with	  quinic	  acid.	  At	  the	  same	  
time,	  a	  lipophilic	  3-­‐pentyl	  side	  chain	  is	  also	  introduced.	  	  One	  feature	  of	  peramivir	  is	  that	  it’s	  injectable,	  


































































1.6.4 Viral	  polymerase	  inhibitor	  
Influenza	  RNA	  polymerase	  complex	  is	  a	  heterotrimer	  of	  PB1,	  PB2	  and	  PA.	  Studies	  show	  that	  PB2	  
binds	  to	  host	  cell	  mRNA	  at	  the	  5’	  end	  and	  PA	  functions	  as	  an	  endonuclease	  to	  cleave	  off	  9-­‐15	  nucleo-­‐
tides	  down-­‐stream	  to	  generate	  a	  primer	  for	  viral	  mRNA	  synthesis.	  (110,	  111)Through	  docking	  models,	  
Iwai	  et	  al	  identified	  a	  33	  macrocyclic	  bisbibenzyl	  compound	  marchantin	  E	  as	  an	  inhibitor	  of	  PA	  endonu-­‐
clease	  activity	  and	  showed	  inhibition	  of	  influenza	  A	  virus	  growth.	  	  (112)	  
Several	  small	  molecules	  have	  been	  identified	  with	  anti	  endonuclease	  activity	  as	  well.	  Compound	  
6	  is	  a	  lead	  compound	  identified	  by	  SAR	  study	  and	  its	  isomer	  compound	  7	  shows	  submilimolar	  IC50.	  An-­‐
other	  class	  of	  viral	  polymerase	  inhibitors	  is	  simple	  phosphate	  derivatives	  (compound	  8-­‐11).	  The	  pro-­‐
posed	  inhibition	  mechanism	  is	  that	  these	  compounds	  coordinate	  to	  zinc	  ion	  at	  the	  active	  site	  of	  the	  pol-­‐
ymerase	  and	  sterically	  interfere	  with	  nucleotide	  phosphate	  binding	  or	  prevent	  the	  pyrophosphate	  re-­‐
lease	  after	  chain	  extension.	  However,	  this	  class	  of	  compounds	  has	  no	  selectivity	  between	  viral	  DNA	  and	  
RNA	  polymerase.	  (113,	  114)	  
Guanosine	  analogues	  ribavirin	  and	  viramidine	  can	  inhibite	  inosine	  5’-­‐monophosphate	  dehydro-­‐
genase	  (IMPDH),	  which	  functions	  in	  the	  de	  novo	  synthesis	  of	  guanine	  nucleotides	  thus	  lower	  intracellu-­‐
lar	  GTP.	  They	  also	  inhibit	  transcription	  and	  elongation	  by	  interfering	  with	  RNA	  dependent	  RNA	  polymer-­‐
ase.	  Inhibition	  of	  ribavirin	  to	  seasonal	  isolates	  of	  H1N1	  and	  H3N2	  viruses,	  influenza	  B	  viruses	  and	  pan-­‐
demic	  H1N1	  influenza	  A	  viruses	  has	  been	  shown	  in	  mouse	  model	  with	  early	  administration	  after	  infec-­‐
tion.	  Viramidine	  is	  less	  potent,	  but	  better	  tolerated.	  Ribavirin	  also	  shows	  efficacy	  in	  preventing	  mortality	  
in	  mice	  infected	  with	  lethal	  H5N1	  virus.	  (115)	  
T-­‐705,	  also	  called	  favipiravir,	  shows	  broad	  spectrum	  in	  inhibition	  of	  RNA	  viruses,	  including	  influ-­‐
enza	  A,	  B	  and	  C.	  T-­‐705	  is	  first	  converted	  to	  monophosphate	  T705RMP	  by	  phosphoribosyl	  transferase	  and	  
subsequently	  to	  triphosphate	  T-­‐705RTP	  by	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nucleotide	  kinase	  in	  host	  cell.	  T-­‐705RTP	  is	  the	  active	  form	  of	  inhibition,	  which	  can	  compete	  with	  
GTP	  in	  RNA	  synthesis.	  Compare	  to	  ribavirin,	  T-­‐705	  has	  much	  lower	  inhibitory	  effect	  on	  cellular	  DNA	  and	  





































































T-705 T-705RNP T-705RTP 	  
Figure	  1.16	  Viral	  polymerase	  inhibitors	  
1.6.5 Nucleoprotein	  (NP)	  inhibitor	  
NP	  is	  a	  key	  component	  of	  RNP,	  which	  encapsidates	  viral	  RNA	  segment	  and	  bind	  with	  polymerase	  
heterotrimer.	  (117)Kao	  et	  al.	  discovered	  a	  compound	  nucleozin,	  which	  can	  induce	  NP	  aggregation	  and	  
inhibit	  NP	  accumulation	  in	  nucleus,	  thereby	  inhibit	  RNP	  formation	  and	  viral	  replication.	  The	  NP	  tail-­‐loop	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binding	  pocket	  and	  RNA	  binding	  groove	  are	  potential	  drug	  targets.(118)	  Shen	  et	  al.	  identified	  compound	  	  
as	  potent	  inhibitor	  of	  NP	  oligomerization	  and	  replication	  of	  influenza	  virus	  by	  binding	  to	  tail-­‐loop	  of	  NP.	  
Fedichev	  et	  al.	  identified	  compound	  M	  as	  a	  potential	  NP	  binder	  by	  docking	  model	  of	  this	  compound	  and	  
RNA	  binding	  groove.	  (119)	  
1.6.6 Summary	  
To	  summarize,	  all	  these	  proteins	  are	  viable	  targets	  that	  could	  be	  exploited	  to	  inhibit	  the	  spread	  
of	  the	  virus.	  Since	  the	  virus	  mutates	  by	  two	  mechanisms,	  it	  is	  very	  important	  that	  we	  pursue	  two	  meth-­‐
ods	  of	  fighting	  the	  virus.	  Early	  detection	  and	  development	  of	  small	  molecules	  asdrug	  candidates.	  In	  this	  
thesis,	  we	  have	  developed	  novel	  methods	  of	  capturing	  the	  virus	  and	  developed	  first	  generation	  poten-­‐
tial	  drug	  candidates	  against	  the	  virus.	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2 NEURAMINIDASE	  RESISTANT	  SIALOSIDE	  MICROARRAY	  FOR	  THE	  DETECTION	  OF	  INFLUENZA	  VI-­‐
RUSES	  
ABSTRACT	  
Glycan	  microarrays	  comprise	  of	  O-­‐linked	  sialosides	  have	  become	  important	  tools	  for	  studying	  in-­‐
fluenza	  virus	  binding	  profile.	  However,	  NA	  inhibitors	  or	  low	  temperature	  is	  required	  in	  performing	  the	  
binding	  assays	  since	  the	  viral	  NA	  can	  hydrolyze	  O-­‐linked	  terminal	  sialic	  acid.	  In	  this	  chapter,	  we	  describe	  
the	  synthesis	  of	  NA	  resistant	  sialosides	  that	  include	  different	  glycosidic	  linkages	  (C-­‐,	  S-­‐	  and	  N-­‐).	  We	  com-­‐
pare	  the	  stability	  of	  these	  sialosides	  with	  O-­‐linked	  sialosides	  and	  demonstrate	  the	  ability	  of	  these	  mole-­‐
cules	  to	  capture	  influenza	  virus	  at	  ambient	  temperature	  without	  the	  addition	  of	  NA	  inhibitors.	  Every	  
strain	  of	  influenza	  virus	  shows	  unique	  binding	  pattern	  on	  the	  microarray.	  
ABBREVIATION	  
Acetate,	  Ac;	  Acetic	  anhydride,	  Ac2O;	  Acetonitrile,	  CH3CN;	  Benzaldehyde	  dimethyl	  acetal,	  BDA	  or	  
PhCH(OMe)2;	  Benzyl	  bromide,	  BnBr;	  Camphorsulfonic	  acid,	  CSA;	  Carbon-­‐13	  nuclear	  magnetic	  resonance,	  
13C-­‐NMR;	  Copper	  (I)	  Iodine,	  CuI;	  Deuterated	  chloroform,	  CDCl3;	  Deuterated	  water,	  D2O;	  Dichloro-­‐
methane,	  DCM	  or	  CH2Cl2;	  Diethyl	  ether,	  Et2O;	  N,N-­‐dimethyl	  formamide,	  DMF;	  Ethanol,	  EtOH;	  Ethyl	  ace-­‐
tate,	  EtOAc;	  High	  resolution	  mass	  spectroscopy,	  HRMS;	  Hydrogen	  gas,	  H2;	  Hydrazine	  acetate,	  
NH2NH2.HOAc;	  Hydrochloric	  acid,	  HCl;	  Sodium	  sulfate,	  Na2SO4;	  Methanol,	  MeOH	  or	  CH3OH;	  Palladium	  
hydroxide	  on	  carbon,	  Pd(OH)2/C;	  Proton	  nuclear	  magnetic	  resonance,	  1H-­‐NMR;	  Pyridine,	  py;	  Room	  tem-­‐
perature,	  RT;	  Sodium	  azide,	  NaN3;	  Sodium	  bicarbonate,	  NaHCO3;	  Sodium	  hydride,	  NaH;	  Sodium	  methox-­‐
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ide,	  NaOMe;	  Tetrahydrofuran,	  THF;	  Thin	  layer	  chromatography,	  TLC;	  Trifluoromethanesulfonic	  anhy-­‐
dride,	  Tf2O;	  Trimethylsilyl	  p-­‐Toluenesulfonic	  acid,	  p-­‐TSA;	  Water,	  H2O.	  
	  
2.1 Introduction	  
Influenza	  virus	  is	  an	  acute	  respiratory	  pathogen	  that	  causes	  considerable	  harm	  to	  humans	  and	  
livestock.(1)	  In	  addition	  to	  seasonal	  influenza	  that	  accounts	  for	  approximately	  200,000	  hospitalizations	  
and	  36,000	  deaths	  per	  year	  in	  the	  United	  States	  alone,	  catastrophic	  pandemics	  such	  as	  the	  1918	  Spanish	  
flu	  (H1N1)	  can	  be	  devastating.(2)	  Early	  detection	  is	  critical	  in	  our	  fight	  against	  this	  deadly	  virus	  because	  
most	  antivirals	  lose	  their	  efficacy	  if	  it	  is	  not	  administered	  within	  24-­‐48	  hours	  after	  onset	  of	  infection(2)	  
and	  because	  influenza	  spreads	  very	  rapidly.	  For	  example,	  the	  2009	  H1N1	  influenza	  virus	  spread	  rapidly	  
across	  the	  globe	  within	  ten	  days,	  resulting	  in	  extraordinary	  measures(3,	  4)	  and	  overwhelming	  public	  
health	  care	  facilities.(5)	  Most	  public	  hospitals	  requested	  sick	  patients	  to	  stop	  coming	  to	  the	  emergency	  
room	  during	  that	  time.	  PCR	  based	  technologies,	  although	  highly	  accurate	  and	  definitive,	  are	  cost	  prohib-­‐
itive	  for	  use	  in	  a	  primary	  care	  setting.	  Antibody	  based	  tests	  are	  point-­‐of-­‐care	  with	  a	  test	  to	  result	  time	  of	  
less	  than	  30	  minutes,	  but	  are	  generally	  used	  for	  surveillance	  because	  they	  suffer	  from	  a	  variety	  of	  issues	  
that	  include	  sensitivity,	  antibody	  degradation	  at	  ambient	  temperature	  and	  cross	  reactivity.(6,	  7)	  Pro-­‐
curement	  of	  antibodies	  for	  emerging	  strains	  is	  also	  a	  problem	  during	  an	  emergency.	  Finally,	  while	  anti-­‐
body	  tests	  are	  less	  expensive	  than	  PCR,	  they	  are	  expensive	  (~	  50$)	  and	  prohibitive	  for	  use	  in	  a	  resource	  
poor	  setting	  and	  are	  generally	  only	  used	  for	  surveillance	  purposes.	  	  
Since	  the	  virus	  binds	  to	  the	  terminal	  residues	  of	  N-­‐acetyl	  neuraminic	  acid	  (or	  sialic	  acid)	  of	  gly-­‐
coproteins	  and	  glycolipids	  to	  gain	  entry	  into	  the	  cell,	  an	  alternate	  receptor	  based	  approach	  based	  on	  
synthetic	  glycans	  could	  potentially	  be	  used	  to	  identify	  and	  type	  the	  virus.(1,	  8,	  9)	  From	  a	  diagnostic	  per-­‐
spective,	  synthetic	  small	  molecule	  analogs	  based	  on	  receptors	  (in	  this	  case,	  glycans)	  present	  a	  novel,	  but	  
largely	  unexplored,	  opportunity	  as	  recognition	  molecules.	  Glycans	  can	  be	  synthesized	  in	  appreciable	  
49 
yields	  economically,	  are	  highly	  robust	  under	  a	  variety	  of	  conditions	  and	  do	  not	  require	  refrigeration.(10-­‐
12)	  An	  added	  advantage	  is	  that	  glycans	  are	  small	  molecules	  and	  this	  provides	  them	  with	  an	  unique	  ad-­‐
vantage	  over	  larger	  recognition	  elements	  such	  as	  antibodies	  or	  aptamers.	  Glycans	  could	  find	  use	  in	  for	  
potential	  applications	  in	  nanobiosensors,	  where	  nanoparticle-­‐glycan	  conjugates	  do	  not	  perturb	  the	  
overall	  size	  of	  the	  nanoparticle.(13)	  Lastly,	  since	  a	  plethora	  of	  glycans	  can	  be	  synthesized	  with	  new	  ad-­‐
vances	  in	  synthetic	  methodologies,	  a	  ‘fingerprint’	  pattern	  of	  recognition	  can	  be	  obtained	  for	  every	  virus	  
type	  that	  binds	  to	  a	  glycan	  microarray.(14-­‐16)	  Indeed,	  multiple	  groups	  have	  used	  this	  approach	  to	  cap-­‐
ture	  hemagluttinin,	  a	  surface	  glycoprotein,	  and	  the	  virus	  using	  microarrays	  of	  O-­‐sialosides,	  synthesized	  
from	  enzymatic	  and	  synthetic	  methods.(17,	  18)	  	  
This	  approach	  has	  advanced	  our	  understanding	  of	  some	  of	  the	  fundamental	  aspects	  of	  virus-­‐
receptor	  interactions;	  glycan	  microarrays	  constructed	  using	  O-­‐sialosides	  have	  been	  used	  (in	  conjunction	  
with	  other	  methods)	  to	  explain	  why	  certain	  virus	  types	  prefer	  2,3	  linkages,	  in	  contrast	  to	  other	  viruses	  
which	  seem	  to	  prefer	  2,6	  linkages.(17-­‐20)However,	  this	  approach	  is	  limited	  in	  scope	  for	  point	  of	  care	  
influenza	  diagnostics,	  because	  neuraminidase	  (NA)	  an	  influenza	  surface	  glycoprotein,	  cleaves	  O-­‐
glycoside	  linkages	  rapidly.(21)	  Indeed,	  most	  publications	  report	  performing	  the	  assays	  with	  influenza	  
viruses	  at	  low	  temperatures	  (4	  0C)	  and/or	  use	  NA	  inhibitors	  to	  avoid	  issues	  with	  NA	  cleaving	  the	  natural	  
O-­‐sialosides.(22-­‐24)	  To	  overcome	  these	  issues	  towards	  our	  ultimate	  goal	  of	  using	  glycans	  as	  a	  practical	  
approach	  to	  capture	  influenza	  viruses,	  we	  synthesized	  NA	  insensitive	  glycans	  with	  S-­‐,	  N-­‐	  or	  C-­‐link,	  (Figure	  
































































































































Figure	  2.1	  Structures	  of	  ten	  sialosides	  used	  to	  construct	  glycan	  microarray	  
	  
2.1.1 Stability	  of	  thiosialoside	  
Thioglycosides	  generally	  exhibit	  enhanced	  stability	  toward	  enzyme-­‐mediated	  hydrolysis	  com-­‐
pared	  to	  their	  oxygen-­‐based	  counterparts.	  Meanwhile,	  they	  maintain	  the	  biochemical	  activities	  of	  the	  
parent	  oligosaccharides.	  (25,	  26)For	  instance,	  Suzuki	  et	  al.	  has	  shown	  that	  thioglycosidic	  analogues	  of	  
gangliosides	  are	  not	  hydrolyzed	  by	  influenza	  NA.(27)	  Von	  Itzstein	  group	  reported	  a	  detailed	  study	  inves-­‐
tigating	  the	  stability	  of	  thiosialosides	  towards	  sialidase	  hydrolysis	  by	  NMR	  spectroscopy.	  In	  this	  study,	  
they	  compared	  the	  stability	  of	  O-­‐	  and	  S-­‐sialosides	  with	  α-­‐2,	  3	  or	  α-­‐2,	  6	  linkage	  to	  galactoside	  toward	  
Vibrio	  cholerae	  sialidase.	  They	  found	  that	  O-­‐sialosides	  were	  mostly	  hydrolyzed	  in	  2h	  while	  S-­‐sialosides	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were	  still	  intact	  after	  14	  days.	  (28)	  Possible	  explanation	  for	  the	  stability	  of	  S-­‐sialosides	  toward	  sialidase	  is	  
that	  the	  slightly	  longer	  C-­‐S	  bond	  causes	  minor	  alteration	  of	  glycoside	  conformation,	  making	  the	  struc-­‐
ture	  less	  suitable	  for	  sialidase	  recognition.	  The	  reduced	  Lewis	  basicity	  of	  sulfur	  might	  also	  contribute	  to	  
the	  stability	  of	  S-­‐sialosides.(29,	  30)	  
2.1.2 Synthesis	  of	  thiosialoside	  
The	  formation	  of	  S-­‐glycosidic	  bond	  is	  usually	  through	  nucleophilic	  substitution	  reaction.	  Two	  
general	  approaches	  can	  be	  adopted	  for	  the	  synthesis	  of	  thiosialosides,	  which	  are	  (a)	  installation	  of	  thio-­‐
acetyl	  group	  at	  the	  anomeric	  carbon	  of	  sialic	  acid	  followed	  by	  selective	  deacetylation	  of	  the	  anomeric	  
thioacetate	  and	  subsequent	  reaction	  with	  sialosyl	  acceptor	  bearing	  a	  good	  leaving	  group	  and	  (b)	  incor-­‐
poration	  of	  the	  sulfur	  into	  the	  sialosyl	  acceptor	  and	  then	  coupling	  with	  the	  2-­‐chloro	  Neu5Ac	  derivative.	  
(Scheme	  1)	  The	  first	  approach	  has	  been	  widely	  used	  in	  the	  synthesis	  of	  α-­‐S-­‐2,	  6-­‐sialosides	  while	  both	  of	  
the	  two	  approaches	  have	  been	  reported	  for	  the	  synthesis	  of	  α-­‐S-­‐2,	  3-­‐sialosides.	  In	  comparison,	  the	  re-­‐
ported	  overall	  yield	  in	  synthesizing	  the	  α-­‐S-­‐2,	  3-­‐sialosides	  following	  the	  second	  approach	  is	  higher.	  


































































Scheme	  2.1	  Two	  approaches	  toward	  the	  synthesis	  of	  thiosialosides	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2.2 Results	  and	  discussion	  
2.2.1 Synthesis	  of	  S-­‐	  and	  N-­‐linked	  sialosides	  
To	  probe	  and	  differentiate	  different	  strains	  of	  influenza	  viruses,	  I	  have	  synthesized	  S-­‐	  and	  N-­‐
linked	  sialosides(SC1-­‐5).	  The	  synthesis	  of	  SC1	  is	  shown	  in	  scheme	  2.	  The	  β-­‐2-­‐Chloro-­‐N-­‐acetylneuraminic	  
acid	  2	  was	  synthesized	  from	  an	  α, β	  mixture	  1	  by	  bubbling	  hydrochloric	  acid	  gas	  through.	  Formation	  of	  
α-­‐2-­‐chloro-­‐N-­‐acetylneuraminic	  acid	  was	  not	  observed.	  2	  was	  not	  stable	  at	  room	  temperature	  therefore	  
was	  used	  within	  a	  shore	  time	  frame	  to	  synthesize	  3	  or	  4,	  which	  possesses	  thioacetyl	  or	  azido	  group	  re-­‐
spectively	  at	  the	  anomeric	  position.	  The	  glycosylation	  reaction	  was	  catalyzed	  by	  a	  phase	  transfer	  catalyst	  
tetrabutylammonium	  hydrogen	  sulfate	  (TBAHS)	  under	  mild	  basic	  condition.	  TBAHS	  was	  chosen	  over	  
other	  halide	  phase	  transfer	  catalyst	  such	  as	  tetrabutylammonium	  bromide	  to	  avoid	  the	  possibility	  of	  
double	  halide	  displacement.	  In	  addition,	  in	  the	  presence	  of	  chloride,	  bromide,	  or	  iodide	  anions,	  scram-­‐
bling	  of	  anomeric	  configuration	  could	  be	  observed.	  (31)	  As	  expected,	  compound	  3	  and	  4	  were	  obtained	  
in	  pure	  α	  configuration	  through	  complete	  anomeric	  conversion	  of	  2,	  which	  indicated	  SN2	  mechanism.	  
Another	  aspect	  that	  worth	  mentioning	  in	  this	  reaction	  is	  the	  choice	  of	  solvent.	  Ethyl	  acetate	  is	  a	  better	  
solvant	  than	  dichloromethane,	  which	  has	  been	  broadly	  used	  in	  phase	  transfer	  catalyzed	  reactions,	  be-­‐
cause	  a	  large	  proportions	  of the	  thiols	  reacted	  with	  dichloromethane	  to	  give	  products	  such	  as	  bis	  (4-­‐
nitrophenylthio)methane	  and	  lower	  the	  yield.	  (32)	  The	  2-­‐azido	  compound	  4	  was	  coupled	  with	  8-­‐chloro-­‐
1-­‐octyne	  through	  Cu(I)	  catalyzed	  “Click”	  reaction	  to	  form	  N-­‐linked	  compound	  5	  with	  almost	  quantitative	  
yield.	  CuI	  was	  slightly	  soluble	  in	  acetonitrile	  and	  could	  be	  easily	  removed	  through	  filtration	  after	  the	  re-­‐
action	  was	  complete.	  The	  chloride	  on	  the	  6-­‐carbon	  linker	  was	  converted	  to	  azide	  (compound	  6)	  then	  





























































Scheme	  2.2	  Synthesis	  of	  SC1	  (7)	  (a)	  (i)	  H+	  resin,	  MeOH,	  rt,	  48h,	  (ii)	  Ac2O,	  DMAP,	  pyridine,	  rt,	  
overnight,	  82%;	  (b)	  HCl(g),	  DCM,	  rt,	  8h,	  100%;	  (c)	  KSAc,	  TBAHS,	  NaHCO3/EtOAc(1:1),	  rt,	  10h,	  75%;	  (d)	  
NaN3,	  TBAHS,	  NaHCO3/EtOAc(1:1),	  rt,	  10h,	  83%;	  (e)	  8-­‐chloro-­‐1-­‐octyne,	  CuI,	  diisopropylethylamine,	  50oC,	  
MeCN,	  6h,	  98%;	  (f)	  NaN3,	  DMF,	  60oC,	  overnight,	  82%;	  (g)(i)	  0.5M	  NaOMe,	  MeOH,	  rt,	  7h,	  (ii)	  0.25M	  
NaOH(aq),	  8h;	  (h)	  H2,	  palladium	  hydroxide	  on	  carbon,	  EtOH,	  24h,	  52%.	  
	  
The	  synthesis	  of	  SC2	  was	  shown	  in	  scheme	  2.3.	  Our	  approach	  was	  to	  install	  the	  thiol	  group	  at	  
the	  3	  position	  on	  the	  galactose	  acceptor	  and	  react	  it	  with	  β-­‐chloro-­‐N-­‐acetylneuraminic	  acid	  2	  via	  a	  SN2	  
type	  reaction	  to	  obtain	  the	  desired	  disaccharide	  as	  the	  alternate	  strategy	  of	  introducing	  the	  thiol	  group	  
on	  the	  N-­‐acetylneuraminic	  acid	  and	  displacing	  a	  good	  leaving	  group	  on	  the	  galactoside	  acceptor	  leads	  to	  
side	  reactions,	  especially	  if	  the	  leaving	  group	  is	  on	  a	  secondary	  carbon.(33,	  34)	  The	  galactoside	  acceptor	  
14	  was	  converted	  from	  guloside	  13,	  which	  was	  synthesized	  from	  the	  known	  β-­‐galatoside	  derivative	  8	  
(35)	  through	  	  a	  number	  of	  protection/deprotection	  steps.	  8	  was	  selectively	  protected	  with	  4-­‐
methylbenzyl	  (PMB)	  through	  a	  two	  step	  reaction.	  The	  cis	  3-­‐	  and	  4-­‐OH	  were	  first	  temporarily	  protected	  
with	  dibutyltin	  oxide.	  The	  formation	  of	  the	  Sn-­‐O	  bonds	  enhanced	  the	  nucleophilicity	  of	  the	  oxygen	  at-­‐
om.	  The	  oxygen	  atom	  at	  the	  equatorial	  position	  was	  more	  nucleophilic	  and	  exclusively	  reacted	  with	  4-­‐
methylbenzylchloride,	  which	  was	  added	  stoichiometrically	  (1.2	  eq).	  Next,	  the	  4,6	  and	  the	  2	  hydroxyl	  
groups	  were	  protected	  in	  a	  one	  pot	  reaction	  using	  benzaldehyde	  dimethyl	  acetal	  and	  benzoyl	  chloride	  
respectively	  to	  yield	  10	  in	  appreciable	  yield.	  	  Conversion	  of	  the	  chloride	  to	  the	  azide	  was	  achieved	  using	  
sodium	  azide	  in	  a	  near	  quantitative	  yield.	  Selective	  removal	  of	  the	  PMB	  group	  through	  oxidative	  cleav-­‐
age	  by	  ceric	  ammonium	  nitrate	  (CAN)	  was	  followed	  by	  inversion	  of	  the	  3	  hydroxyl	  group	  from	  the	  equa-­‐
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torial	  to	  the	  axial	  position.	  Treating	  compound	  12	  first	  with	  triflic	  anhydride	  to	  active	  the	  hydroxyl	  group	  
and	  then	  inverting	  it	  using	  tetrabutyl	  ammonium	  nitrite	  at	  a	  slightly	  elevated	  temperature	  yielded	  gulo-­‐
side	  derivative	  13.	  We	  found	  that	  this	  reaction	  is	  not	  straightforward,	  specifically,	  the	  tetrabutylammo-­‐
nium	  nitrate	  has	  to	  be	  completely	  oxygen	  and	  moisture	  free,	  else	  the	  compound	  reverts	  to	  the	  galacto-­‐
side	  derivative	  12.	  Activation	  of	  the	  axial	  hydroxyl	  using	  triflic	  anhydride,	  followed	  by	  SN2	  type	  substitu-­‐
tion	  by	  potassium	  thioacetate	  resulted	  in	  the	  desired	  installation	  of	  the	  thiol	  group	  on	  the	  3	  position	  of	  
the	  galactoside	  derivative	  14.	  Selective	  removal	  of	  the	  acetate	  in	  14	  using	  hydrazinium	  acetate	  was	  fol-­‐
lowed	  by	  reaction	  with	  the	  N-­‐acetylneuraminic	  acid	  chloride	  derivative	  2	  in	  the	  presence	  of	  a	  commer-­‐
cial	  cryptand	  to	  yield	  the	  2,3	  S-­‐linked	  derivative	  15,	  in	  reasonable	  yield.	  The	  product	  was	  confirmed	  by	  
NMR	  and	  mass	  spectroscopic	  analysis;	  the	  hydrogen	  and	  the	  carbon	  at	  the	  3	  position	  of	  galactose	  reso-­‐
nated	  at	  4.60	  and	  101.0	  ppm,	  respectively,	  and	  the	  anomeric	  carbon	  of	  sialic	  acid	  resonated	  at	  96.6	  
ppm.	  	  After	  removal	  of	  the	  benzylidene	  group,	  deprotection	  of	  the	  acetate,	  benzoyl	  and	  ester	  functional	  
groups	  in	  15	  under	  basic	  conditions,	  followed	  by	  hydrogenation	  of	  the	  azide	  yielded	  the	  desired	  2,3	  S-­‐
sialoside	  glycoconjugate	  SC2	  with	  a	  pendant	  amine	  for	  conjugation	  to	  activated	  carboxyl	  acid	  surfaces.	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Scheme	  2.3	  Synthesis	  of	  Sc2 (17) (a)	  (i)	  Bu2SnO,	  MeOH,	  reflux,	  8h,	  (ii)	  PMBCl,	  Bu4NBr,	  toluene,	  
70oC,	  8h,	  80%;	  (b)	  (i)benzaldehyde	  dimethyl	  acetal,	  p-­‐TSA,	  MeCN,	  rt,	  5min,	  (ii)	  BzCl,	  pyridine,	  rt,	  8h,	  70%;	  
(c)	  NaN3,	  DMF,	  60oC,	  100%;	  (d)	  CAN,	  MeCN/H2O(16:1),	  rt,	  30min,	  68%;	  (e)	  (i)	  Tf2O,	  pyridine,	  DCM,	  -­‐25oC,	  
25min,	  (ii)	  Bu4NNO2,	  MeCN,	  50oC,	  overnight,	  70%;	  (f)	  (i)	  Tf2O,	  pyridine,	  DCM,	  -­‐25oC	  to	  rt,	  90min,	  (ii)	  KSAc,	  
DMF,	  60oC	  ,	  overnight,	  84%;	  (g)	  (i)	  hydrazinium	  acetate,	  DMF,	  rt,	  2h,	  (ii)	  NaH,	  DMF,	  then	  2,	  Kryptofix	  21,	  
rt;	  (h)	  80%	  AcOH(aq),	  45oC,	  overnight,	  32%	  over	  3	  steps;	  (i)	  (i)	  0.5M	  NaOMe,	  MeOH,	  rt,	  overnight,	  (ii)	  
0.25M	  NaOH(aq),	  8h;	  (j)	  H2,	  palladium	  hydroxide	  on	  carbon,	  EtOH,	  48h,	  70%.	  
	  
The	  synthesis	  of	  SC3	  has	  been	  previously	  reported.	  (36)The	  synthesis	  of	  SC4	  (23)	  and	  SC5	  were	  
shown	  in	  scheme	  4	  and	  5,	  respectively.	  Through	  proper	  protection/deprotection	  strategy,	  the	  free	  hy-­‐
droxyl	  group	  at	  3	  or	  6	  position	  was	  reacted	  with	  propargyl	  chlororide	  and	  yielded	  propargylated	  com-­‐
pounds	  20	  and	  27	  respectively.	  The	  “click”	  reactions	  resulted	  in	  the	  formation	  of	  the	  triazole	  linkage	  
were	  done	  under	  the	  same	  condition	  as	  the	  synthesis	  of	  SC1.	  Deprotection	  and	  convertion	  of	  azide	  to	  



























































































Scheme	  2.4	  Synthesis	  of	  SC4	  (23)	  (a)	  BnBr,	  NaH,	  THF,	  reflux,	  6h,	  83%;	  (b)	  CAN,	  MeCN/H2O(16:1),	  
rt,	  2h,	  55%;	  (c)	  propargyl	  bromide,	  NaH,	  THF,	  60oC,	  3h,	  75%;	  (d)	  4,	  CuI,	  diisopropylethylamine,	  MeCN,	  rt,	  
91%;	  (e)	  NaN3,	  DMF,	  60oC,	  overnight,	  58%;	  (f)	  (i)	  0.5M	  NaOMe,	  MeOH,	  rt,	  overnight,	  (ii)	  	  0.25M	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Scheme	  2.5	  Synthesis	  of	  SC5	  (30)	  (a)	  (i)	  Bu2SnO,	  MeOH,	  reflux,	  8h,	  (ii)	  TBDMSCl,	  toluene,	  100oC,	  
6h,	  63%;	  (b)	  BnBr,	  NaH,	  THF,	  reflux,	  6h,	  73%;	  (c)	  I2,	  MeOH,	  reflux,	  3h,	  72%;	  (d)	  propargyl	  bromide,	  NaH,	  
THF,	  60oC,	  17h,	  83%;	  (e)	  4,	  CuI,	  diisopropylethylamine,	  MeCN,	  rt,	  91%;	  (f)	  NaN3,	  DMF,	  60oC,	  overnight,	  
50%;	  (g)	  (i)	  0.5M	  NaOMe,	  MeOH,	  rt,	  overnight,	  (ii)	  0.25M	  NaOH(aq),	  8h;	  (h)	  H2,	  palladium	  hydroxide	  on	  
carbon,	  EtOAc/EtOH(1:1),	  48h,	  60%.	  
	  
The	  synthesis	  of	  C-­‐linked	  sialosides	  (SC6-­‐8)	  was	  performed	  by	  Dr.	  Yang	  Yang,	  a	  postdoctoral	  fel-­‐
low	  in	  our	  laboratories.	  The	  detailed	  procedure	  is	  not	  discussed	  in	  the	  dissertation.	  	  
2.2.2 Glycan	  microarray	  fabrication	  
With	  the	  sialosides	  in	  hand,	  we	  first	  immobilized	  them	  on	  standard	  ELISA	  plate	  with	  maleimide	  
coated	  wells	  and	  tested	  the	  binding	  ability	  toward	  recombinant	  HA	  proteins,	  as	  described	  by	  our	  group	  
previously.(35)	  Unfortunately,	  despite	  several	  efforts	  that	  included	  a	  variety	  of	  blocking	  methods	  and	  
using	  ELISA	  plates	  from	  different	  manufacturers,	  we	  found	  that	  the	  non-­‐specific	  binding	  were	  substan-­‐
tial,	  therefore	  most	  of	  the	  binding	  signals	  were	  buried	  in	  the	  noise.	  Also,	  we	  were	  consuming	  significant	  
amount	  of	  material	  for	  a	  single	  assay.	  For	  instance,	  a	  minimum	  of	  30	  μg	  of	  compounds	  were	  required	  in	  
a	  single	  well	  (based	  on	  the	  minimum	  coating	  concentration	  of	  750	  μM	  volume	  of	  100	  μl)	  and	  90	  μg	  for	  
58 
one	  target	  protein	  (triplicate	  is	  the	  minimum	  requirement	  for	  ELISA	  assay).	  To	  overcome	  this	  problem,	  
we	  switched	  to	  microarray	  technology,	  which	  utilizes	  a	  miniature	  version	  of	  ELISA	  plate:	  microscope	  
glass	  slide.	  	  The	  robotic	  printing	  technique	  is	  automatic,	  and	  most	  important,	  highly	  economic	  consider-­‐
ing	  the	  consumption	  of	  precious	  glycans.	  The	  pin	  of	  the	  robotic	  microarray	  printer	  withdraws	  only	  ~0.6	  
μl	  of	  glycan	  solution	  and	  prints	  up	  to	  8	  replicate	  spots.	  (according	  to	  microarray	  printer	  manual)	  	  	  
Since	  our	  compounds	  all	  possess	  primary	  amine	  on	  the	  terminal	  of	  the	  linker,	  we	  chose	  slides	  
that	  were	  prefabricated	  with	  PEG	  and	  N-­‐hydroxysuccinimide	  (NHS)	  activated	  carboxyl	  groups.	  The	  hy-­‐
drophilic	  long	  chain	  of	  PEG	  can	  significanlly	  decrease	  non-­‐specific	  binding	  and	  the	  activated	  ester	  is	  
ready	  to	  react	  with	  amine	  to	  form	  amide	  bond	  under	  neutral	  or	  mild	  basic	  conditions.	  In	  printing	  condi-­‐
tion	  optimization	  study	  (data	  not	  shown),	  we	  printed	  amine-­‐functionalized	  mannoside	  at	  different	  con-­‐
centrations	  under	  different	  pHs	  (5.5,	  7.4	  and	  8.4)	  and	  incubated	  with	  Alexa	  Fluor@633	  labeled	  lectin	  
Concanavalin	  A	  (ConA)	  to	  find	  out	  the	  optimal	  printing	  condition.	  	  We	  found	  that	  when	  the	  printing	  was	  
done	  under	  pH	  8.4,	  the	  binding	  of	  mannoside	  to	  ConA	  was	  significant	  even	  at	  a	  printing	  concentration	  of	  
6.25	  μM.	  At	  pH	  7.4,	  a	  minimum	  of	  12.5	  μM	  mannoside	  solution	  was	  required	  for	  printing.	  While	  at	  pH	  
5.5,	  the	  printing	  was	  much	  less	  efficient.	  We	  found	  that	  a	  glycan	  concentration	  of	  200	  μM	  provides	  an	  
excellent	  signal	  to	  noise	  ratio	  and	  we	  used	  that	  concentration	  for	  all	  our	  studies.	  	  A	  systematic	  study	  
that	  correlated	  the	  printing	  concentration	  and	  surface	  saturation	  also	  supported	  our	  findings.	  Liang	  et	  
al.(37)	  used	  fluorescein	  isothiocyanate	  (FITC)	  cadaverine,	  a	  fluorescent	  dye	  as	  model	  molecule	  and	  
printed	  it	  in	  concentrations	  ranging	  from	  100	  mM	  to	  1	  fM	  on	  the	  same	  commercial	  available	  NHS-­‐ester	  
slide	  that	  we	  used.	  They	  scanned	  the	  slide	  before	  and	  after	  washing	  and	  measured	  the	  surface	  coverage	  
of	  FITC.	  They	  found	  that	  at	  concentrations	  below	  100	  μM,	  the	  fraction	  of	  surface	  coverage	  increased	  as	  
the	  concentration	  increased,	  whereas	  the	  surface	  saturated	  over	  500	  μM.	  The	  density	  of	  maximum	  load-­‐
ing	  was	  found	  to	  be	  1014	  molecules/cm2,	  which	  was	  similar	  to	  most	  peptides	  or	  sugars	  attached	  to	  an	  
SPR	  biosensor	  surface.	  (38,	  39)	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2.2.3 Lectin	  and	  HA	  binding	  study	  
After	  the	  printing	  was	  complete,	  we	  tested	  the	  binding	  of	  sialosides	  with	  lectins	  that	  are	  known	  
to	  bind	  to	  terminal	  sialic	  acid.	  The	  first	  lectin	  we	  tested	  was	  Wheat	  germ	  agglutinin	  (WGA),	  which	  
showed	  binding	  to	  N-­‐acetylglucosamine	  and	  N-­‐acetylneuraminic	  acid	  (sialic	  acid)	  in	  previous	  studies.	  
(40,	  41)	  An	  NMR	  binding	  study	  showed	  that	  WGA	  preferred	  the	  α-­‐2,	  3	  over	  α-­‐2,	  6-­‐linkage	  when	  bound	  
to	  sialic	  acid	  (KD	  =	  0.73mM	  with	  α-­‐2,	  3-­‐sialyllactose;	  KD	  =	  5.3mM	  with	  α-­‐2,	  6-­‐sialyllactose).	  (40)	  The	  bind-­‐
ing	  profile	  of	  WGA	  on	  our	  sialoside	  microarray	  is	  shown	  in	  figure	  2.3A.	  In	  accordance	  with	  the	  NMR	  
binding	  study,	  WGA	  showed	  moderate	  binding	  to	  SC9	  (α-­‐O-­‐2,	  3-­‐sialyllactoside)	  while	  very	  weak	  binding	  
to	  SC10	  (α-­‐O-­‐2,	  6-­‐sialyllactoside).	  A	  similar	  binding	  preference	  was	  also	  seen	  with	  the	  thiosialoside	  pair:	  
WGA	  showed	  highest	  binding	  to	  SC2	  (α-­‐S-­‐2,	  3-­‐sialylgalactoside)	  among	  all	  ten	  sialosides,	  whereas	  only	  
moderate	  binding	  to	  SC3	  (α-­‐S-­‐2,	  6-­‐sialylgalactoside).	  This	  results	  indicated	  that	  the	  replacement	  of	  O-­‐	  
with	  S-­‐	  did	  not	  change	  the	  conformation	  of	  glycans	  to	  the	  extend	  that	  could	  alter	  the	  WGA	  binding	  spec-­‐
ificity.	  On	  the	  contrary,	  this	  binding	  preference	  of	  WGA	  was	  not	  observed	  when	  bound	  to	  N-­‐linked	  sialo-­‐
sides.	  In	  fact,	  both	  SC4	  and	  SC5	  showed	  only	  weak	  to	  moderate	  binding	  to	  WGA,	  which	  might	  be	  result-­‐
ed	  from	  the	  conformational	  change	  induced	  by	  the	  insertion	  of	  a	  rigid	  ring	  to	  replace	  glycosidic	  bond.	  
Moderate	  to	  strong	  binding	  were	  observed	  with	  the	  two	  N-­‐	  and	  C-­‐linked	  monosaccharides	  SC1	  and	  SC6	  
and	  C-­‐linked	  trisaccharide	  SC8,	  while	  binding	  to	  C-­‐linked	  disaccharide	  SC7	  was	  hardly	  seen.	  
We	  also	  obtained	  the	  binding	  profile	  of	  three	  other	  lectins	  that	  have	  been	  reported	  to	  bound	  to	  
sialic	  acid,	  including	  Sambucus	  nigra	  agglutinin	  (SNA)	  (Figure	  2.3B),	  Maackia	  amurensis	  leukoagglutinin	  
(MAL-­‐I)	  and	  M.	  amurensis	  hemagglutinin	  (MAL-­‐II)	  (Figure	  2.3D).	  SNA	  was	  first	  reported	  to	  bind	  to	  D-­‐
galactose	  and	  N-­‐acetylgalatosamine,	  and	  then	  was	  found	  to	  be	  capable	  of	  recognizing	  terminal	  sialic	  
acid,	  preferably	  with	  α-­‐2,	  6-­‐linkage.(42)	  We	  observed	  the	  highest	  binding	  was	  with	  SC10	  (α-­‐O-­‐2,	  6-­‐
sialyllactoside)	  while	  significant	  binding	  to	  SC9	  (α-­‐O-­‐2,	  3-­‐sialyllactoside)	  was	  also	  seen.	  The	  binding	  of	  
SC3	  (α-­‐S-­‐2,	  6-­‐sialylgalactoside)	  was	  also	  strong,	  compared	  to	  its	  α-­‐S-­‐2,	  3-­‐linked	  analogue	  SC2.	  Similar	  to	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WGA,	  SNA	  also	  showed	  moderate	  binding	  to	  the	  N-­‐linked	  monosaccharides	  SC1,	  but	  did	  not	  bind	  well	  
with	  N-­‐linked	  disaccharides	  and	  all	  three	  C-­‐linked	  sialosides.	  MAL-­‐I	  and	  MAL-­‐II	  showed	  very	  weak	  bind-­‐
ing	  to	  S-­‐	  and	  N-­‐linked	  sialosides	  while	  weak	  to	  moderate	  binding	  to	  O-­‐	  and	  C-­‐linked	  sialosides	  depending	  
on	  the	  structures.	  	  
Next	  we	  incubated	  the	  microarray	  slide	  with	  influenza	  hemagluttinin	  (HA)	  H1N1	  
A/Brisbane/59/2007,	  which	  was	  premixed	  with	  primary	  and	  secondary	  antibodies	  in	  the	  ratio	  of	  4:2:1.	  
We	  observed	  binding	  signals	  from	  SC7,	  SC9	  and	  SC10,	  but	  not	  the	  rest	  of	  the	  sialosides	  (Figure	  2.3C).	  
Combining	  the	  results	  from	  WGA	  (WGA	  bound	  to	  all	  sialosides	  except	  SC7	  and	  SC10	  in	  moderate	  to	  high	  
level)	  and	  HA	  binding	  studies,	  we	  concluded	  that	  all	  ten	  sialosides	  were	  immobilized	  on	  the	  slide.	  
	  
Figure	  2.2	  Lectin	  and	  HA	  protein	  binding	  profile	  on	  sialoside	  microarray.	  Microarray	  was	  incu-­‐
bated	  with	  (A)	  Rhodamine	  labeled	  WAG	  (100μg/ml).	  	  (B)	  Biotinylated	  SNA	  (100μg/ml)	  then	  rhodamine	  
labeled	  streptavidin	  (C)	  Recombinant	  HA	  protein	  of	  H1N1	  A/Brisbane/59/2007	  (100μg/ml)	  premixed	  
with	  anti-­‐H1	  rabbit	  polyclonal	  antibody	  and	  Alexa	  Fluor®633	  labeled	  goat	  anti	  rabbit	  secondary	  antibody	  
(4:2:1).	  	  (D)	  Biotinylated	  MAL-­‐I	  and	  MAL-­‐II	  (100μg/ml)	  then	  rhodamine	  labeled	  streptavidin.	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2.2.4 NA	  resistance	  assay	  
Next,	  we	  compared	  the	  stability	  of	  sialosides	  with	  different	  linkages	  towards	  NA	  to	  evaluate	  the	  
feasibility	  of	  using	  the	  microarray	  to	  detect	  virus	  at	  ambient	  temperature	  without	  adding	  NA	  inhibitors.	  
We	  first	  treated	  the	  slide	  with	  H1N1	  NA	  at	  rt	  for	  2h	  and	  then	  incubated	  it	  with	  either	  fluorescent	  labeled	  
WGA	  or	  HA	  (A/Brisbane/59/2007),	  which	  were	  premixed	  with	  primary	  and	  labeled	  secondary	  antibod-­‐
ies.	  The	  WGA	  binding	  profile	  before	  and	  after	  NA	  treatment	  of	  the	  printed	  slide	  is	  shown	  in	  Figure	  2.4A.	  
Through	  the	  side-­‐to-­‐side	  comparison,	  we	  can	  clearly	  see	  that	  the	  binding	  of	  WGA	  to	  S-­‐,	  and	  N-­‐linked	  si-­‐
alosides	  (SC1-­‐SC5)	  is	  almost	  unchanged,	  indicating	  NA	  did	  not	  hydrolyze	  these	  sialosides.	  We	  also	  still	  
see	  the	  binding	  signal	  for	  SC9	  after	  NA	  treatment,	  which	  was	  expected	  to	  be	  hydrolyzed	  by	  NA.	  One	  pos-­‐
sible	  reason	  is	  that	  the	  WGA	  can	  bind	  to	  the	  residual	  lactoside	  on	  the	  microarray	  after	  the	  NA	  cleaves	  
the	  terminal	  O-­‐linked	  sialic	  acid.	  However,	  when	  HA	  (A/Brisbane/59/2007)	  is	  used	  (Figure	  2.4B),	  we	  see	  
that	  the	  signal	  of	  SC9,	  the	  α-­‐2,	  3-­‐O-­‐linked	  sialoside,	  is	  completely	  lost,	  which	  is	  a	  clear	  indication	  that	  the	  
viral	  NA	  cleaves	  α-­‐2,	  3-­‐O-­‐linkages	  very	  efficiently	  even	  when	  present	  on	  a	  solid	  surface.	  In	  contrast,	  the	  
signal	  of	  the	  C-­‐sialoside	  SC7	  binding	  remained	  unchanged.	  The	  signal	  intensity	  of	  the	  α-­‐2,	  6-­‐O-­‐linked	  si-­‐
aloside,	  SC10	  decreases	  slightly,	  but	  is	  not	  completely	  lost	  as	  seen	  with	  α-­‐2,	  3-­‐O-­‐linked	  sialoside	  SC9.	  
Increasing	  the	  NA	  incubation	  time	  doesn’t	  produce	  a	  different	  result,	  we	  observed	  similar	  fluorescent	  
readings	  (data	  not	  shown),	  indicating	  that	  the	  α-­‐2,	  3-­‐O-­‐linked	  sialoside	  is	  cleaved	  more	  rapidly	  than	  α-­‐2,	  
6-­‐O-­‐linked	  sialoside.	  A	  NA	  substrate	  specificity	  study	  also	  shows	  similar	  result.	  (43)	  Li	  et	  al.	  screened	  the	  
substrate	  specificity	  of	  27	  NAs	  (N1-­‐N9),	  including	  both	  human	  and	  avian	  viral	  NA	  using	  a	  colorimetric	  
assay	  with	  1h	  duration	  of	  hydrolysis.	  They	  found	  that	  α-­‐2,	  3-­‐linked	  sialosides	  were	  hydrolyzed	  more	  effi-­‐
cient	  than	  α-­‐2,	  6-­‐linked	  sialosides	  in	  solution	  toward	  all	  NAs.	  When	  assuming	  the	  standard	  compound	  
Siaα2	  −	  3GalβpNP(NP:	  	  para-­‐nitrophenol)	  was	  completely	  hydrolyzed	  during	  the	  assay,	  only	  40%	  or	  less	  
of	  Siaα2	  −	  6GalβpNP	  was	  cleaved	  off	  by	  most	  NAs.	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Figure	  2.3	  Stability	  comparison	  of	  sialosides	  with	  S-­‐,	  N-­‐,	  C-­‐	  and	  O-­‐linkages	  towards	  NA.	  (A)	  Rho-­‐
damine	  labeled	  WAG	  (100μg/ml)	  (Green);	  First	  NA	  (N1,	  3.3	  U,	  1U=1,000	  pmol/min),	  then	  rhodamine	  
labeled	  WAG	  (100μg/ml)	  (Red).	  (B)	  H1	  (100μg/ml)	  premixed	  with	  anti-­‐H1	  rabbit	  polyclonal	  antibody	  and	  
Alexa	  Fluor®633	  labeled	  goat	  anti	  rabbit	  secondary	  antibody	  (4:2:1)(Green);	  First	  NA	  (N1,	  3.3	  U,	  
1U=1,000	  pmol/min),	  then	  H1-­‐antibody	  complex	  (Red).	  All	  experiments	  were	  performed	  in	  triplicate	  on	  
three	  different	  days.	  Error	  bars	  represent	  mean	  ±	  SEM	  of	  three	  independent	  experiments.	  
	  
To	  understand	  this	  behavior,	  we	  performed	  molecular	  modeling	  studies.	  The	  crystal	  structures	  
of	  1,	  3-­‐sialyllactose	  and	  6-­‐siallylactose	  were	  downloaded	  from	  PDB	  and	  Sybyl-­‐X®	  was	  used	  for	  docking	  
studies.	  3-­‐sialyllactose	  and	  6-­‐sialyllactose	  was	  fitted	  into	  the	  known	  sialic	  acid	  binding	  pocket	  of	  N1.	  
(Figure	  2.5)	  Eight	  amino	  acids	  of	  NA	  have	  direct	  interactions	  with	  sialic	  acid	  in	  the	  binding	  pocket	  and	  
two	  of	  them	  Asp151	  and	  Tyr406	  function	  as	  the	  acid	  and	  base	  in	  the	  catalytic	  process.	  As	  can	  be	  seen	  in	  
the	  two	  structures,	  the	  distance	  between	  the	  glycosidic	  oxygen	  of	  3-­‐sialyllactose	  with	  the	  key	  amino	  ac-­‐
id,	  Asp151	  (3.741	  A)	  is	  smaller	  than	  that	  with	  6-­‐sialyllactose	  (4.042	  A);	  meanwhile,	  the	  distance	  between	  
the	  anomeric	  carbon	  of	  3-­‐sialyllactose	  with	  Tyr406	  (3.778	  A)	  is	  also	  smaller	  than	  that	  with	  6-­‐sialyllactose	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(5.007	  A),	  suggesting	  that	  the	  2,3	  O-­‐sialosides	  provides	  a	  better	  fit	  for	  the	  hydrolysis	  as	  opposed	  to	  the	  
2,6	  O-­‐linkages.	  The	  longer	  hydrolysis	  time	  of	  2,6	  O-­‐linked	  sialosides	  could	  potentially	  be	  exploited	  in	  the	  
development	  of	  multivalent	  inhibitors	  of	  certain	  influenza	  types,	  which	  prefer	  2,6	  O-­‐linkages.	  
	  
Figure	  2.4	  Molecular	  modeling	  of	  influenza	  N1	  bound	  to	  (A)	  2,3-­‐sialyllactose	  and	  (B)	  2,6-­‐
sialyllactose	  using	  SYBYL-­‐X®.	  The	  2,3	  linkage	  is	  a	  better	  fit	  than	  the	  2,6	  linkage.	  	  
	  
Acknowledging	  that	  S-­‐,	  N-­‐	  and	  C-­‐linked	  sialosides	  are	  resistant	  to	  NA	  hydrolysis,	  we	  also	  want	  to	  
demonstrate	  the	  stability	  of	  these	  sialosides	  toward	  intact	  influenza	  viruses	  in	  comparison	  to	  O-­‐linked	  
sialosides.	  The	  approach	  we	  adopted	  was	  different	  then	  the	  NA	  hydrolysis	  study	  because	  intact	  virus	  has	  
more	  complex	  structure	  (HA	  and	  NA	  present	  at	  the	  same	  time)	  and	  binding	  behavior	  compared	  to	  re-­‐
combinant	  enzyme	  NA.	  Instead	  of	  detecting	  the	  binding	  signal	  of	  influenza	  virus,	  we	  designed	  an	  exper-­‐
iment	  that	  detects	  the	  residue	  after	  hydrolysis.	  Take	  SC9	  for	  instance,	  if	  the	  terminal	  sialic	  acid	  is	  cleaved	  
off,	  the	  remaining	  residue	  would	  be	  lactoside,	  which	  can	  be	  detected	  by	  lectin	  Ricinus	  Communis	  Agglu-­‐
tinin-­‐120	  (RCA-­‐120).	  We	  included	  amine	  functionalized	  N-­‐acetylgalactoside	  as	  a	  positive	  control	  on	  the	  
printed	  slide	  as	  well	  as	  SC8	  (C-­‐linkage)	  and	  SC9	  (O-­‐linkage)	  for	  direct	  comparison.	  First	  we	  incubated	  the	  
printed	  slide	  with	  two	  strains	  of	  influenza	  viruses	  (H1N1:	  A/Solomon	  Island/3/06;	  H3N2	  
A/Hongkong/8/68)	  at	  pH	  5.5,	  37oC	  for	  4h	  to	  ensure	  a	  complete	  cleavage.	  Then	  we	  incubated	  the	  virus-­‐
treated	  slide	  with	  biotinylated	  RCA120	  followed	  by	  rhodamine	  labeled	  streptavidin.	  The	  binding	  result	  is	  
shown	  in	  Figure	  2.6.	  Neither	  SC8	  or	  SC9	  shows	  binding	  to	  RCA120	  before	  treated	  with	  intact	  influenza	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viruses.	  However,	  SC9	  shows	  significant	  binding	  signal	  after	  incubated	  with	  H1N1	  virus,	  whereas	  SC8	  still	  
don’t	  show	  binding.	  This	  results	  indicate	  that	  the	  O-­‐linked	  SC9	  was	  hydrolyzed	  by	  virus	  while	  SC8	  re-­‐
mained	  intact.	  The	  binding	  signal	  of	  SC9	  to	  RCA120	  after	  treated	  with	  H3N2	  virus	  is	  lower,	  indicating	  
that	  the	  hydrolysis	  is	  not	  complete.	  
	  
Figure	  2.5	  Stability	  comparison	  of	  sialosides	  with	  C-­‐	  and	  O-­‐linkages	  towards	  intact	  influenza	  vi-­‐
ruses.	  	  	  Printed	  slide	  was	  first	  incubated	  with	  influenza	  virus	  (A/Solomon	  Island/3/2006	  2X103	  PFU	  or	  
A/Hongkong/8/68	  8X102	  PFU)	  at	  37oC,	  pH	  5.5	  for	  4h,	  then	  biotinylated	  RCA120	  and	  finally	  rhodamine	  
labeled	  streptavidin.	  
	  
2.2.5 Virus	  binding	  and	  detection	  sensitivity	  assay	  
Having	  demonstrated	  the	  stability	  of	  S-­‐,	  N-­‐	  and	  C-­‐linked	  sialosides	  toward	  viral	  NA	  and	  intact	  in-­‐
fluenza	  viruses,	  we	  wanted	  to	  test	  their	  capturing	  ability	  of	  influenza	  viruses.	  Without	  premixing	  with	  NA	  
inhibitors,	  we	  introduced	  BLP	  (betapropiolactone)	  inactivated	  influenza	  virus	  A/Puerto	  Rico/8/34	  (BEI	  
resources)	  at	  different	  concentrations	  to	  the	  printed	  slides,	  incubated	  at	  rt	  for	  1	  h,	  followed	  by	  incuba-­‐
tion	  of	  primary	  and	  fluorescently	  labeled	  rhodamine	  secondary	  antibody.	  This	  was	  followed	  by	  scanning	  
the	  slides	  using	  a	  Genepix	  scanner	  at	  635	  nm.	  The	  fluorescence	  image	  shows	  that	  all	  eight	  sialosides	  
captured	  the	  virus.	  (Figure	  2.7A)	  We	  found	  non-­‐specific	  binding	  is	  negligent	  to	  the	  control	  PEG	  ligand.	  
We	  observe	  differential	  binding	  to	  the	  different	  glycans,	  the	  N-­‐linked	  sialosides	  seems	  to	  bind	  with	  a	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higher	  affinity	  than	  the	  C-­‐	  or	  S-­‐	  linked	  sialosides.	  (Figure	  2.7B).	  	  Next,	  we	  determined	  the	  binding	  pattern	  
of	  a	  different	  influenza	  strain	  A/Brisbane/59/2007	  (BEI	  resources).	  As	  seen	  in	  Figure	  2.7D,	  the	  binding	  
pattern	  is	  markedly	  different	  for	  this	  strain.	  Finally,	  we	  wanted	  to	  find	  the	  limit	  of	  detection	  by	  using	  
different	  concentrations	  of	  the	  virus.	  We	  choose	  SC5	  and	  we	  were	  excited	  to	  observe	  that	  we	  can	  detect	  
the	  virus	  at	  a	  concentration	  as	  low	  as	  35	  CEID50	  (Chicken	  Embryo	  Infectious	  Dose).	  	  	  
	  
Figure	  2.6	  Influenza	  virus	  binding	  studies.	  (A)	  Fluorescence	  image	  of	  microarray	  containing	  8	  si-­‐
alosides	  (SC1-­‐SC8),	  which	  was	  incubated	  with	  virus	  A/Puerto	  Rico/8/34	  of	  3.5	  X103	  CEID50,	  then	  poly-­‐
clonal	  anti-­‐influenza	  virus	  A/Puerto	  Rico/8/34	  rooster	  antiserum,	  detected	  by	  Alexa	  Fluor®633	  labeled	  
goat	  anti-­‐chicken	  IgG.	  (B)	  Finger	  print	  binding	  pattern	  of	  virus	  A/Puerto	  Rico/8/34	  of	  3.5	  X	  103	  CEID50.	  
(C)	  SC5	  binds	  to	  virus	  of	  different	  titers.	  (D)	  Finger	  print	  binding	  pattern	  of	  influenza	  A/Brisbane/59/2007	  
of	  3.1	  X103	  CEID50.	  The	  binding	  virus	  was	  detected	  by	  ferret	  hyperimmune	  sera	  to	  influenza	  
A/Brisbane/59/2007	  and	  rhodamine	  labeled	  goat	  anti-­‐ferret	  IgG.	  	  Error	  bars	  represent	  mean	  ±standard	  
error	  of	  three	  independent	  experiments.	  Statistical	  analysis	  using	  a	  student	  t-­‐test	  was	  performed	  com-­‐
paring	  the	  binding	  ability	  of	  each	  ligand.	  Ligands	  were	  separated	  into	  four	  groups,	  that	  includes	  *,**	  	  
and	  ***	  	  groups	  and	  there	  were	  no	  statistical	  differences	  between	  each	  group	  (P	  >	  0.05).	  	  	  #,	  significantly	  
reduced	  binding	  compared	  to	  *	  group	  (P	  <	  0.0005);	  	  ##,	  significantly	  reduced	  binding	  of	  the	  *	  group	  
compared	  to	  **	  group	  (P	  <	  0.005);	  	  ###,	  significantly	  reduced	  binding	  of	  the	  **	  group	  compared	  to	  ***	  
group	  (P	  <	  0.05).	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With	  2	  strains	  of	  influenza	  viruses	  showing	  different	  binding	  patterns	  to	  our	  microarray,	  we	  
wanted	  to	  expand	  our	  scope	  of	  detection.	  We	  used	  active	  viruses	  cultured	  from	  MDCK	  cell	  instead	  of	  
the	  BLP	  inactivated	  viruses	  originated	  from	  chicken	  embryo	  to	  eliminate	  the	  possible	  interference	  of	  BLP	  
in	  the	  binding	  pattern.	  The	  virus	  titer	  was	  measured	  by	  plaque	  forming	  assay,	  therefore	  we	  used	  plaque-­‐
forming	  unit	  (PFU)	  as	  the	  titer	  unit.	  The	  six	  strains	  we	  tested	  include	  five	  H1N1	  and	  one	  H3N2	  viruses	  
and	  the	  titer	  of	  these	  strains	  were	  adjusted	  to	  3X104	  PFU/ml	  before	  incubation	  with	  the	  printed	  slide.	  
The	  binding	  profiles	  are	  shown	  in	  Figure	  2.8.	  Even	  with	  expanded	  target	  range,	  we	  still	  observed	  unique	  
binding	  pattern	  of	  every	  strain.	  This	  reinforces	  our	  previous	  statement	  that	  every	  virus	  type	  should	  ex-­‐
hibit	  differences	  in	  binding	  to	  different	  sialoside	  structures	  glycans	  leading	  to	  a	  “fingerprint”	  pattern	  of	  
recognition	  for	  all	  strains,	  including	  emerging	  strains.	  Interestingly,	  we	  also	  observed	  different	  binding	  
patterns	  of	  the	  same	  strain	  from	  different	  cultures	  (chicken	  embryo	  vs	  MDCK	  cell),	  which	  also	  under-­‐
went	  different	  treatment	  (BLP	  inactivation	  vs	  no	  inactivation)(Figure	  2.7B	  and	  Figure	  2.8A).	  A	  detailed	  
study	  analyzing	  the	  impact	  of	  different	  inactivation	  protocols	  on	  the	  NA	  and	  HA	  activity	  of	  influenza	  vi-­‐
ruses	  have	  shown	  that	  16h	  of	  BLP	  treatment	  of	  a	  H3N2	  strain	  A/Wisconsin/67/2005	  resulted	  in	  over	  
90%	  loss	  in	  the	  HA	  titer.(44)	  Since	  HA	  is	  the	  key	  element	  in	  the	  binding	  event,	  the	  change	  in	  HA	  titer	  can	  
lead	  to	  alteration	  of	  the	  binding	  pattern.	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Figure	  2.7	  Binding	  profiles	  of	  different	  strains	  of	  MDCK	  cell	  adapted	  influenza	  viruses.	  	  
2.3 Experimental	  section	  
2.3.1 Materials	  
All	  chemical	  reagents	  were	  of	  analytical	  grade,	  used	  as	  supplied	  without	  further	  purification	  un-­‐
less	  indicated.	  The	  acidic	  ion-­‐exchange	  resin	  used	  was	  Dowex-­‐50	  and	  Amberlite	  (H+	  form).	  	  Analytical	  
thin	  layer	  chromatography	  (TLC)	  was	  conducted	  on	  silica	  gel	  60-­‐F254	  (Merck).	  Plates	  were	  visualized	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under	  UV	  light,	  and/or	  by	  treatment	  with	  acidic	  cerium	  ammonium	  molybdate	  followed	  by	  heating.	  Col-­‐
umn	  chromatography	  was	  conducted	  using	  silica	  gel	  (230-­‐400	  mesh)	  from	  Qualigens.	  	  1H	  and	  13C	  NMR	  
spectra	  were	  recorded	  on	  Bruker	  AMX	  400MHz	  spectrometer.	  Chemical	  shifts	  are	  reported	  in	  δ	  (ppm)	  
units	  using	  13C	  and	  residual	  1H	  signals	  from	  deuterated	  solvents	  as	  references.	  Spectra	  were	  analyzed	  
with	  Mest-­‐Re-­‐C	  Lite	  (Mestrelab	  Research)	  and/or	  iNMR.	  Electrospray	  ionization	  mass	  spectra	  were	  rec-­‐
orded	  on	  a	  Micromass	  Q	  Tof	  2	  (Waters)	  and	  data	  were	  analyzed	  with	  MassLynx	  4.0	  (Waters)	  software.	  
2.3.2 Synthesis	  procedure	  and	  compound	  characterization	  
Methyl	  5-­‐Acetamido-­‐4,7,8,9-­‐tetra-­‐O-­‐acetyl-­‐3,5-­‐dideoxy-­‐2-­‐[4-­‐(6-­‐chlorohexyl)-­‐1H-­‐1,2,3-­‐triazol-­‐
1-­‐yl]-­‐D-­‐glycero-­‐α -­‐galacto-­‐non-­‐2-­‐ulopyranosylonate	  (5):	  
In	   an	   aluminum	   foil-­‐rapped	   flask	   containing	   41	   (377mg,	   0.73mmol)	   and	   8-­‐chloro-­‐1-­‐octyne	  
(126mg,	   1.09mmol,	   1.5eq),	   10ml	   of	   acetonitrile	   was	   added,	   followed	   by	   addition	   of	   N,	   N-­‐
diisopropylethylamine	  (361ul,	  2.18mmo,	  3eq)	  and	  copper	  (I)	  iodine	  (277mg,	  1.46mmol,	  2eq).	  The	  reac-­‐
tion	  mixture	  was	   kept	   stirring	   overnight	   at	   60oC,	   concentrated	   and	   loaded	   onto	   a	   silica	   column.	  Hex-­‐
ane/acetone	  (2:3)	  was	  used	  as	  eluent	  to	  afford	  5	  (405mg,	  84%).	  	  
1H-­‐NMR	  (400	  MHz;	  CDCl3):	  δ=7.68	   (s,	  1H,	   triazole-­‐H),	  5.50	   (d,	  1H,	  NH,	   J=10.0Hz),	  5.45-­‐5.43	   (m,	  
1H,	  H-­‐7),	  5.39	  (d,	  1H,	  H-­‐8,	  J	  =	  8.8	  Hz),	  5.19-­‐5.12	  (m,	  1H,	  H-­‐4),	  4.32-­‐4.27	  (m,	  2H,	  H-­‐9a,	  H-­‐9b),	  4.16-­‐4.05	  (m,	  
2H,	  H-­‐5,	  H-­‐6),	  3.77	  (s,	  3H,	  OMe),	  3.54	  (t,	  2H,	  CH2Cl,	  J	  =	  6.7	  Hz),	  2.75-­‐2.71	  (m,	  2H,	  linker-­‐H),	  2.67	  (d,	  1H,	  H-­‐
3e,	  J	  =	  12.6	  Hz),	  2.18	  (s,	  3H),	  2.15	  (app	  d,	  1H,	  H-­‐3a,	  J	  =	  3.3	  Hz),	  2.12	  (s,	  3H,	  OAc),	  2.08,	  2.06	  (s,	  6H,	  OAc),	  
1.91	   (s,	   3H,	  NAc),	   1.82-­‐1.68	   (m,	   4H,	   linker-­‐H),	   1.53-­‐1.37	   (m,	   4H,	   linker-­‐H).	   13C	  NMR	   (400	  MHz;	   CDCl3):	  
δ=170.9,	   170.6,	   170.3,	   170.1,	   166.6,	   148.9,	   119.7,	   88.3,	   73.7,	   68.6,	   68.0,	   66.9,	   62.3,	   54.0,	   49.2,	   45.1,	  
36.0,	   32.5,	   28.9,	   28.5,	   26.5,	   25.5,	   23.2,	   21.3,	   20.9,	   20.8.	  HRMS	   (ESI):	  m/z	   calcd	   for	   [C28H41ClN4O12Na]+:	  
683.2388.	  Found:	  683.2280.	  
Methyl	  5-­‐Acetamido-­‐4,7,8,9-­‐tetra-­‐O-­‐acetyl-­‐3,5-­‐dideoxy-­‐2-­‐[4-­‐(6-­‐azidohexyl)-­‐1H-­‐1,2,3-­‐triazol-­‐1-­‐
yl]-­‐D-­‐glycero-­‐α -­‐galacto-­‐non-­‐2-­‐ulopyranosylonate	  (6):	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Compound	  5	   (405mg,	  0.61mmol)	  was	  dissolved	   in	  6ml	  of	   anhydrous	  N,	  N-­‐dimethylformamide	  
and	  sodium	  azide	   (200mg,	  3.05mmol,	  5eq)	  was	  added.	  The	  reaction	  mixture	  was	  stirred	  at	  60oC	  over-­‐
night,	  diluted	  with	  ethyl	  acetate	  (20ml),	  washed	  with	  water	  and	  brine.	  The	  organic	  layer	  was	  dried	  over	  
Na2SO4,	   filtered,	   concentrated,	   and	   purified	   by	   silica	   column	   using	   hexane/acetone	   (2:3)	   as	   eluent.	  
White	  solid	  6	  was	  obtained	  (344mg,	  82%).	  
1H-­‐NMR	  (400	  MHz;	  CDCl3):	  δ=7.68	   (s,	  1H,	   triazole-­‐H),	  5.49-­‐5.44	   (m,	  1H,	  H-­‐7),	  5.40-­‐5.36	   (m,	  2H,	  
NH,	  H-­‐8),	  5.21-­‐5.14	  (m,	  1H,	  H-­‐4),	  4.33-­‐4.28	  (m,	  2H,	  H-­‐9a,	  H-­‐9b),	  4.16-­‐4.06	  (m,	  2H,	  H-­‐5,	  H-­‐6),	  3.79	  (s,	  3H,	  
OMe),	  3.28	  (t,	  2H,	  CH2N3,	  J	  =	  6.9	  Hz),	  2.74	  (t,	  2H,	  linker-­‐H,	  J	  =	  7.8	  Hz),	  2.69	  (d,	  1H,	  H-­‐3e,	  J3e,3a	  =	  12.6	  Hz,),	  
2.20	  (s,	  3H,	  OAc),	  2.16	  (app	  d,	  1H,	  H-­‐3a,	  J	  =	  4.0	  Hz),	  2.13	  (s,	  3H,	  OAc),	  2.09,	  2.07	  (s,	  6H,	  OAc),	  1.92	  (s,	  3H,	  
NAc),	  1.74-­‐1.71	  (m,	  2H,	  linker-­‐H),	  1.65-­‐1.61	  (m,	  2H,	  linker-­‐H),	  1.44-­‐1.43	  (m,	  4H,	  linker-­‐H).	  13C	  NMR	  (400	  
MHz;	  CDCl3):	  δ=170.75,	  170.58,	  170.39,	  170.26,	  170.0,	  166.6,	  148.8,	  119.7,	  88.3,	  73.7,	  68.7,	  68.1,	  67.0,	  
62.4,	  53.9,	  51.3,	  49.0,	  36.0,	  28.91,	  28.72,	  28.68,	  26.4,	  25.5,	  23.1,	  21.2,	  20.81,	  20.76,	  20.72.	  HRMS	  (ESI):	  
m/z	  calcd	  for	  [C28H42N7O12]+:	  668.2891.	  Found:	  668.2884.	  
5-­‐Acetamido-­‐3,5-­‐dideoxy-­‐2-­‐[4-­‐(6-­‐aminohexyl)-­‐1H-­‐1,2,3-­‐triazol-­‐1-­‐yl]-­‐D-­‐glycero-­‐α -­‐galacto-­‐non-­‐
2-­‐ulopyranosidic	  acid	  (7):	  
6	   (58mg,	  0.087mmol)	  was	  dissolved	   in	  2ml	  of	  methanol	  and	  0.1ml	  of	  0.5M	  sodium	  methoxide	  
was	   added.	   The	   reaction	  mixture	   was	   kept	   stirring	   overnight	   at	   room	   temperature,	   neutralized	   with	  
acidic	   ion-­‐exchange	   resin	   and	   concentrated.	   The	   residue	  was	   redissolved	   in	   5ml	  of	   0.25M	  sodium	  hy-­‐
droxide	  solution.	  After	  stirring	  at	  room	  temperature	  overnight,	  acidic	  ion-­‐exchange	  resin	  was	  added	  to	  
neutralize	  the	  base	  and	  removed	  by	  filtration.	  Water	  was	  evaporated	  and	  the	  residue	  was	  dissolved	  in	  
10ml	  of	  ethanol.	  Catalytic	  amount	  of	  palladium	  hydroxide	  (20%	  on	  carbon)	  was	  added	  and	  the	  mixture	  
was	  kept	  under	  hydrogen	  atmosphere	  (5	  atm)	  for	  10h.	  Palladium	  hydroxide	  was	  removed	  by	  filtration	  
and	  ethanol	  was	  evaporated.	  The	  residue	  was	  purified	  by	  Bio	  gel	  P-­‐2	  column	  and	  white	  powder	  7	  (25mg,	  
62%)	  was	  obtained	  after	  lyophilization.	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1H-NMR (400 MHz; D2O): δ=7.93-7.87 (m, 1H), 4.05-4.04 (m, 1H), 3.96-3.71 (m, 7H), 3.58-3.37 
(m, 4H), 3.26-3.21 (m, 1H), 3.18-3.12 (m, 1H), 2.89-2.85 (m, 2H), 2.79-2.79 (m, 1H), 2.69-2.62 (m, 2H), 
2.20-2.13 (m, 1H), 1.98 (s, 3H), 1.60-1.53 (m, 4H), 1.29-1.20 (m, 4H).	   13C	   NMR	   (400MHz;	  MeOD):	  
δ=21.25,	  24.43,	  24.56,	  25.44,	  25.60,	  26.89,	  26.99,	  27.62,	  27.94,	  28.34,	  28.60,	  39.24,	  39.28,	  39.48,	  52.45,	  
53.73,	  63.03,	  63.22,	  65.84,	  67.87,	  68.71,	  70.38,	  70.98,	  71.66,	  74.74,	  79.42,	  86.53,	  90.65,	  120.15,	  122.18,	  
147.00,	  147.33,	  174.19.	  HRMS	  (ESI):	  m/z	  calcd	  for	  [C20H32ClO7]+:	  460.2408	  Found:	  460.2430.	  
6-­‐Chlorohexyl	  3-­‐O-­‐	  (4-­‐methoxybenzyl)-­‐β -­‐D-­‐galactopyranoside	  (9)	  
Compound	  82	  (1.78g,	  5.9mmol)	  was	  dissolved	  in	  40ml	  of	  anhydrous	  methanol	  and	  dibutyltin	  ox-­‐
ide	   (2.22g,	  8.9mmol,	  1.5	  eq)	  was	  added.	  The	  reaction	  mixture	  was	  refluxed	   for	  ~4	  h	  until	   the	  solution	  
became	  clear.	  The	  solvent	  was	  evaporated	  and	  the	  residue	  was	  redissolved	  in	  40ml	  of	  toluene	  followed	  
by	   addition	   of	   4-­‐methoxybenzylchloride	   (1.2ml,	   8.9mmol,	   1.5	   eq)	   and	   tetrabutylammonium	   bromide	  
(953mg,	  2.9mmol,	  0.5	  eq).	  The	  reaction	  mixture	  was	  stirred	  overnight	  at	  60oC,	  concentrated	  and	  purified	  
by	   column	   chromatography	   using	   hexane/ethyl	   acetate	   (1:3)	   as	   eluent.	   White	   solid	   9	   was	   obtained	  
(1.91g,	  4.7mmol,	  80%).	  	  	  
1H	  NMR	  (400MHz,	  CDCl3):	  δ=7.32	  (d,	  2H,	  ArH,	  J=	  8.8Hz),	  6.91	  (d,	  2H,	  ArH,	  J=8.4Hz),	  4.70	  (app	  s,	  
2H),	  4.26	  (d,	  1H,	  H-­‐1,	  J=8.0Hz),	  4.01-­‐3.91	  (m,	  3H),	  3.87-­‐3.79	  (m,	  4H,	  OMe),	  3.78-­‐3.75	  (m,	  1H),	  3.57-­‐3.54	  
(m,	  3H,	  CH2Cl),	  3.52-­‐3.49	  (m,	  1H),	  3.40	  (dd,	  1H,	  H-­‐3,	  J3,4=3.6Hz,	  J3,2=9.6Hz),	  2.62	  (s,	  1H,	  OH),	  2.39-­‐2.37	  (m,	  
1H,	  OH),	  2.23-­‐2.18	   (m,	  1H,	  OH),	  1.83-­‐1.76	   (m,	  2H,	   linker-­‐CH2),	  1.70-­‐1.63	   (m,	  2H,	   linker-­‐CH2),	  1.52-­‐1.37	  
(m,	  4H,	  linker-­‐CH2).	  13C	  NMR	  (400MHz,	  CDCl3):	  δ=159.6,	  129.6,	  114.1	  103.0,	  79.8,	  76.7,	  76.6,	  74.3,	  71.8,	  
71.0,	   69.8,	   67.2,	   62.6,	   55.3,	   45.0,	   32.5,	   29.4,	   26.6,	   25.3.	   HRMS	   (ESI):	   m/z	   calcd	   for	   [C20H31ClO7Na]+:	  
441.1656.	  Found:	  441.1667.	  
6-­‐Chlorohexyl	  2-­‐O-­‐benzoyl-­‐4,	  6-­‐benzylidene-­‐3-­‐O-­‐	  (4-­‐methoxybenzyl)-­‐β -­‐D-­‐galactopyranoside	  
(10)	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Compound	  9	  (638mg,	  1.58mmol)	  was	  dissolved	  in	  20ml	  of	  anhydrous	  acetonitrile	  and	  benzalde-­‐
hyde	  dimethyl	  acetal	  (477ul,	  3.2mmol,	  2	  eq)	  was	  added.	  Catalytic	  amount	  of	  p-­‐toluenesulfonic	  acid	  was	  
added	   to	   adjust	   the	   pH	   to	   2.	   The	   reaction	   mixture	   was	   stirred	   at	   room	   temperature	   for	   5min	   and	  
quenched	  by	  addition	  of	  triethylamine.	  The	  solvent	  was	  evaporated	  and	  the	  residue	  was	  redissolved	  in	  
10ml	  of	  pyridine.	  Benzoyl	  chloride	   (553ul,	  4.74mmol,	  3	  eq)	  was	  added	  dropwise	  and	  the	  reaction	  was	  
allowed	  to	  proceed	  overnight	  at	  room	  temperature.	  30ml	  of	  ethyl	  acetate	  was	  added	  and	  pyridine	  was	  
washed	  off	  using	  1M	  HCl.	  The	  organic	  layer	  was	  washed	  one	  more	  time	  with	  water,	  dried	  over	  Na2SO4	  
and	   concentrated.	   Compound	   10	   (669mg,	   1.1mmol,	   70%)	   was	   obtained	   after	   purification	   by	   column	  
chromatography	  (hexane/ethyl	  acetate=2:1).	  
1H-NMR (400 MHz; CDCl3): δ=8.05 (d, 2H, Ar, J = 7.1 Hz,), 7.60 (dd, 3H, Ar, J = 7.5, 1.7 Hz), 
7.48 (t, 2H, Ar, J = 7.7 Hz), 7.40-7.38 (m, 3H, Ar), 7.18 (d, 2H, Ar, J = 8.6 Hz), 6.74 (d, 2H, Ar, J = 8.7 
Hz), 5.62 (dd, H-2, J2,3 = 10.1 Hz, J2,1 = 8.0 Hz), 5.55 (s, 1H, CHPh), 4.65 (d, 1H, CH2Ph, J = 12.5 Hz), 
4.58-4.54 (m, 2H, H-1, CH2Ph), 4.36 (dd, 1H, H-6a, J6a,6b= 12.2, J6a,5= 1.2 Hz), 4.23 (d, 1H, H-4, J4,3 = 
3.3 Hz), 4.09 (dd, 1H, H-6b, J6b, 6a = 12.3, J6a,5 = 1.6 Hz), 3.94 (dt, 1H, OCH2, J = 9.6, 5.9 Hz), 3.77 (s, 
3H, OCH3), 3.74 (dd, 1H, H-3, J3,2=10.1, J3,4=3.6 Hz), 3.46 (dt, 1H, OCH2, J = 7.6, 2.0 Hz), 3.43 (s, 1H, 
H-5), 3.33 (tq, 2H J = 6.7, 3.3 Hz, CH2Cl), 1.54-1.44 (m, 4H, linker-H), 1.28-1.18 (m, 4H, linker-H). 13C	  
NMR	  (400MHz;	  CDCl3):	  δ=165.1,	  159.2,	  137.7,	  133.0,	  130.3,	  129.92,	  129.77,	  129.3,	  129.0,	  128.3,	  128.2,	  
126.5,	  113.7,	  101.34,	  101.28,	  76.5,	  73.3,	  70.81,	  70.63,	  69.2,	  69.0,	  66.7,	  55.2,	  45.0,	  32.4,	  29.2,	  26.5,	  25.2.	  
HRMS	  (ESI):	  m/z	  calcd	  for	  [C34H39ClO8Na]+:	  633.2231.	  Found:	  633.2255. 
6-­‐Azidohexyl	  2-­‐O-­‐benzoyl-­‐4,	  6-­‐benzylidene-­‐3-­‐O-­‐	  (4-­‐methoxybenzyl)-­‐β -­‐D-­‐galactopyranoside	  (11)	  	  
10	   (669mg,	   1.1mmol)	   was	   dissolved	   in	   15ml	   of	   N,	   N-­‐dimethylformamide	   and	   sodium	   azide	  
(712mg,	  11mmol,	  10	  eq)	  was	  added.	  The	   reaction	  mixture	  was	   stirred	  overnight	  at	  60oC,	  diluted	  with	  
30ml	  of	  ethyl	  acetate	  and	  washed	  with	  water	   (10ml)	  twice.	  The	  organic	   layer	  was	  concentrated,	  dried	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over	   Na2SO4,	   concentrated	   and	   purified	   by	   flash	   chromatography	   using	   hexane/ethyl	   acetate	   (2:1)	   as	  
eluent.	  Compound	  11	  (676mg,	  100%)	  was	  obtained.	  
1H-NMR (400 MHz; CDCl3): δ=8.06-8.04 (m, 2H, Ar), 7.62-7.59 (m, 3H, Ar), 7.49 (t, 2H, Ar, J 
= 7.7 Hz), 7.41-7.36 (m, 3H, Ar), 7.18 (d, 2H, Ar, J = 8.6 Hz), 6.74 (d, 2H, Ar, J = 8.6 Hz), 5.63 (dd, 1H, 
H-2, J2,3 = 10.0 Hz, J2,1 = 8.0 Hz), 5.55 (s, 1H, CHPh), 4.65 (d, 1H, CH2Ar, J = 12.5 Hz), 4.57-4.54 (m, 
2H, H-1, CH2Ar), 4.36-4.33 (m, 1H), 4.25 (d, 1H, H-4, J4,3 = 3.4 Hz), 4.10 (dd, 1H, H-6b, J6b, 6a = 12.2, 
J6a,5 = 1.4 Hz), 3.94 (q, 1H, J = 7.7 Hz), 3.76 (s, 3H, OCH3), 3.73 (d, 1H, H-3, J = 3.5 Hz, 1H), 3.45 (dt, J 
= 7.6, 1.9 Hz, 1H), 3.42 (s, 1H, H-5), 3.04 (td, 2H, CH2N3, J = 7.0, 1.9 Hz), 1.57-1.42 (m, 2H, linker-H), 
1.33-1.15 (m, 6H, linker-H). 13C	   NMR	   (400	  MHz;	   CDCl3):	   δ=165.1,	   159.2,	   137.8,	   133.0,	   130.3,	   129.9,	  
129.8,	  129.3,	  128.9,	  128.3,	  128.1,	  126.6,	  113.7,	  101.36,	  101.22,	  73.2,	  70.8,	  70.6,	  69.21,	  69.03,	  66.7,	  55.2,	  
51.2,	  29.2,	  28.6,	  26.3,	  25.4.	  HRMS	  (ESI):	  m/z	  calcd	  for	  [C34H39N3O8Na]+:	  640.2635.	  Found:	  640.2640. 
6-­‐Azidohexyl	  2-­‐O-­‐benzoyl-­‐4,	  6-­‐benzylidene-­‐β -­‐D-­‐galactopyranoside	  (12)	  	  
11	  (676mg,	  1.1mmol)	  was	  dissolved	  in	  30ml	  of	  acetonitrile/H2O	  (16:1)	  and	  cerium	  (IV)	  ammoni-­‐
um	  nitrate	  (1.8g,	  3.3mmol,	  3	  eq)	  was	  added.	  The	  reaction	  mixture	  was	  stirred	  at	  room	  temperature	  for	  
30min	   and	   quenched	  with	   saturated	   sodium	   thiosulfate	   solution.	   The	   organic	   layer	  was	  washed	  with	  
water,	   dried	   over	   Na2SO4	  and	   concentrated.	   The	   residue	  was	   purified	   by	   flash	   chromatography	   using	  
hexane/ethyl	  acetate	  (1:1)	  and	  afforded	  compound	  12	  (371mg,	  68%).	  	  
1H-NMR (400 MHz; CDCl3): δ=8.10-8.07 (m, 2H, Ar), 7.60-7.55 (m, 3H, Ar), 7.47 (t, 2H, Ar, J 
= 7.7 Hz), 7.41 (dd, 3H, Ar, J = 5.0, 1.9 Hz), 5.60 (s, 1H, CH2Ph), 5.38 (dd, 1H, H-2, J2,3 = 9.9, J2,1 = 8.1 
Hz), 4.60 (d, 1H, H-1, J = 8.0 Hz), 4.39 (dd, 1H, H-6a, J6a,6b= 12.3 Hz, J6a, 5=0.9 Hz), 4.29 (d, 1H, H-5, J 
= 3.7 Hz), 4.13 (dd, 1H, J6b,6a = 12.4 Hz, J6a, 5=1.6 Hz), 3.99-3.92 (m, 2H, H-3, OCH2), 3.56 (s, 1H, H-4), 
3.53-3.49 (m, 1H, OCH2), 3.09-3.05 (m, 2H, CH2N3), 2.68-2.66 (m, 1H, OH), 1.57-1.52 (m, 2H, linker-
H), 1.37-1.33 (m, 2H, linker-H), 1.28-1.22 (m, 4H, linker-H). 13C	  NMR	  (400	  MHz;	  CDCl3):	  δ	  166.1,	  137.4,	  
133.2,	  129.8,	  129.3,	  128.4,	  128.3,	  126.5,	  101.6,	  101.0,	  75.7,	  72.9,	  71.8,	  69.4,	  69.1,	  66.6,	  51.2,	  29.3,	  28.6,	  
26.3,	  25.5.	  HRMS	  (ESI):	  m/z	  calcd	  for	  [C26H31N3O7Na]+:	  520.2060.	  Found:	  520.2031. 
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6-­‐Azidohexyl	  2-­‐O-­‐benzoyl-­‐4,	  6-­‐benzylidene-­‐β -­‐D-­‐gulopyranoside	  (13)	  	  
12	   (206mg,	   0.414mmol)	   was	   dissolved	   in	   20ml	   of	   dichloromethane	   and	   pyridine	   (167ul,	  
2.07mmol,	  5	  eq)	  was	  added.	  The	  mixture	  was	  cooled	  to	  -­‐25oC	  and	  trifluoromethanesulfonic	  anhydride	  
(1M	   solution	   in	   dichloromethane,	   820ul,	   2	   eq)	  was	   added	  dropwise.	   The	   reaction	  mixture	  was	   slowly	  
warmed	  to	  room	  temperature.	  After	  stirring	  for	  50min,	  TLC	  indicated	  the	  reaction	  was	  completed.	  The	  
reaction	  mixture	  was	  diluted	  with	  20ml	  of	  dichloromethane	  and	  washed	  sequentially	  with	  saturated	  so-­‐
dium	  bicarbonate,	  1M	  HCl	  and	  water.	  The	  organic	   layer	  was	  dried	  over	  Na2SO4	  and	  concentrated.	  The	  
residue	  was	  dissolved	  in	  25ml	  of	  acetonitrile	  and	  tetrabutylammonium	  nitrite	  (597mg,	  2.07mmol,	  5	  eq)	  
was	  added.	  The	  reaction	  mixture	  was	  stirred	  overnight	  at	  50oC,	  concentrated	  and	   loaded	  onto	  a	  silica	  
column	  and	  eluted	  with	  hexane/ethyl	  acetate	  (1:1).	  Compound	  13	  was	  obtained	  (142mg,	  70%).	  
1H-NMR (400 MHz; CDCl3): δ=8.06 (d, 2H, Ar, J = 7.2 Hz), 7.62-7.55 (m, 3H, Ar), 7.48 (s, 2H, 
Ar), 7.38-7.36 (m, 3H, Ar), 5.54 (s, 1H, CHPh), 5.37 (dd, 1H, H-2, J2,1 = 8.4, J2,3 = 3.1 Hz), 5.04 (d, 1H, 
H-1, J = 8.4 Hz), 4.37-4.30 (m, 2H, H-3, H-6a), 4.08-4.02 (m, 2H, H-6b, H-5), 3.99-3.91 (m, 1H, OCH2), 
3.84 (s, 1H, H-4), 3.52-3.46 (m, 1H, OCH2), 3.05 (t, 2H, CH2N3, J = 6.8 Hz), 1.56-1.44 (m, 2H, linker-H), 
1.35-1.31 (m, 2H, linker-H), 1.25-1.19 (m, 4H, linker-H). 13C	  NMR	   (400	  MHz;	  CDCl3):	   δ	   165.2,	   137.7,	  
133.4,	  129.85,	  129.75,	  129.1,	  128.5,	  128.2,	  126.4,	  101.2,	  98.1,	  76.4,	  71.2,	  69.36,	  69.3,	  69.1,	  65.6,	  51.2,	  
29.3,	  28.6,	  26.3,	  25.5.	  HRMS	  (ESI):	  m/z	  calcd	  for	  [C26H31N3O7Na]+:	  520.2086.	  Found:	  520.2061. 
6-­‐Azidohexyl	  3-­‐S-­‐acetyl-­‐2-­‐O-­‐benzoyl-­‐4,	  6-­‐benzylidene-­‐β -­‐D-­‐galactopyranoside	  (14)	  	  
13	   (114mg,	   0.29mmol)	   was	   dissolved	   in	   10ml	   of	   dichloromethane	   and	   pyridine	   (115ul,	  
1.45mmol,	  5	  eq)	  was	  added.	  The	  mixture	  was	  cooled	  to	  -­‐25oC	  and	  trifluoromethanesulfonic	  anhydride	  
(1M	  solution	   in	  dichloromethane,	  820ul,	  2	  eq)	   	  was	  added	  dropwise.	  The	   reaction	  mixture	  was	  slowly	  
warmed	  to	  room	  temperature.	  After	  stirring	  for	  90min,	  TLC	  indicated	  the	  reaction	  was	  completed.	  The	  
reaction	  mixture	  was	  diluted	  with	  20ml	  of	  dichloromethane	  and	  washed	  sequentially	  with	  saturated	  so-­‐
dium	  bicarbonate,	  1M	  HCl	  and	  water.	  The	  organic	   layer	  was	  dried	  over	  Na2SO4	  and	  concentrated.	  The	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residue	  was	  dissolved	   in	  8ml	  of	  N,	  N-­‐dimethylformamide	  and	  potassium	  acetate	  (196mg,	  1.74mmol,	  6	  
eq)	  was	  added.	  The	  reaction	  mixture	  was	  stirred	  overnight	  at	  60oC,	  diluted	  with	  20ml	  of	  ethyl	  acetate	  
and	  washed	  with	  water	   (3x10ml).	   The	  organic	   layer	  was	   dried	   over	  Na2SO4,	   concentrated	   and	   loaded	  
onto	   a	   silica	   column	   and	   eluted	  with	   hexane/ethyl	   acetate	   (1:1).	   Compound	   14	   (83mg,	   65%)was	   ob-­‐
tained.	  
1H-NMR (400 MHz; CDCl3): δ=8.03-8.01 (m, 2H, Ar), 7.59-7.54 (m, 3H, Ar), 7.46 (t, 2H, Ar, J 
= 7.7 Hz), 7.40 (d, 3H, Ar, J = 6.8 Hz), 5.58 (s, 1H, CHPh), 5.46 (dd, 1H, H-2, J2,1 = 7.7 Hz, J2,3 = 11.5 
Hz), 4.71 (d, 1H, H-1, J = 7.8 Hz), 4.38 (d, 1H, H-6a, J = 12.4 Hz), 4.26 (dd, 1H, H-3, J3,2 = 11.5 Hz, J3,4 
= 3.3 Hz), 4.16-4.10 (d, 1H, H-5, J = 2.5 Hz), 4.11 (dd, 1H, H-6b, J6b, 6a= 12.5 Hz, J 6b,5 =1.5 Hz), 3.98-
3.92 (m, 1H, OCH2), 3.72 (s, 1H, H-4), 3.51-3.45 (m, 1H, OCH2), 3.04 (t, 2H, CH2N3, J = 6.9 Hz), 2.23 (s, 
3H, SAc), 1.56-1.44 (m, 2H, linker-H), 1.33-1.25 (m, 2H, linker-H), 1.19-1.16 (m, 4H, linker-H). 13C	  
NMR	  (400	  MHz;	  CDCl3):	  δ=195.0,	  165.2,	  137.4,	  133.1,	  129.79,	  129.74,	  129.0,	  128.4,	  128.2,	  126.3,	  102.5,	  
101.3,	  75.9,	  69.16,	  69.13,	  69.04,	  68.5,	  51.2,	  46.9,	  30.5,	  29.2,	  28.6,	  26.3,	  25.4.	  HRMS	  (ESI):	  m/z	  calcd	  for	  
[C28H33N3O7SNa]+:	  578.1937.	  Found:	  578.1929. 
6-­‐Azidohexyl	  S-­‐	  (Methyl	  5-­‐Acetamido-­‐4,	  5,	  8,	  9-­‐tetra-­‐O-­‐acetyl-­‐3,	  5-­‐dideoxy-­‐D-­‐glycero-­‐α -­‐D-­‐
galacto-­‐2-­‐nonulopyranosylonate)-­‐	  (2-­‐3)-­‐2-­‐O-­‐benzoyl-­‐4,	  6-­‐benzylidene-­‐3-­‐thio-­‐β -­‐D-­‐galactopyranoside	  
(15)	  
14	  (83mg,	  0.15mmol)	  was	  dissolved	  in	  4ml	  of	  degassed	  N,	  N-­‐dimethylformamide.	  The	  solution	  
was	  flushed	  with	  argon	  for	  10min	  and	  hydrazine	  acetate	  (28mg,	  0.3mmol,	  2	  eq)	  was	  added.	  The	  reaction	  
was	  stirred	  under	  argon	  at	  room	  temperature	  for	  90min,	  diluted	  with	  10ml	  of	  ethyl	  acetate	  and	  washed	  
with	  water	  (2x5ml).	  The	  organic	  layer	  was	  dried	  over	  Na2SO4	  and	  concentrated	  in	  vacuum.	  
1H-NMR (400 MHz; CDCl3): δ=8.09-8.07 (m, 2H), 7.60-7.56 (m, 3H), 7.48 (t, J = 7.8 Hz, 2H), 
7.41-7.39 (m, 3H), 5.61 (s, 1H), 5.34 (dd, J = 11.0, 7.9 Hz, 1H), 4.58 (d, J = 7.8 Hz, 1H), 4.36 (d, J = 12.3 
Hz, 1H), 4.17 (d, J = 2.6 Hz, 1H), 4.11 (dd, J = 12.4, 1.6 Hz, 1H), 3.96-3.91 (m, 1H), 3.62 (s, 1H), 3.49-
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3.44 (m, 1H), 3.15 (td, J = 10.9, 3.0 Hz, 1H), 3.06-3.02 (m, 2H), 2.24 (d, J = 10.8 Hz, 1H), 1.55-1.44 (m, 
2H), 1.33-1.16 (m, 8H).  
The intermediate thiol was dissolved in 2ml of degassed N,	  N-­‐dimethylformamide	  and	  sodium	  
hydride	  (24mg	  of	  a	  60%	  suspension	  in	  mineral	  oil,	  0.6mmol,	  4	  eq)	  was	  added.	  The	  mixture	  was	  stirred	  
under	  argon	  for	  about	  1min	  and	  a	  mixture	  of	  2	  (159mg,	  0.3mmol,	  2	  eq)	  and	  Kryptofix 21	  (7mg,	  
0.015mmol,	  0.1	  eq)	  in	  2ml	  of	  degassed	  N,	  N-­‐dimethylformamide	  was	  added.	  The	  reaction	  mixture	  was	  
stirred	  overnight	  under	  argon	  at	  room	  temperature,	  diluted	  with	  10ml	  of	  ethyl	  acetate	  and	  washed	  se-­‐
quentially	  with	  1M	  HCl,	  saturated	  sodium	  bicarbonate	  solution	  and	  water.	  The	  organic	  layer	  was	  dried	  
over	  Na2SO4,	  concentrated	  and	  purified	  by	  chromatography	  using	  hexane/acetone	  (3:2)	  as	  eluent.	  A	  
mixture	  of	  desired	  product	  15	  and	  unreacted	  2	  was	  obtained.	  
6-­‐Azidohexyl	  S-­‐	  (Methyl	  5-­‐Acetamido-­‐4,	  5,	  8,	  9-­‐tetra-­‐O-­‐acetyl-­‐3,	  5-­‐dideoxy-­‐D-­‐glycero-­‐α -­‐D-­‐
galacto-­‐2-­‐nonulopyranosylonate)-­‐	  (2-­‐3)-­‐2-­‐O-­‐benzoyl-­‐3-­‐thio-­‐β -­‐D-­‐galactopyranoside	  (16)	  
The	  mixture	  of	  15	  and	  unreacted	  2	  was	  dissolved	  in	  10ml	  of	  80%	  acetic	  acid	  solution	  and	  stirred	  
24h	   at	   45oC.	   The	   solvent	   was	   evaporated	   and	   the	   residue	   was	   loaded	   onto	   a	   silica	   column.	   Hex-­‐
ane/acetone	  (1:1)	  was	  used	  as	  eluent	  to	  afford	  white	  solid	  16	  (42mg,	  32%	  over	  3	  steps).	  
1H-NMR (400 MHz; CDCl3): δ=8.15 (d, 2H, Ar, J = 7.1 Hz), 7.59 (t, 1H, Ar, J = 7.4 Hz), 7.48 (t, 
2H, Ar, J = 7.6 Hz), 5.63-5.58 (ddd, 1H, H-8’, J = 9.8, 5.9, 2.5 Hz), 5.22-5.15 (m, 3H, H-2, H-7’, NH), 
4.90 (d, 1H, H-1, J = 7.7 Hz), 4.83-4.76 (m, 1H, H-4’), 4.39 (dd, 1H, H-9a’, J9a’, 9b’ = 12.3, J9’a, 8=2.3 Hz), 
4.05 (dd, 1H, H-9b’, J = 12.5, J =5.8 Hz), 3.93-3.85 (m, 5H, H-5’, H-4, OCH2, H-6a, H-6b), 3.79-3.74 (m, 
4H, OMe, H-6’), 3.70 (dd, 1H, H-3, J3,2 = 11.7, J3,4 = 2.6 Hz), 3.62 (s, 1H, H-5), 3.56-3.51 (m, 1H, 
OCH2), 3.13 (d, 1H, OH, J = 4.4 Hz), 3.04-3.00 (m, 2H, CH2N3), 2.61 (dd, 1H, H-3’eq, J3eq,3ax = 12.8 Hz, 
J3eq,4 = 4.6 Hz), 2.55 (s, 1H, OH), 2.21 (s, 3H), 2.19 (d, 1H, H-3a’, J = 2.8 Hz), 2.08 (s, 3H), 1.99 (s, 3H), 
1.95-1.89 (m, 2H), 1.84 (s, 3H), 1.69 (s, 3H), 1.50-1.44 (m, 2H), 1.26 (s, 4H), 1.15 (t, J = 6.4 Hz, 4H). 13C	  
NMR	   (400	   MHz;	   CDCl3):	   δ	   170.93,	   170.79,	   170.23,	   170.18,	   169.4,	   165.8,	   133.0,	   130.3,	   130.1,	   128.3,	  
102.3,	  81.4,	  75.1,	  73.5,	  70.4,	  69.8,	  69.3,	  69.2,	  67.4,	  66.8,	  63.0,	  62.5,	  53.2,	  51.2,	  49.1,	  48.1,	  37.4,	  29.3,	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28.5,	  26.3,	  25.5,	  23.2,	  21.5,	  20.8,	  20.5. HRMS	  (ESI):	  m/z	  calcd	   for	   [C39H54N4O18SNa]+:	  921.3052.	  Found:	  
921.3062.	  
6-­‐Aminohexyl	  S-­‐	  (5-­‐Acetamido-­‐3,	  5-­‐dideoxy-­‐D-­‐glycero-­‐α -­‐D-­‐galacto-­‐2-­‐nonulopyranosylonate)-­‐	  
(2-­‐3)-­‐3-­‐thio-­‐β -­‐D-­‐galactopyranoside	  (17)	  
16	  (47mg,	  0.052mmol)	  was	  dissolved	  in	  2ml	  of	  methanol	  and	  0.1ml	  of	  0.5M	  sodium	  methoxide	  
was	   added.	   The	   reaction	  mixture	   was	   kept	   stirring	   overnight	   at	   room	   temperature,	   neutralized	   with	  
acidic	   ion-­‐exchange	   resin	   and	   concentrated.	   The	   residue	  was	   redissolved	   in	   5ml	  of	   0.25M	  sodium	  hy-­‐
droxide	  solution.	  After	  stirring	  at	  room	  temperature	  overnight,	  acidic	  ion-­‐exchange	  resin	  was	  added	  to	  
neutralize	  the	  base	  and	  removed	  by	  filtration.	  Water	  was	  evaporated	  and	  the	  residue	  was	  dissolved	  in	  
10ml	  of	  ethanol.	  Catalytic	  amount	  of	  palladium	  hydroxide	  (20%	  on	  carbon)	  was	  added	  and	  the	  mixture	  
was	  kept	  under	  hydrogen	  atmosphere	  (5	  atm)	  for	  10h.	  Palladium	  hydroxide	  was	  removed	  by	  filtration	  
and	  ethanol	  was	  evaporated.	  White	  powered	  17	  (21mg,	  70%)	  was	  obtained	  after	  lyophilization.	  	  
1H-NMR (400 MHz; MeOD): δ=4.31 (d, J = 7.3 Hz, 1H), 3.93-3.88 (m, 3H), 3.86-3.82 (m, 1H), 
3.76-3.51 (m, 10H), 3.46 (dd, J = 11.4, 2.7 Hz, 1H), 3.37 (dd, J = 11.3, 7.3 Hz, 1H), 3.33 (dt, J = 3.2, 1.6 
Hz, 2H), 3.29 (d, J = 6.8 Hz, 2H), 2.92 (dd, J = 12.3, 3.4 Hz, 1H), 2.03 (s, 3H), 1.73 (dd, J = 11.6, 11.2 
Hz, 1H), 1.67-1.60 (m, 4H), 1.43 (t, J = 3.5 Hz, 4H).	  13C	  NMR	  (400	  MHz;	  CDCl3):	  δ=173.97,	  173.87,	  131.0,	  
129.0,	  127.6,	  104.7,	  84.1,	  77.6,	  75.6,	  71.6,	  69.01,	  68.94,	  68.71,	  68.59,	  68.1,	  63.0,	  61.6,	  52.4,	  51.4,	  51.0,	  
41.5,	  29.2,	  28.5,	  26.2,	  25.3,	  21.3.	  HRMS	  (ESI):	  m/z	  calcd	  for	  [C23H43N2O13S]+:	  587.2486.	  Found:	  587.2365. 
6-­‐Chlorohexyl	  2,4,6-­‐O-­‐benzyl-­‐3-­‐O-­‐	  (4-­‐methoxybenzyl)-­‐β -­‐D-­‐galactopyranoside	  (18)	  
Compound	  9	  (900mg,	  2.25mmol)	  was	  dissolved	  in	  45ml	  of	  anhydrous	  tetrahydrofuran	  and	  
cooled	  to	  0oC.	  Sodium	  hydride	  (1.35g	  of	  a	  60%	  suspension	  in	  mineral	  oil,	  33.7mmol,	  15	  eq)	  was	  added	  in	  
small	  portions.	  The	  suspension	  was	  stirred	  for	  about	  5min	  and	  benzyl	  bromide	  (1.6ml,	  13.5mmol,	  6	  eq)	  
was	  added.	  The	  reaction	  mixture	  was	  refluxed	  for	  6h	  and	  cooled	  to	  0	  oC.	  1M	  HCl	  was	  added	  dropwise	  to	  
neutralize	  excessive	  sodium	  hydride.	  The	  mixture	  was	  diluted	  with	  50ml	  of	  ethyl	  acetate.	  The	  organic	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layer	  was	  washed	  with	  water	  (3x20ml),	  dried	  over	  Na2SO4,	  filtered	  and	  concentrated.	  The	  residue	  was	  
purified	  by	  column	  chromatography	  using	  hexane/ethyl	  acetate	  (8:1)	  as	  eluent.	  White	  solid	  18	  was	  ob-­‐
tained	  (1.29g,	  83%).	  
1H-NMR (400 MHz; CDCl3): δ=7.38-7.30 (m, 17H, Ar), 6.87 (d, 2H, Ar, J = 8.7 Hz), 4.94 (t, 2H, 
OCH2Ph, J = 11.3 Hz), 4.79 (d, 1H, H-6a, J6a, 6b = 11.0 Hz), 4.68 (d, 1H, H-4, J = 3.1 Hz), 4.63 (d, 1H, H-
6b, J = 11.7 Hz), 4.44 (q, 2H, OCH2Ph, J = 9.1 Hz), 4.35 (d, 1H, H-1, J = 7.7 Hz), 3.97-3.91 (m, 1H, 
OCH2), 3.87 (dd, 1H, H-4, J = 2.6, 0.3 Hz), 3.82 (s, 3H, OCH3), 3.80-3.78 (m, 1H, H-2), 3.60-3.58 (m, 
2H, OCH2Ph), 3.56-3.49 (m, 4H, OCH2, H-3, CH2Cl), 1.76-1.71 (m, 2H, linker-H), 1.68-1.63 (m, 2H, 
linker-H), 1.46-1.41 (m, 4H, linker-H). 13C	  NMR	  (400	  MHz;	  CDCl3):	  δ=138.9,	  138.7,	  138.0,	  130.6,	  129.2,	  
128.4,	  128.15,	  128.01,	  127.88,	  127.5,	  113.8,	  104.0,	  81.9,	  79.6,	  75.2,	  74.5,	  73.55,	  73.51,	  73.43,	  72.7,	  69.8,	  
69.0,	   55.3,	   45.1,	   32.5,	   29.6,	   26.7,	   25.5.	   HRMS	   (ESI):	   m/z	   calcd	   for	   [C41H49ClO7Na]+:	   711.3065.	   Found:	  
711.3065. 
6-­‐Chlorohexyl	  2,4,6-­‐O-­‐benzyl-­‐β -­‐D-­‐galactopyranoside	  (19)	  
18	  (1.28g,	  1.86mmol)	  was	  dissolved	  in	  40ml	  of	  acetonitrile/H2O	  (16:1)	  and	  cerium	  (IV)	  ammoni-­‐
um	  nitrate	  (3.06g,	  5.58mmol,	  3	  eq)	  was	  added.	  The	  reaction	  mixture	  was	  stirred	  at	  room	  temperature	  
for	  2h	  and	  quenched	  with	  saturated	  sodium	  thiosulfate	  solution.	  The	  organic	  layer	  was	  washed	  with	  wa-­‐
ter,	  dried	  over	  Na2SO4,	  filtered	  and	  concentrated.	  The	  residue	  was	  purified	  by	  flash	  chromatography	  us-­‐
ing	  hexane/ethyl	  acetate	  (3:1)	  and	  afforded	  compound	  19	  (587mg,	  55%).	  	  
1H-NMR (400 MHz; CDCl3): δ=7.39-7.30 (m, 15H), 4.98 (d, 1H, J = 11.5 Hz, H-6a), 4.80 (d, 1H, 
H-6b), 4.72-4.65 (m, 2H, OCH2Ph), 4.54-4.46 (m, 2H, OCH2Ph), 4.36 (d, 1H, H-1, J = 7.4 Hz), 3.99-3.93 
(m, 1H, OCH2), 3.89 (d, 1H, H-4, J = 3.0 Hz), 3.69-3.64 (m, 4H, OCH3, OCH2), 3.58 (dd, 1H, H-2, J2,3 = 
9.6 Hz, J2,1 = 7.6 Hz), 3.54-3.50 (m, 3H, H-3, CH2N3), 2.27 (d, 1H, OH, J = 4.8 Hz), 1.78-1.73 (m, 2H, 
linker-H), 1.69-1.65 (m, 2H, linker-H), 1.47-1.41 (m, 4H, linker-H). 13C	  NMR	  (400	  MHz;	  CDCl3):	  
δ=138.52,	  138.49,	  137.9,	  128.50,	  128.45,	  128.33,	  128.22,	  128.05,	  127.8,	  103.8,	  79.6,	  75.5,	  75.0,	  74.6,	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74.1,	  73.59,	  73.54,	  69.7,	  68.8,	  45.0,	  32.5,	  29.6,	  26.7,	  25.5. HRMS	  (ESI):	  m/z	  calcd	  for	  [C33H41ClO6Na]+:	  
591.2490.	  Found:	  591.2258. 
6-­‐Chlorohexyl	  2,4,6-­‐O-­‐benzyl-­‐3-­‐O-­‐propargyl-­‐β -­‐D-­‐galactopyranoside	  (20)	  
Compound	  19	  (116mg,	  0.20mmol)	  was	  dissolved	  in	  5ml	  of	  anhydrous	  tetrahydrofuran	  and	  
cooled	  to	  0oC.	  Sodium	  hydride	  (41mg	  of	  a	  60%	  suspension	  in	  mineral	  oil,	  1mmol,	  5	  eq)	  was	  added.	  The	  
suspension	  was	  stirred	  for	  about	  2min	  and	  propargyl	  bromide	  (60ul,	  0.4mmol,	  2	  eq)	  was	  added.	  The	  re-­‐
action	  mixture	  was	  stirred	  at	  50oC	  for	  3h	  and	  cooled	  to	  0	  oC.	  1M	  HCl	  was	  added	  dropwise	  to	  neutralize	  
excessive	  sodium	  hydride.	  The	  mixture	  was	  diluted	  with	  10ml	  of	  ethyl	  acetate.	  The	  organic	  layer	  was	  
washed	  with	  water	  (3x5ml),	  dried	  over	  Na2SO4,	  filtered	  and	  concentrated.	  The	  residue	  was	  purified	  by	  
column	  chromatography	  using	  hexane/ethyl	  acetate	  (5:1)	  as	  eluent.	  White	  solid	  20	  was	  obtained	  (93mg,	  
75%).	  
1H-NMR (400 MHz; CDCl3): δ=7.43-7.30 (m, 15H, Ar), 4.95 (t, 2H, OCH2Ph, J = 10.8Hz), 4.77 
(d, 1H, H-6a, J = 11.1 Hz), 4.68 (d, H-6b, J = 11.8 Hz), 4.51-4.43 (m, 2H, OCH2Ph), 4.39-4.36 (m, 3H, 
H-1, OCH2Ph), 3.99-3.95 (m, 2H, H-4, OCH2), 3.78 (dd, 1H, H-2, J2,3 = 9.7 Hz, J2,1 = 7.7 Hz), 3.64-3.58 
(m, 4H, H-5, H-3, OCH2CCH), 3.54-3.50 (m, 3H, OCH2, CH2Cl), 2.47 (t, 1H, alkyn-H, J = 2.4 Hz), 1.78-
1.73 (m, 2H, linker-H), 1.70-1.65 (m, 2H, linker-H), 1.47-1.42 (m, 4H, linker-H). 13C	  NMR	  (400	  MHz;	  
CDCl3):	  δ=	  138.81,	  138.65,	  138.0,	  128.50,	  128.45,	  128.32,	  128.18,	  127.96,	  127.91,	  127.6,	  103.9,	  81.7,	  
80.4,	  79.6,	  75.1,	  74.56,	  74.40,	  74.0,	  73.57,	  73.46,	  69.8,	  69.0,	  58.7,	  45.1,	  32.6,	  29.6,	  26.7,	  25.5.	  HRMS	  
(ESI):	  m/z	  calcd	  for	  [C36H43ClO6Na]+:	  629.2646.	  Found:	  629.2631. 
Chloro-­‐click-­‐	  (2-­‐3)	  disaccharide	  (21)	  
In	  a	  flask	  containing	  20	   (93mg,	  0.15mmol)	  and	  4	  (87mg,	  0.16mmol,	  1.1	  eq),	  2ml	  of	  acetonitrile	  
was	  added,	  followed	  by	  addition	  of	  N,	  N-­‐diisopropylethylamine	  (50ul,	  0.3mmol,	  2	  eq)	  and	  copper	  (I)	  io-­‐
dine	  (29mg,	  0.15mmol,	  1eq).	  The	  reaction	  mixture	  was	  kept	  stirring	  overnight	  at	  60oC,	  concentrated	  and	  
loaded	  onto	  a	  silica	  column.	  Hexane/acetone	  (2:3)	  was	  used	  as	  eluent	  to	  afford	  21	  (156mg,	  91%).	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1H-NMR (400 MHz; CDCl3): δ=8.02 (s, 1H), 7.41-7.24 (m, 18H), 5.47-5.43 (m, 1H), 5.40-5.37 
(m, 1H), 5.28 (dd, J = 9.9, 0.3 Hz, 1H), 5.19 (td, J = 10.9, 3.9 Hz, 1H), 4.93 (t, J = 12.7 Hz, 3H), 4.85-
4.79 (m, 2H), 4.64 (d, J = 11.8 Hz, 1H), 4.48-4.39 (m, 2H), 4.37 (d, J = 7.6 Hz, 1H), 4.33 (d, J = 1.8 Hz, 
1H), 4.19 (dd, J = 12.8, 2.5 Hz, 1H), 4.13 (d, J = 9.9 Hz, 1H), 4.02 (dd, J = 12.3, 5.4 Hz, 1H), 3.97-3.92 
(m, 2H), 3.83-3.77 (m, 2H), 3.69 (s, 3H), 3.64-3.61 (m, 1H), 3.61-3.56 (m, 2H), 3.52-3.47 (m, 5H), 3.44-
3.43 (m, 1H), 2.70-2.64 (m, 1H), 2.12 (s, 3H), 2.10 (s, 3H), 2.08 (s, 3H), 2.01 (s, 3H), 1.93 (s, 3H), 1.76-
1.70 (m, 3H), 1.66-1.64 (m, 2H), 1.44-1.42 (m, 4H).	  13C	  NMR	  (101	  MHz;	  CDCl3):	  δ	  170.8,	  170.5,	  170.3,	  
170.00,	  169.96,	  166.5,	  146.1,	  138.90,	  138.71,	  138.0,	  128.54,	  128.40,	  128.28,	  128.09,	  128.04,	  127.84,	  
127.72,	  127.5,	  121.6,	  103.9,	  88.4,	  82.8,	  79.6,	  75.0,	  74.4,	  73.71,	  73.51,	  69.7,	  69.1,	  68.5,	  67.8,	  66.8,	  64.8,	  
62.2,	  54.0,	  49.3,	  45.1,	  36.1,	  32.5,	  29.6,	  26.7,	  25.5,	  23.2,	  21.2,	  20.85,	  20.76,	  20.71.	  HRMS	  (ESI):	  m/z	  calcd	  
for	  [C56H71ClN4O18Na]+:	  1145.4349.	  Found:	  1145.4332.	  
Azido-­‐click-­‐	  (2-­‐3)	  disaccharide	  (22)	  
Compound	  21	   (129mg,	  0.11mmol)	  was	  dissolved	  in	  2ml	  of	  anhydrous	  N,	  N-­‐dimethylformamide	  
and	  sodium	  azide	   (37mg,	  0.55	  mmol,	  5eq)	  was	  added.	  The	   reaction	  mixture	  was	   stirred	  at	  50oC	  over-­‐
night,	  diluted	  with	  ethyl	  acetate	  (8ml),	  washed	  with	  water	  and	  brine.	  The	  organic	  layer	  was	  dried	  over	  
Na2SO4,	   filtered,	   concentrated,	   and	   purified	   by	   silica	   column	   using	   hexane/acetone	   (2:3)	   as	   eluent.	  
White	  solid	  22	  was	  obtained	  (78mg,	  58%).	  
1H-NMR (400 MHz; CDCl3): δ=8.02 (s, 1H), 7.40-7.25 (m, 20H), 5.45-5.43 (m, 1H), 5.40-5.37 
(m, 1H), 5.22-5.15 (m, 1H), 4.93 (dd, J = 13.3, 11.5 Hz, 3H), 4.85-4.79 (m, 3H), 4.65-4.62 (m, 1H), 4.48-
4.42 (m, 2H), 4.39-4.33 (m, 2H), 4.21-4.17 (m, 1H), 4.15-4.13 (m, 1H), 4.04-3.99 (m, 1H), 3.97-3.91 (m, 
2H), 3.82-3.78 (m, 1H), 3.69 (s, 3H), 3.62 (t, J = 4.9 Hz, 1H), 3.60-3.56 (m, 3H), 3.54-3.46 (m, 3H), 3.44 
(dd, J = 4.5, 0.3 Hz, 1H), 3.24-3.21 (m, 2H), 2.69-2.63 (m, 1H), 2.12-2.08 (m, 8H), 2.00 (s, 3H), 1.93 (s, 
3H), 1.64-1.55 (m, 4H), 1.41-1.39 (m, 4H). 13C NMR (400 MHz; CDCl3): δ=170.8, 170.5, 170.0, 166.5, 
162.5, 146.1, 138.9, 138.7, 128.54, 128.40, 128.28, 128.09, 128.02, 127.83, 127.72, 127.5, 121.6, 103.9, 
88.4, 82.8, 79.6, 75.0, 74.4, 73.7, 73.5, 69.7, 69.1, 68.5, 67.80, 67.78, 66.9, 64.8, 62.2, 54.0, 51.4, 36.5, 
80 
36.2, 31.4, 29.72, 29.61, 28.8, 26.6, 25.8, 23.2, 21.2, 20.85, 20.76, 20.71. HRMS	  (ESI):	  m/z	  calcd	  for	  
[C56H71N7O18Na]+:	  1152.4753.	  Found:	  1152.4617.	  
Amino-­‐click-­‐	  (2-­‐3)	  disaccharide	  (23)	  
22	  (58mg,	  0.087mmol)	  was	  dissolved	  in	  2ml	  of	  methanol	  and	  0.1ml	  of	  0.5M	  sodium	  methoxide	  
was	   added.	   The	   reaction	  mixture	   was	   kept	   stirring	   overnight	   at	   room	   temperature,	   neutralized	   with	  
acidic	   ion-­‐exchange	   resin	   and	   concentrated.	   The	   residue	  was	   redissolved	   in	   5ml	  of	   0.25M	  sodium	  hy-­‐
droxide	  solution.	  After	  stirring	  at	  room	  temperature	  overnight,	  acidic	  ion-­‐exchange	  resin	  was	  added	  to	  
neutralize	  the	  base	  and	  removed	  by	  filtration.	  Water	  was	  evaporated	  and	  the	  residue	  was	  dissolved	  in	  
10ml	  of	  ethanol.	  Catalytic	  amount	  of	  palladium	  hydroxide	  (20%	  on	  carbon)	  was	  added	  and	  the	  mixture	  
was	  kept	  under	  hydrogen	  atmosphere	  (5	  atm)	  for	  10h.	  Palladium	  hydroxide	  was	  removed	  by	  filtration	  
and	   ethanol	   was	   evaporated.	   The	   residue	   was	   purified	   by	   Bio	   gel	   P-­‐2	   column	   and	   white	   powder	   23	  
(25mg,	  62%)	  was	  obtained	  after	  lyophilization.	  	  
1H-NMR (400 MHz; D2O): δ=7.90 (s, 1H), 4.33-4.31 (m, 1H), 4.07 (dd, J = 0.6, 0.2 Hz, 1H), 
3.97-3.91 (m, 2H), 3.85-3.67 (m, 8H), 3.58-3.38 (m, 9H), 2.91 (t, J = 7.5 Hz, 1H), 2.19-2.14 (m, 1H), 
2.00-1.96 (m, 4H), 1.79-1.67 (m, 2H), 1.57-1.53 (m, 4H), 1.32-1.31 (m, 4H). HRMS	  (ESI):	  m/z	  calcd	  for	  
[C26H45N5O14Na]+:	  674.2861.	  Found:	  674.2863. 
6-­‐Chlorohexyl	  6-­‐O-­‐	  t-­‐butyldimethylsilyl-­‐β -­‐D-­‐galactopyranoside	  (24)	  
Compound	  8	   (370mg,	  1.24mmol)	  was	  dissolved	   in	  20ml	  of	  anhydrous	  methanol	  and	  dibutyltin	  
oxide	  (462mg,	  1.86mmol,	  1.5	  eq)	  was	  added.	  The	  reaction	  mixture	  was	  refluxed	  for	  ~4	  h	  until	  the	  solu-­‐
tion	  became	  clear.	  The	  solvent	  was	  evaporated	  and	  the	  residue	  was	  redissolved	  in	  10ml	  of	  toluene	  fol-­‐
lowed	   by	   addition	   of	   t-­‐butyldimethylchloride	   (280mg,	   1.86mmol,	   1.5	   eq).	   The	   reaction	   mixture	   was	  
stirred	   overnight	   at	   100oC,	   concentrated	   and	   purified	   by	   column	   chromatography	   using	   hexane/ethyl	  
acetate	  (1:1)	  as	  eluent.	  24	  was	  obtained	  (324mg,	  63%).	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1H-NMR (400 MHz; CDCl3): δ=4.23 (d, J = 7.6 Hz, 1H), 4.04 (d, J = 2.6 Hz, 1H), 3.95-3.85 (m, 
3H), 3.66 (d, J = 7.8 Hz, 1H), 3.60-3.59 (m, 1H), 3.57-3.54 (m, 3H), 3.50 (dd, J = 12.5, 6.3 Hz, 1H), 3.13-
3.12 (m, 1H), 3.02 (d, J = 3.6 Hz, 1H), 2.87 (d, J = 0.4 Hz, 1H), 1.80 (t, J = 7.3 Hz, 2H), 1.66 (t, J = 7.3 
Hz, 2H), 1.48-1.40 (m, 4H), 0.91 (s, 9H), 0.10 (d, J = 1.7 Hz, 6H). 13C NMR (400 MHz; CDCl3): δ 103.0, 
74.4, 73.7, 72.1, 69.7, 68.9, 62.5, 45.0, 32.5, 29.5, 26.6, 25.8, 25.3, 18.3. HRMS	  (ESI):	  m/z	  calcd	  for	  
[C18H37ClO6SiNa]+:	  435.1946.	  Found:	  435.1959.	  
6-­‐Chlorohexyl	  2,3,4-­‐O-­‐	  benzyl-­‐6-­‐O-­‐	  t-­‐butyldimethylsilyl-­‐β -­‐D-­‐galactopyranoside	  (25)	  
24	  (314mg,	  0.76mmol)	  was	  dissolved	  in	  25ml	  of	  anhydrous	  tetrahydrofuran	  and	  cooled	  to	  0oC.	  
Sodium	  hydride	  (456g	  of	  a	  60%	  suspension	  in	  mineral	  oil,	  11.4mmol,	  15	  eq)	  was	  added.	  The	  suspension	  
was	  stirred	  for	  about	  2min	  and	  benzyl	  bromide	  (542ul,	  4.56mmol,	  6	  eq)	  was	  added.	  The	  reaction	  mix-­‐
ture	  was	  refluxed	  overnight	  and	  cooled	  to	  0	  oC.	  1M	  HCl	  was	  added	  dropwise	  to	  neutralize	  excessive	  so-­‐
dium	  hydride.	  The	  mixture	  was	  diluted	  with	  40ml	  of	  ethyl	  acetate.	  The	  organic	  layer	  was	  washed	  with	  
water	  (3x20ml),	  dried	  over	  Na2SO4,	  filtered	  and	  concentrated.	  The	  residue	  was	  purified	  by	  column	  
chromatography	  using	  hexane/ethyl	  acetate	  (8:1)	  as	  eluent.	  White	  solid	  25	  was	  obtained	  (420mg,	  81%).	  
1H-NMR (400 MHz; CDCl3): δ=7.34 (dt, J = 15.1, 7.6 Hz, 15H), 4.96 (dd, J = 16.6, 11.2 Hz, 2H), 
4.80 (dd, J = 11.4, 4.1 Hz, 2H), 4.69 (dd, J = 28.6, 11.8 Hz, 2H), 4.35 (d, J = 7.7 Hz, 1H), 3.98-3.92 (m, 
1H), 3.88 (d, J = 2.7 Hz, 1H), 3.83 (dd, J = 9.6, 7.8 Hz, 1H), 3.71 (dd, J = 6.5, 2.9 Hz, 2H), 3.54-3.50 (m, 
4H), 3.38 (t, J = 6.6 Hz, 1H), 1.77-1.72 (m, 2H), 1.69-1.64 (m, 2H), 1.46-1.43 (m, 4H), 0.90 (s, 9H), 0.06 
(s, 6H). 13C NMR (400 MHz; CDCl3): δ=138.9, 128.34, 128.27, 128.10, 128.02, 127.6, 104.0, 82.2, 79.7, 
75.11, 75.07, 73.7, 73.1, 69.7, 61.8, 32.5, 29.6, 26.7, 25.9, 25.5, 18.2. HRMS	  (ESI):	  m/z	  calcd	  for	  
[C39H55ClO6SiNa]+:	  705.3354.	  Found:	  705.	  705.3333.	  
6-­‐Chlorohexyl	  2,3,4-­‐O-­‐	  benzyl	  -­‐β -­‐D-­‐galactopyranoside	  (26)	  
25	  (656mg,	  0.96mmol)	  was	  dissolved	  in	  20ml	  of	  methanol	  and	  iodine	  (200mg,	  1%	  w/v)	  was	  add-­‐
ed.	  The	  reaction	  mixture	  was	  refluxed	  for	  3h	  and	  the	  iodine	  was	  neutralized	  with	  saturated	  sodium	  thio-­‐
sulfate	  solution.	  The	  mixture	  was	  diluted	  with	  20ml	  of	  ethyl	  acetate	  and	  the	  aqueous	  layer	  was	  extract-­‐
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ed	  with	  10ml	  of	  ethyl	  acetate.	  The	  organics	  were	  combined	  and	  washed	  with	  water	  (2x10ml),	  dried	  over	  
Na2SO4,	  filtered	  and	  concentrated.	  The	  residue	  was	  purified	  by	  column	  chromatography	  using	  hex-­‐
ane/ethyl	  acetate	  (2:1)	  as	  eluent.	  26	  was	  obtained	  (392mg,	  72%).	  
1H-NMR (400 MHz; CDCl3): δ=7.38-7.31 (m, 15H), 4.97 (t, J = 11.1 Hz, 2H), 4.86-4.75 (m, 3H), 
4.69 (d, J = 11.8 Hz, 1H), 4.38 (d, J = 7.8 Hz, 1H), 3.99-3.93 (m, 1H), 3.88-3.83 (m, 1H), 3.80-3.75 (m, 
2H), 3.57-3.47 (m, 5H), 3.40-3.37 (m, 1H). 13C NMR (101 MHz; CDCl3): δ 138.7, 138.43, 138.24, 128.7, 
128.46, 128.32, 128.0, 127.6, 104.1, 82.3, 79.7, 75.2, 74.5, 74.1, 73.4, 72.8, 69.9, 62.0, 45.0, 32.5, 29.6, 
26.7, 25.5. HRMS	  (ESI):	  m/z	  calcd	  for	  [C33H41ClO6Na]+:	  591.2489.	  Found:	  591.2484.	  
6-­‐Chlorohexyl	  2,3,4-­‐O-­‐benzyl-­‐6-­‐O-­‐propargyl-­‐β -­‐D-­‐galactopyranoside	  (27)	  
Compound	  26	  (381mg,	  0.67mmol)	  was	  dissolved	  in	  10ml	  of	  anhydrous	  tetrahydrofuran	  and	  
cooled	  to	  0oC.	  Sodium	  hydride	  (134mg	  of	  a	  60%	  suspension	  in	  mineral	  oil,	  3.34mmol,	  5	  eq)	  was	  added.	  
The	  suspension	  was	  stirred	  for	  about	  2min	  and	  propargyl	  bromide	  (200ul,	  1.34mmol,	  2	  eq)	  was	  added.	  
The	  reaction	  mixture	  was	  stirred	  at	  50oC	  for	  17h	  and	  cooled	  to	  0oC.	  1M	  HCl	  was	  added	  dropwise	  to	  neu-­‐
tralize	  excessive	  sodium	  hydride.	  The	  mixture	  was	  diluted	  with	  20ml	  of	  ethyl	  acetate.	  The	  organic	  layer	  
was	  washed	  with	  water	  (3x10ml),	  dried	  over	  Na2SO4,	  filtered	  and	  concentrated.	  The	  residue	  was	  purified	  
by	  column	  chromatography	  using	  hexane/ethyl	  acetate	  (3:1)	  as	  eluent.	  White	  solid	  20	  was	  obtained	  
(336mg,	  83%).	  
1H NMR (400 MHz; CDCl3): δ=7.39-7.29 (m, 15H), 4.96 (dd, J = 17.5, 11.3 Hz, 2H), 4.81-4.68 
(m, 4H), 4.37 (d, J = 7.7 Hz, 1H), 4.05 (t, J = 2.3 Hz, 2H), 3.98-3.93 (m, 1H), 3.90 (s, 1H), 3.83 (dd, J = 
9.6, 7.8 Hz, 1H), 3.66-3.58 (m, 2H), 3.53 (td, J = 8.6, 4.5 Hz, 5H). 13C NMR (400 MHz; CDCl3): δ 
138.80, 138.61, 138.51, 128.47, 128.39, 128.29, 128.19, 128.03, 127.6, 104.0, 82.1, 79.6, 75.2, 74.7, 74.5, 
73.28, 73.24, 73.08, 69.8, 68.7, 58.6, 45.1, 32.5, 29.6, 26.7, 25.5. HRMS	  (ESI):	  m/z	  calcd	  for	  
[C36H43ClO6Na]+:	  629.2646.	  Found:	  629.2629.	  
Chloro-­‐click-­‐	  (2-­‐6)	  disaccharide	  (28)	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In	  a	   flask	  containing	  27	   (97mg,	  0.19mmol)	  and	  4	   (114mg,	  0.19mmol,	  1	  eq),	  2ml	  of	  acetonitrile	  
was	   added,	   followed	   by	   addition	   of	   N,	   N-­‐diisopropylethylamine	   (62ul,	   0.38mmol,	   2eq)	   and	   copper	   (I)	  
iodine	  (54mg,	  0.28mmol,	  1.5eq).	  The	  reaction	  mixture	  was	  kept	  stirring	  overnight	  at	  60oC,	  concentrated	  
and	  loaded	  onto	  a	  silica	  column.	  Hexane/acetone	  (2:3)	  was	  used	  as	  eluent	  to	  afford	  21	  (192mg,	  91%).	  	  
1HNMR (400 MHz; CDCl3): δ=7.93 (s, 1H, triazole-H), 7.37-7.26 (m, 15H, Ar), 5.53-5.38 (m, 
4H, NH, H-7’, H-8’), 5.22-5.15 (m, 1H, H-4’), 4.94 (dd, 2H, OCH2Ph, J = 16.9, 11.3 Hz), 4.79-4.67 (m, 
4H, OCH2Ph), 4.60 (d, 1H, H-6a, J6b,6a = 12.1 Hz), 4.49 (d, 1H, H-6b, J6b,6a = 12.1 Hz), 4.37-4.32 (m, 2H, 
H-1, H-9a’), 4.23 (dd, 1H, H-9b’, J9b’,9a’ = 12.4Hz, J9b’,8’=2.3 Hz), 4.14-4.03 (m, 2H, H-5’), 3.97-3.89 (m, 
2H, H-4, OCH2), 3.84-3.79 (m, 2H, H-6’, H-2), 3.76 (s, 3H, OMe), 3.69-3.63 (m, 2H, H-5, H-3), 3.59-
3.47 (m, 6H, OCH2-Triazole, OCH2Ar, CH2Cl), 2.65 (t, 1H, H-3e’, J = 12.6 Hz), 2.17-2.13 (m, 4H, OAc, 
H-3a’), 2.10, 2.09 (s, 2x3H, OAc), 2.03 (s, 3H, OAc), 1.92 (s, 3H, OAc), 1.75-1.71 (m, 2H, linker-H), 
1.66-1.63 (m, 2H, linker-H), 1.43-1.42 (m, 4H, linker-H).	  13C NMR (400 MHz; CDCl3): δ=170.8, 170.5, 
170.32, 170.19, 170.0, 166.5, 145.2, 138.81, 138.67, 138.52, 128.47, 128.35, 128.26, 128.19, 128.01, 
127.5, 121.8, 103.9, 88.4, 82.2, 79.5, 75.1, 74.5, 73.7, 73.3, 72.9, 69.8, 69.5, 68.5, 67.9, 66.8, 64.4, 62.3, 
54.1, 49.2, 45.0, 36.2, 32.5, 29.6, 26.7, 25.5, 23.2, 21.3, 20.85, 20.75. HRMS	   (ESI):	   m/z	   calcd	   for	  
[C56H71ClN4O18Na]+:	  1145.4349.	  Found:	  1145.4371.	  
	  
Azido-­‐click-­‐	  (2-­‐6)	  disaccharide	  (29)	  
29	  was	  synthesized	  from	  28	   (182mg,	  0.16mmol)	  and	   in	  an	  analogues	  manner	  described	   in	  the	  
synthesis	  of	  23.	  Purification	  by	  Bio	  gel	  P-­‐2	  column	  followed	  by	   lyophilization	  yielded	  white	  powder	  30	  
(25mg,	   62%).	   Compound	   28	   (182mg,	   0.16mmol)	   was	   dissolved	   in	   3ml	   of	   anhydrous	   N,	   N-­‐
dimethylformamide	  and	  sodium	  azide	   (105mg,	  1.6	  mmol,	  10eq)	  was	  added.	  The	  reaction	  mixture	  was	  
stirred	  at	   55oC	  overnight,	   diluted	  with	  ethyl	   acetate	   (8ml),	  washed	  with	  water	   and	  brine.	   The	  organic	  
layer	  was	  dried	  over	  Na2SO4,	  filtered,	  concentrated,	  and	  purified	  by	  silica	  column	  using	  hexane/acetone	  
(2:3)	  as	  eluent.	  White	  solid	  29	  was	  obtained	  (91mg,	  50%).	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1H NMR (400 MHz; CDCl3): δ=7.93 (s, 1H, triazole-H), 7.35-7.28 (m, 15H, Ar), 5.57-5.35 (m, 
4H, NH, H-7’, H-8’), 5.22-5.15 (m, 1H, H-4’), 4.94 (dd, 2H, OCH2Ar, J = 16.6, 11.4 Hz), 4.80-4.67 (m, 
4H, OCH2Ph), 4.60 (d, 1H, H-6a, J6b,6a = 12.1 Hz), 4.50 (d, 1H, H-6b, J6b,6a = 12.0 Hz), 4.37-4.32 (m, 2H, 
H-1, H-9a’), 4.23 (dd, 1H, H-9b’, J9b’,9a’ = 12.3Hz, J9b’,8’=1.8), 4.13-4.04 (m, 3H, H-5’), 3.95-3.90 (m, 2H, 
H-4, OCH2), 3.84-3.73 (m, 5H, H-6’, H-2, OMe), 3.67 (t, J = 5.7 Hz, 2H), 3.59-3.46 (m, 4H), 3.22 (t, J = 
6.9 Hz, 2H), 2.65 (t, 1H, H-3e’, J = 12.6 Hz), 2.18-2.13 (m, 4H, OAc, H-3a’), 2.11, 2.09 (s, 6H, 2xOAc), 
2.04 (s, 3H, OAc), 1.92 (s, 3H, OAc), 1.65-1.54 (m, 4H, linker-H), 1.42-1.36 (m, 4H, linker-H).	  13C	  NMR	  
(400	  MHz;	  CDCl3):	  δ=170.8,	  170.55,	  170.37,	  170.21,	  170.0,	  166.4,	  145.2,	  138.84,	  138.68,	  138.53,	  128.46,	  
128.34,	  128.25,	  128.20,	  128.0,	  127.5,	  121.8,	  103.9,	  88.4,	  82.2,	  79.5,	  75.1,	  74.5,	  73.7,	  73.36,	  73.33,	  72.9,	  
69.8,	  69.4,	  68.5,	  67.9,	  66.9,	  64.4,	  62.3,	  54.0,	  51.4,	  49.2,	  29.6,	  28.8,	  26.6,	  25.8,	  23.2,	  21.3,	  20.84,	  20.77,	  
20.74.	  HRMS	  (ESI):	  m/z	  calcd	  for	  [C56H71N7O18Na]+:	  1152.4753.	  Found:	  1152.4744.	  
Amino-­‐click-­‐	  (2-­‐6)	  disaccharide	  (30)	  
30	  was	  synthesized	  from	  29	  (58mg,	  0.087mmol)	  in	  an	  analogues	  manner	  describe	  in	  the	  synthe-­‐
sis	  of	  23.	  Purification	  by	  Bio	  gel	  P-­‐2	  column	  followed	  by	  lyophilization	  yielded	  white	  powder	  30	  (25mg,	  
62%).	  HRMS	  (ESI):	  m/z	  calcd	  for	  [C26H45N5O14Na]+:	  674.2861.	  Found:	  674.3046.	  
2.3.3 Glycan	  microarray	  fabrication	  
Microarrays	  were	  printed	  using	  a	  OmniGrid	  Micro	  system.	  About	  0.6	  nl	  of	  200	  uM	  of	  amine	  con-­‐
taining	  glycans	  in	  printing	  buffer	  (300	  mM	  phosphate	  containing	  0.005%	  Tween-­‐20,	  pH	  8.5)	  was	  depos-­‐
ited	  onto	  NHS-­‐activated	  glass	  slides	  by	  robotic	  pin.	  Each	  compound	  was	  printed	  in	  a	  replicate	  of	  eight.	  
For	  the	  conjugation	  to	  be	  completed,	  the	  printed	  slides	  were	  kept	  in	  an	  atmosphere	  of	  55%	  humidity	  for	  
30	  min	  and	  dried	  in	  desiccator	  at	  least	  overnight	  before	  use.	  Next,	  the	  unreacted	  NHS	  groups	  were	  
quenched	  by	  blocking	  buffer	  (50mM	  ethylamine	  in	  50mM	  borate	  buffer,	  pH	  8.6)	  and	  the	  slides	  were	  
dried	  under	  continuous	  airflow	  before	  assays	  with	  proteins/viruses.	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2.3.4 Lectin	  and	  HA	  binding	  study	  
50µl	  of	  rhodamine	  labeled	  wheat	  germ	  agglutinin	  (WGA,	  Vector	  Laboratories)	  or	  precomplexed	  
HA	  (Protein	  Sciences,	  HA	  protein:	  primary	  antibody:	  secondary	  antibody=4:2:1,	  30	  min	  on	  ice)	  was	  ap-­‐
plied	  directly	  onto	  printed	  slide	  at	  the	  concentration	  of	  100ug/ml	  in	  PBST	  buffer	  (PBS	  containing	  0.005%	  
Tween-­‐20)	  and	  covered	  with	  a	  microscope	  slide.	  The	  printed	  slide	  was	  incubated	  at	  rt	  for	  1h.	  Unbound	  
proteins	  were	  washed	  away	  in	  the	  wash	  step,	  in	  which	  the	  printed	  slide	  was	  immersed	  into	  3	  X	  50ml	  of	  
PBST	  buffer,	  1	  X	  50ml	  of	  PBS	  buffer	  and	  4	  X	  50ml	  of	  DI	  water	  successively.	  Slides	  were	  dried	  under	  con-­‐
tinuous	  airflow	  and	  stored	  in	  a	  dark	  environment	  before	  image	  analysis.	  
2.3.5 NA	  treatment	  
Printed	  slides	  were	  incubated	  with	  either	  one	  of	  NAs:	  H1N1	  and	  H5N1	  NA	  (Sino	  Biotechnology	  
Inc.)	  at	  rt	  for	  2h	  and	  then	  washed	  with	  3X50ml	  of	  PBST	  buffer,	  1X50ml	  of	  PBS	  buffer	  and	  4X50ml	  of	  DI	  
water	  successively.	  
2.3.6 Inactivated	  influenza	  virus	  binding	  assay	  
BPL-­‐inactivated	  influenza	  virus	  A/Puerto	  Rico/8/1934	  stock	  solution	  (BEI	  Resources)	  was	  serially	  
diluted	  in	  PBST	  buffer	  to	  make	  the	  final	  concentration	  of	  3.5X104,	  3.5X103,	  3.5X102,	  respectively.	  50	  μl	  of	  
the	  diluted	  virus	  containing	  solutions	  were	  applied	  onto	  printed	  slides	  and	  covered	  with	  a	  microscope	  
slide.	  The	  slides	  were	  incubated	  at	  rt	  for	  1h,	  washed	  with	  several	  times	  with	  buffer	  and	  dried.	  50 μl	  of	  
anti	  sera	  (1:100	  dilution)	  was	  applied	  and	  incubated	  for	  1h	  followed	  by	  wash	  step.	  50 μl	  of	  secondary	  
antibody	  (1:250	  dilution)	  was	  applied	  onto	  the	  surface	  and	  incubated	  in	  dark	  for	  1h.	  The	  slides	  were	  
washed,	  dried	  and	  kept	  in	  dark	  before	  image	  analysis.	  
2.3.7 Active	  influenza	  virus	  binding	  assay	  
The	  active	  influenza	  viruses	  were	  propagated	  in	  MDCK	  cell	  in	  our	  lab.	  The	  detailed	  procedure	  
can	  be	  found	  in	  the	  experimental	  section	  of	  Chapter	  III.	  The	  titer	  of	  different	  viral	  strains	  was	  adjusted	  to	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3X104	  PFU/ml	  before	  incubation.	  	  One	  printed	  slide	  was	  divided	  into	  8	  separated	  wells	  by	  a	  plastic	  8-­‐well	  
divider.	  All	  10	  sialosides	  were	  printed	  in	  each	  well.	  200	  μl	  of	  virus	  suspension	  in	  PBST	  buffer	  was	  added	  
to	  each	  well	  and	  the	  slide	  was	  incubated	  at	  rt	  for	  1h,	  followed	  by	  several	  wash.	  200	  μl	  of	  anti	  sera	  
(1:1000	  dilution)	  was	  applied	  and	  incubated	  for	  1h	  followed	  by	  wash	  step.	  200	  μl	  of	  secondary	  antibody	  
(1:1000	  dilution)	  was	  applied	  onto	  the	  surface	  and	  incubated	  in	  dark	  for	  1h.	  The	  slides	  were	  washed,	  
dried	  and	  kept	  in	  dark	  before	  image	  analysis.	  
2.3.8 Image	  acquisition	  and	  analysis	  
Fluorescence	  intensities	  were	  detected	  by	  GenePix	  4000B	  scanner	  and	  image	  analyses	  were	  car-­‐
ried	  out	  by	  using	  Adobe	  Photoshop	  CS6.	  	  Data	  were	  plotted	  by	  using	  Microsoft	  EXCEL	  software.	  
2.4 Conclusion	  and	  future	  direction	  
To	  summarize,	  I	  have	  synthesized	  five	  S-­‐	  and	  N-­‐linked	  sialosides,	  together	  with	  the	  three	  C-­‐
linked	  sialosides	  synthesized	  by	  Dr.	  Yang	  Yang	  and	  two	  commercial	  available	  O-­‐linked	  sialosides,	  we	  
were	  able	  to	  fabricate	  a	  small	  robust	  sialoside	  microarray.	  We	  were	  able	  to	  probe	  sialic	  acid	  binding	  pro-­‐
teins	  such	  as	  lectins	  and	  viral	  HA.	  We	  also	  demonstrated	  the	  stability	  of	  these	  sialosides	  towards	  viral	  NA	  
and	  intact	  influenza	  viruses.	  In	  addition,	  we	  demonstrated	  the	  ability	  of	  these	  sialosides	  to	  capture	  viral	  
particles,	  presumably	  through	  binding	  to	  both	  HA	  and	  NA,	  at	  ambient	  temperature	  and	  without	  addition	  
of	  inhibitors.	  Previously,	  we	  have	  demonstrated	  that	  glycans	  are	  highly	  robust(12)	  and	  therefore	  these	  
could	  be	  readily	  translated	  to	  a	  field	  deployable	  device.	  We	  are	  currently	  involved	  in	  expanding	  the	  
scope	  of	  this	  work	  by	  synthesizing	  a	  larger	  library	  of	  robust	  sialosides	  and	  developing	  a	  ‘fingerprint	  pat-­‐
tern	  of	  recognition”	  for	  different	  influenza	  virus	  types.	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3 INHIBITION	  OF	  INFLUENZA	  VIRUSES	  USING	  BIVALENT	  THIOSIALOSIDES	  	  
*The	  work	  presented	  in	  this	  chapter	  has	  been	  published	  in	  Bioorganic	  &	  Medicinal	  Chemistry	  




The	  circulating	  influenza	  viruses	  have	  started	  to	  develop	  resistance	  to	  currently	  available	  antivi-­‐
ral	  drugs	  such	  as	  Oseltamivir®	  and	  Zanamivir®,	  therefore	  novel	  influenza	  inhibitors	  are	  in	  high	  demand.	  In	  
this	  chapter,	  we	  describe	  the	  design	  and	  inhibitory	  activity	  evaluation	  of	  a	  new	  class	  of	  NA	  inhibitors.	  
Combining	  the	  robustness	  of	  thiosialosides,	  increased	  intrinsic	  affinity	  by	  C-­‐4	  modification	  and	  valency,	  
these	  compounds	  show	  IC50	  values	  ranging	  from	  low	  micromolar	  to	  high	  nanomolar	  in	  enzyme	  inhibi-­‐
tion	  and	  plaque	  reduction	  assays	  with	  two	  intact	  viruses,	  Influenza	  H1N1	  (A/California/07/2009)	  and	  












NA	  inhibitors	  including	  Oseltamivir®,	  Zanamivir®,	  and	  Peramivir®	  (Figure	  3.1B-­‐D)	  are	  the	  first-­‐line	  
defense	  drugs	  used	  to	  treat	  influenza	  infection.	  (1)	  These	  FDA	  approved	  anti-­‐influenza	  drugs	  are	  sialic	  
acid	  analogs	  that	  mimic	  the	  transition	  state	  of	  sialic	  acid	  in	  the	  binding	  pocket	  of	  NA.	  Due	  to	  the	  struc-­‐
tural	  similarity,	  they	  fit	  well	  in	  the	  NA	  active	  site	  and	  can	  compete	  with	  natural	  sialylated	  receptors	  and	  
prevent	  NA	  from	  cleaving	  the	  terminal	  sialic	  acid	  (Figure	  3.1A)	  from	  cell	  surface.	  As	  a	  result,	  the	  newly	  
synthesized	  viral	  particles	  can	  not	  detach	  from	  the	  cell	  surface	  due	  to	  HA	  binding	  thus	  can	  not	  effective-­‐
ly	  infect	  other	  host	  cells.	  However,	  in	  recent	  years,	  some	  strains	  of	  influenza	  viruses	  have	  developed	  re-­‐
sistance	  to	  these	  inhibitors.	  In	  a	  2009	  surveillance	  study	  in	  northern	  Vietnam,	  all	  19	  clinical	  samples	  con-­‐
taining	  seasonal	  H1N1	  isolate	  showed	  resistance	  to	  Oseltamivir®.(2)	  Another	  study	  identified	  a	  mutated	  
pandemic	  A	  (H1N1)2009	  strain	  that	  was	  resistant	  to	  both	  Zanamivir®	  and	  Oseltamivir®.(3)	  The	  emerging	  
of	  drug	  resistant	  strain	  raises	  the	  need	  for	  development	  of	  novel	  anti-­‐influenza	  drugs.	  Recently,	  Wither	  
group	  reported	  a	  new	  class	  of	  mechanism	  based	  NA	  inhibitors,	  which	  showed	  broad	  spectrum	  activity	  
against	  influenza	  virus	  including	  oseltamivir	  resistant	  strains	  in	  vitro	  and	  in	  animal	  models.	  (4,	  5)(Figure	  
1E,	  F)	  Compared	  to	  transition	  state	  analogs,	  these	  compounds	  don’t	  possess	  double	  bond	  and	  are	  more	  
similar	  to	  natural	  substrate,	  with	  fluorine	  at	  the	  3	  position	  and	  amine	  or	  guanidine	  group	  at	  the	  4	  posi-­‐
tions.	  The	  design	  of	  almost	  all	  NA	  inhibitors	  is	  based	  on	  the	  structure	  of	  natural	  substrate,	  sialic	  acid	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Figure	  0.1	  Structures	  of	  sialic	  acid	  (A),	  analogues	  as	  NA	  inhibitors	  (B:	  Oseltamivir;	  C:Zanamivir;	  D:	  
Penamivir)	  and	  NA	  substrate	  (G:	  2-­‐O-­‐(4-­‐methylumbelliferyl)-­‐N-­‐acetylneuraminic	  acid	  substrate;	  H:	  NA 
STAR	  1,2-­‐dioxetane	  substrate).	  
	  
3.1.1 Multivalent	  NA	  inhibitor	  
Along	  with	  the	  modification	  of	  sialic	  acid	  at	  the	  3	  or	  4	  position,	  a	  different	  strategy	  that	  adopts	  
multivalency	  can	  also	  be	  used	  to	  develop	  novel	  NA	  inhibitors.	  Immunoelectron	  microscopy	  studies	  of	  
labeled	  influenza	  virus	  reveal	  that	  an	  individual	  viral	  particle	  possesses	  200-­‐300	  copies	  of	  trimeric	  HA	  
and	  50-­‐100	  copies	  of	  tetrameric	  NA.	  HAs	  distribute	  uniformly	  on	  the	  virion	  while	  NAs	  cluster	  in	  discrete	  
area.(6,	  7)	  Due	  to	  the	  oligomeric	  nature	  of	  NA	  and	  clustered	  distribution,	  polyvalent	  sialic	  acid	  may	  be	  
good	  candidate	  as	  NA	  inhibitor.	  In	  fact,	  our	  innate	  defense	  system	  has	  demonstrated	  the	  value	  of	  poly-­‐
valent	  sialic	  acid.	  For	  instance,	  respiratory	  epithelial	  cells	  can	  release	  endogenous	  sialylated	  proteins	  
called	  mucins	  to	  capture	  viral	  particles.	  Similarly,	  a	  highly	  sialylated	  salivary	  mucin	  protein	  MUC5B	  shows	  
inhibition	  to	  influenza	  viruses.	  	  (8-­‐10)	  There	  are	  several	  studies	  showing	  the	  anti-­‐viral	  activity	  of	  multiva-­‐
lent	  sialic	  acid	  bound	  to	  linear	  polymer	  backbone	  and	  dendrimers.	  Compared	  to	  the	  monomeric	  sialic	  
acid,	  these	  sialylated	  polymers	  show	  greater	  inhibitory	  effect,	  with	  IC50	  value	  in	  the	  micromo-­‐
lar/submicromolar	  range.	  (11-­‐13)	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Our	  design	  of	  novel	  NA	  inhibitors	  is	  to	  combine	  the	  C-­‐4	  modification	  of	  sialic	  acid	  and	  increased	  
valency.	  We	  introduced	  amine/guanidine	  group	  at	  the	  4	  position	  of	  sialic	  acid,	  because	  under	  physiolog-­‐
ical	  pH,	  these	  two	  groups	  are	  positively	  charged	  and	  can	  interact	  with	  the	  trio	  of	  negatively-­‐charged	  
amino	  acids	  present	  in	  the	  binding	  pocket	  of	  NA.	  (14,	  15)We	  introduced	  sulfur	  at	  the	  anomeric	  position	  
(C-­‐2),	  because	  we	  have	  demonstrated	  the	  robustness	  of	  thiosialosides	  in	  the	  microarray	  studies	  and	  
other	  groups	  have	  also	  confirmed	  that	  influenza	  virus	  does	  not	  readily	  cleave	  thiosialosides	  in	  solution.	  
(16,	  17)	  In	  addition,	  thiol	  group	  is	  good	  nucleophile,	  which	  can	  readily	  react	  with	  triflates	  and/or	  bro-­‐
mides	  present	  on	  multivalent	  scaffolds	  and	  yield	  multivalent	  molecules.	  The	  structures	  of	  our	  synthetic	  




































































Figure	  0.2	  Structures	  of	  monovalent	  and	  bivalent	  thiosialosides	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3.1.2 Method	  of	  assessing	  influenza	  virus	  susceptibility	  to	  NA	  inhibitors	  
Currently,	  cell-­‐based	  assays	  and	  functional	  NA	  inhibition	  assays	  are	  the	  two	  major	  types	  of	  
methods	  in	  assessing	  influenza	  virus	  susceptibility	  to	  NA	  inhibitors.	  The	  cell-­‐based	  assay	  was	  first	  intro-­‐
duced	  by	  Hayden	  et	  al.	  to	  determine	  50%	  inhibition	  of	  M2	  inhibitors	  amantadine	  and	  rimantadine.	  This	  
method	  utilizeds	  Madin-­‐Darby	  canine	  kidney	  cell	  monolayers	  and	  a	  plaque	  inhibition	  assay.	  Similar	  to	  
bacteria,	  virus	  can	  form	  “colony”	  on	  the	  cell	  monolayer	  when	  a	  single	  viral	  particle	  propagates	  and	  lyses	  
adjacent	  cells,	  leaving	  round	  shape	  plaque	  on	  the	  cell	  layer.	  Depending	  on	  the	  way	  of	  introducing	  the	  
virus	  inhibitors	  (premix	  with	  virus	  before	  incubation	  or	  introduce	  after	  virus	  inoculation),	  the	  number	  or	  
size	  of	  plaques	  will	  be	  reduced.	  The	  IC50	  is	  expressed	  by	  50%	  reduction	  of	  plaque	  number	  or	  sizes.	  	  	  
The	  functional	  NA	  inhibition	  assays	  rely	  on	  the	  enzymatic	  nature	  of	  viral	  NA,	  which	  can	  hydro-­‐
lyze	  terminal	  neuraminic	  acid.	  The	  substrates	  used	  in	  this	  type	  of	  assay	  are	  all	  sialic	  acid	  analogues,	  with	  
a	  small	  fluorescent	  of	  chemiluminescent	  molecule	  conjugated	  to	  the	  anomeric	  position	  of	  sialic	  acid.	  
(Figure	  3.1	  G,	  H)	  Upon	  cleavage	  by	  the	  NA	  enzyme,	  a	  luminescent	  or	  a	  fluorescent	  signal	  will	  be	  pro-­‐
duced.	  The	  fluorescent	  (FL)	  assay	  employs	  2-­‐O-­‐	  (4-­‐methylumbelliferyl)-­‐N-­‐acetylneuraminic	  acid	  sub-­‐
strate	  (MUNANA)	  and	  chemiluminescent	  (CL)	  assay	  uses	  the	  1,2-­‐dioxetane	  derivative	  of	  neuraminic	  acid	  
substrate	  in	  the	  influenza	  neuraminidase	  inhibitor	  resistance	  detection	  (NA-­‐Star)	  kit.(18)	  The	  formation	  
of	  the	  fluorescent	  or	  luminescent	  molecules	  can	  be	  detected	  in	  real	  time	  and	  the	  NA	  hydrolysis	  kinetic	  
can	  be	  determined.	  The	  NA	  activity	  is	  usually	  expressed	  as	  amount	  of	  substrate	  formation/min.	  The	  re-­‐
sults	  of	  the	  NI	  assays	  are	  expressed	  as	  the	  50%	  inhibitory	  concentration	  (IC50),	  which	  represents	  the	  NAI	  
concentration	  that	  inhibits	  50%	  of	  the	  enzyme	  activity	  of	  the	  virus	  in	  a	  way	  that	  the	  initial	  hydrolysis	  
speed	  is	  reduced	  by	  50%.	  Compared	  to	  the	  cell-­‐based	  assay,	  NA	  inhibition	  assay	  dose	  not	  involve	  the	  
HA-­‐receptor	  binding,	  thus	  reflect	  the	  actual	  sensitivity	  to	  NA	  inhibitors.	  In	  order	  to	  obtain	  thorough	  
evaluation	  of	  inhibitory	  activity	  of	  our	  synthetic	  compounds,	  we	  performed	  both	  functional	  NA	  inhibi-­‐
tion	  and	  cell-­‐based	  assay.	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3.2 Results	  and	  discussion	  
3.2.1 Inhibition	  assay	  with	  recombinant	  NA	  
We	  evaluated	  the	  inhibitory	  activity	  of	  our	  monovalent	  and	  bivalent	  thiosialosides	  using	  com-­‐
mercially	  available	  fluorescent	  substrate	  2'-­‐(4-­‐Methylumbelliferyl)-­‐α-­‐D-­‐N-­‐acetylneuraminic	  acid	  (MU-­‐
NANA)	  (Figure	  1G).	  We	  first	  tested	  two	  recombinant	  soluble	  viral	  NAs	  (N1	  and	  N2)	  as	  the	  enzyme.	  We	  
premixed	  the	  compounds	  with	  NA	  before	  adding	  to	  the	  substrate	  solution	  to	  allow	  adequate binding. 
The hydrolysis of substrate was monitored during a time course of 2h to ensure maximum cleavage and 
the fluorescent signal was measured and recorded every one minute to obtain kinetic curve, which can be 
used to calculate the velocity of the enzymatic reaction. We defined the IC50 as the concentration of 
compounds required to decrease the initial hydrolysis velocity (V0) by 50%. At lower concentration of 
inhibitors, although the initial velocity decreases, the substrate can still be fully hydrolyzed. In this case, 
we observe the kinetic curve reach a plateau at certain time point. Therefore, we used only the linear	  
slope	  between	  0-­‐35	  min	  to	  calculate	  V0	  .	  (Figure	  3.3)	  The	  IC50	  values	  were	  obtained	  from	  three	  inde-­‐
pendent	  experiments	  for	  each	  compound	  and	  are	  given	  in	  Table	  1.	  We	  included	  commercial	  drugs	  
Zanamivir®	  and	  Ostelimivir®	  with	  IC50	  at	  the	  nanomolar	  range	  as	  positive	  controls.	  Introduction	  of	  amine	  
group	  at	  the	  4	  position	  (SA)	  decreases	  the	  IC50	  to	  micromolar	  levels	  for	  both	  N1	  (127±29)	  and	  N2	  
(178±20)	  compared	  to	  unmodified	  sialic	  acid	  (Data	  not	  shown).	  Generally,	  the	  bivalent	  sialosides	  (C6-­‐SA,	  
C12-­‐SA,	  TetraEG-­‐SA,	  PentaEG-­‐SA	  and	  HexaEG-­‐SA)	  exhibit	  higher	  inhibitory	  activity	  compared	  to	  the	  
monomer,	  with	  approximately	  1.5	  to	  5	  fold	  decrease	  in	  IC50.	  The	  decrease	  is	  more	  significant	  for	  N1.	  
However,	  the	  two	  compounds	  with	  longer	  spacers	  (PentaEG-­‐SA	  and	  HexaEG-­‐SA)	  were	  less	  	  efficacious	  
compared	  to	  the	  SA	  against	  the	  N2	  enzyme.	  Introduction	  of	  the	  guanidine	  group	  increase	  inhibition	  
more	  than	  the	  amine	  group,	  with	  IC50	  values	  at	  high	  nanomolar	  to	  micromolar	  range.	  The	  monomer	  SG	  
shows higher inhibition towards H1 than H2 (0.1±0.02	  vs	  1±0.1).	  The	  IC50	  values	  for	  the	  bivalent	  com-­‐
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pounds	  (C6-­‐SG,	  C12-­‐SG,	  TetraEG-­‐SG,	  PentaEG-­‐SG	  and	  HexaEG-­‐SG),	  irrespective	  of	  the	  spacers,	  fall	  into	  
the	  submicromolar	  range,	  which	  are	  similar	  to	  SG	  for	  both	  enzymes.	  In	  summary,	  compounds	  with	  guan-­‐
idine	  group	  at	  the	  4-­‐position	  show	  better	  inhibitory	  activity	  toward	  soluble	  NAs	  than	  amino	  compounds.	  
In	  addition,	  the	  N1	  NA	  with	  the	  more	  open	  binding	  pocket	  and	  a	  flexible	  loop	  is	  more	  susceptible	  to	  our	  
synthetic	  compounds,	  compared	  to	  N2	  NA,	  which	  has	  a	  preset	  binding	  pocket,	  (20).	  	  
 
Figure	  0.3	  NA	  inhibition	  assays	  with	  H3N2	  recombinant	  NA	  for	  C6-­‐SA	  
	  
3.2.2 Inhibition	  assay	  with	  intact	  influenza	  viruses	  
Next,	  we	  performed	  the	  same	  assay	  with	  two	  strains	  of	  intact	  viruses,	  H1N1	  
(A/California/07/2009)	  and	  H3N2	  (Influenza	  A/Hongkong/8/68)	  to	  test	  the	  inhibitory	  activity	  of	  these	  
compounds	  toward	  the	  transmembrane	  NAs	  present	  on	  the	  viral	  membrane.	  We	  observe	  a	  similar	  trend	  
as	  the	  soluble	  NAs.	  The	  monomeric	  amino	  compound	  SA	  exhibits	  an	  IC50	  value	  of	  60	  μM	  for	  both	  
strains	  while	  the	  bivalent	  molecules	  exhibit	  decreased	  IC50	  values	  up	  to	  5	  fold.	  Similar	  to	  the	  inhibition	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of	  soluble	  NAs,	  the	  amino	  compounds	  with	  longer	  spacers	  (PentaEG-­‐SA	  and	  HexaEG-­‐SA)	  show	  lower	  
inhibition	  to	  both	  strains	  of	  viruses,	  presumably	  because	  the	  spacer	  is	  too	  long	  and	  floppy	  to	  exhibit	  a	  
bidentate	  effect.	  The	  guanidine	  monomer	  SG	  has	  an	  IC50	  value	  of	  about	  1	  μM	  for	  both	  strains,	  which	  is	  
50-­‐fold	  lower	  than	  SA.	  The	  bivalent	  compounds	  (C6-­‐SG,	  C12-­‐SG,	  TetraEG-­‐SG,	  PentaEG-­‐SG	  and	  HexaEG-­‐
SG)	  show	  lower	  IC50	  compared	  to	  the	  monomer,	  ranging	  from	  250	  nm	  to	  2.4	  μM	  for	  both	  viruses.	  
Among	  these	  bivalent	  compounds,	  C6-­‐SG	  with	  the	  shortest	  carbon	  linker	  shows	  the	  best	  inhibitory	  activ-­‐
ity.	  With	  these	  results,	  we	  confirm	  our	  hypothesis	  that	  using	  the	  combination	  of	  4-­‐position	  modification	  
and	  increased	  valency	  can	  significantly	  decreases	  the	  IC50	  values	  from	  the	  millimolar	  range	  (unmodified	  
monomeric	  sialic	  acid)	  to	  the	  nanomolar	  range.	  	  
A	  cross	  comparison	  of	  the	  inhibitory	  towards	  soluble	  NAs	  and	  intact	  influenza	  viruses	  by	  the	  
same	  compound	  reveals	  that	  most	  compounds	  show	  lower	  IC50	  (higher	  inhibition)	  toward	  intact	  influ-­‐
enza	  viruses	  compared	  to	  soluble	  NA	  of	  the	  same	  type.	  (e.g.	  C12-­‐SA	  IC50	  H3N2	  virus:	  15±9;	  soluble	  NA	  
from	  H3N2	  virus:	  40±1)	  This	  result	  indicates	  that	  multivalent	  effect	  plays	  an	  important	  role	  in	  the	  inhibi-­‐
tion	  activity	  of	  our	  bivalent	  compounds.	  The	  NAs	  present	  on	  the	  membrane	  of	  intact	  influenza	  viruses	  
are	  homotetramers	  with	  four	  sialic	  acid	  binding	  sites	  on	  each	  copy	  of	  NA,	  while	  the	  soluble	  NAs	  are	  pre-­‐
sent	  as	  a	  mixture	  of	  monomers,	  dimers,	  trimers	  and	  some	  tetramers.	  The	  bivalent	  compounds	  can	  pos-­‐
sibly	  bind	  to	  two	  binding	  sites	  of	  the	  same	  viral	  NA	  with	  less	  entropy	  cost(21)	  therefore	  the	  binding	  is	  








Name	   Virus	   NA	  from	  Virus	  
	  
H3N2(µM)	   H1N1(µM)	   H5N1(µM)	   H3N2(µM)	  
SA	   64±14	   56±6	   127±29	   178±20	  
C6-­‐SA	   11.6±3.5	   9.9±1.8	   20±5	   32±5	  
C12-­‐SA	   15±9	   11±1	   31±7	   40±1	  
TetraEG-­‐SA	   11±5	   9.8±2.4	   28±3	   39±14	  
PentaEG-­‐SA	   21±3	   36±4	   64±14	   178±20	  
HexaEG-­‐SA	   33±15	   45±1	   85±12	   216±56	  
SG	   0.55±0.02	   0.8±0.1	   0.1±0.02	   1±0.1	  
C6-­‐SG	   0.25±0.05	   0.26±0.03	   0.2±0.02	   4.2±1.2	  
C12-­‐SG	   0.5±0.3	   0.8±0.06	   0.73±0.03	   12±2	  
TetraEG-­‐SG	   1.78±1.3	   2.4±0.4	   2.5±0.1	   10±1	  
PentaEG-­‐SA	   1±0.6	   1.2±0.2	   1.1±0.1	   10±2	  
HexaEG-­‐SA	   0.5±0.2	   0.9±0.1	   0.57±0.06	   11±2	  
Zanamivir®	   ~0.001	   ~0.01	   ~0.04	   ~0.04	  
Oseltamivir	  ®	   ~0.008	   ~0.01	   ~0.05	   ~0.05	  
	  
Table	  0.1	  IC50	  values	  for	  the	  inhibition	  of	  soluble	  NAs	  and	  intact	  virus	  by	  the	  gemini	  sialoside	  
analogs.	  The	  influenza	  strains	  used	  in	  these	  studies	  were	  Influenza	  H1N1	  (A/California/07/2009)	  and	  
H3N2	  (A/Hongkong/8/68)	  
	  
3.2.3 Plaque	  size	  reduction	  assay	  
We	  also	  tested	  the	  efficacy	  of	  these	  compounds	  to	  inhibit	  the	  virus	  in	  cell-­‐based	  systems.	  We	  
performed	  a	  plaque	  size	  reduction	  assay	  for	  all	  compounds.	  Briefly,	  we	  inoculate	  the	  cell	  monolayer	  
with	  viruses	  for	  30	  minutes	  and	  removed	  the	  viral	  suspension.	  The	  compounds	  were	  introduced	  along	  
with	  agarose	  plug,	  which	  was	  used	  to	  cover	  the	  cell,	  and	  arrest	  the	  spread	  of	  the	  viruses.	  	  The	  images	  of	  
plaque	  size	  reduction	  assays	  using	  two	  different	  strains	  of	  influenza	  viruses	  (H1N1	  and	  H3N2)	  are	  shown	  
in	  Figure	  3.4	  and	  Figure	  3.5.	  The	  IC50	  values	  based	  on	  50%	  decrease	  in	  plaque	  size	  are	  summarized	  in	  
Table	  2.	  We	  observe	  a	  similar	  trend	  of	  inhibition	  for	  all	  compounds	  as	  was	  seen	  with	  the	  cell	  free	  sys-­‐
tem.	  The	  bivalent	  amino	  compounds	  show	  a	  1o-­‐fold	  lower	  IC50	  compared	  to	  the	  monomer	  SA	  for	  both	  
H1N1	  and	  H3N2	  strains.	  The	  guanidine	  monomer	  SG	  has	  similar	  IC50	  to	  amino	  dimers..	  The	  bivalent	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guanidine	  derivatives	  (C6-­‐SG,	  C12-­‐SG,	  TetraEG-­‐SG,	  PentaEG-­‐SG	  and	  HexaEG-­‐SG)	  further	  lower	  the	  IC50	  
value	  to	  10-­‐1000	  nM	  range.	  	  
The	  two	  strains	  of	  influenza	  viruses	  exhibit	  different	  susceptibilities	  to	  zanamivir	  as	  well	  as	  the	  
bivalent	  thiosialosides	  on	  the	  cell-­‐based	  assay.	  The	  plaque	  size	  reduction	  assay	  shows	  that	  the	  H3N2	  
strain	  is	  more	  susceptible	  than	  H1N1	  strain,	  with	  a	  10-­‐fold	  lower	  of	  IC50	  of	  all	  the	  compounds.	  However,	  
the	  trend	  is	  not	  observed	  on	  the	  NA	  inhibition	  assay.	  One	  possible	  reason	  is	  that	  the	  pandemic	  H1N1	  
strain	  has	  much	  lower	  NA	  activity	  as	  well	  as	  HA	  avidity	  to	  the	  sialylated	  receptors	  compared	  the	  H3N2	  
strain.(22)	  As	  previously	  mentioned,	  nascent	  viruses	  remain	  attached	  to	  the	  cell	  surface	  via	  HA	  binding	  
during	  budding	  until	  NA	  removes	  sialic	  acids	  to	  release	  the	  progeny.	  A	  balanced	  HA/NA	  activity	  is	  im-­‐
portant	  for	  efficient	  transmission	  of	  influenza	  viruses.	  In	  the	  case	  of	  the	  pandemic	  H1N1	  strain,	  the	  low	  
NA	  activity	  is	  compensate	  with	  low	  HA	  avidity,	  therefore,	  even	  though	  NA	  is	  inhibited	  and	  less	  efficient	  
in	  cleaving	  terminal	  sialic	  acid,	  the	  progeny	  viral	  particle	  can	  still	  move	  to	  seek	  other	  uninfected	  host	  
cells.	  (23)In	  the	  NA	  inhibition	  assay,	  since	  HA	  binding	  is	  not	  involved,	  the	  result	  only	  reflects	  the	  actual	  





Figure	  0.4	  Images	  of	  the	  plaque	  size	  reduction	  assay	  by	  the	  sialosides	  synthesized	  





Figure	  0.5	  Images	  of	  the	  plaque	  size	  reduction	  assay	  by	  the	  sialosides	  synthesized	  














Name	   Virus	  
	  
H3N2	  (µM)	   H1N1	  (µM)	  
SA	   10-­‐100	  	   >100	  
C6-­‐SA	   10-­‐100	   100	  
C12-­‐SA	   10-­‐100	   100	  
TetraEG-­‐SA	   10-­‐100	   100	  
PentaEG-­‐SA	   10-­‐100	   100	  
HexaEG-­‐SA	   10-­‐100	   100	  
SG	   10-­‐100	   10	  
C6-­‐SG	   0.01-­‐0.1	   1	  
C12-­‐SG	   0.1	   1	  
TetraEG-­‐SG	   0.1	   1	  
PentaEG-­‐SG	   .01-­‐0.1	   1	  
HexaEG-­‐SG	   0.1-­‐1.0	   1	  
Zanamivir®	   0.001	   0.01	  
Oseltamivir	  ®	   0.001-­‐0.01	   0.001-­‐0.01	  
 
	  
Table	  0.2	  IC50	  values	  of	  influenza	  strains	  by	  the	  gemini	  sialosides	  based	  on	  50%	  decrease	  in	  
plaque	  size.	  The	  strains	  used	  in	  these	  studies	  were	  Influenza	  H1N1	  (A/California/07/2009)	  and	  H3N2	  
(A/Hongkong/8/68)	  
	  
3.3 Experimental	  section	  
3.3.1 Synthesis	  of	  bivalent	  thiosialosides	  
*	  The	  synthesis	  was	  performed	  by	  Dr.	  Yang	  Yang,	  a	  postdoctoral	  fellow	  in	  our	  laboratories.	  The	  
detailed	  procesures	  and	  characterization	  are	  not	  shown	  in	  this	  dissertation.	  
3.3.2 	  Cell	  and	  viruses	  
MDCK	  (NBL2)	  (ATCC®	  CCL34™)	  cells	  were	  cultured	  in	  DMEM	  medium	  (Life	  Technologies,	  USA)	  
with	  10%	  fetal	  bovine	  serum	  and	  1%	  antibiotic-­‐antimycotic.	  The	  viruses	  were	  obtained	  through	  the	  NIH	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  Influenza	  A	  Virus,	  
A/Hong	  Kong/8/1968	  (H3N2)	  egg	  isolate	  (produced	  in	  eggs),	  NR-­‐346	  and	  Influenza	  A/California/07/2009	  
(H1N1)	  egg	  isolate	  (produced	  in	  eggs),	  NR-­‐13663.	  	  
3.3.3 Virus	  propagation	  
The	  viruses	  used	  in	  the	  plaque	  reduction	  assay	  and	  the	  MUNANA	  based	  enzyme	  inhibition	  assay	  
were	  propagated	  from	  the	  initial	  virus	  stocks.	  MDCK	  cells	  were	  grown	  to	  100%	  confluent	  and	  then	  in-­‐
fected	  with	  a	  1:10,000	  dilution	  of	  the	  initial	  stock	  of	  virus	  isolates.	  The	  cells	  were	  subsequently	  grown	  in	  
DMEM	  with	  0.3%	  BSA	  and	  1%	  antibiotic-­‐antimycotic	  for	  three	  days.	  Supernatants	  of	  the	  cultures	  were	  
collected	  and	  followed	  by	  ultracentrifugation	  at	  70,000g	  for	  3	  hours	  to	  purify	  and	  concentrate	  the	  virus-­‐
es.	  Viruses	  had	  their	  plaque	  forming	  units	  (pfu)	  determined	  by	  plaque	  assay	  in	  MDCK	  cells	  as	  previously	  
described	  (19)	  and	  were	  stored	  in	  Phosphate	  Buffered	  Saline	  (PBS)	  at	  -­‐80	  degrees	  until	  using.	  	  
3.3.4 NA	  inhibition	  assay	  
*	  The	  inhibition	  assay	  was	  performed	  by	  Dr.	  Yang	  Yang,	  a	  postdoctoral	  fellow	  in	  our	  laborato-­‐
ries.	  	  	  
	  	  	  	  	  	  	  Assays	  were	  conducted	  in	  0.1	  M	  sodium	  acetate	  buffer	  pH	  5.5	  containing	  10	  mM	  CaCl2.	  
MUNANA	  (Sigma)	  was	  used	  as	  the	  fluorescent	  substrate.	  Serial	  dilutions	  of	  inhibitors	  were	  premixed	  
with	  the	  protein	  or	  virus	  for	  30	  min.	  The	  fluorescence	  was	  monitored	  at	  3	  min	  intervals	  for	  2	  h	  after	  ad-­‐
dition	  of	  the	  substrate.	  The	  IC50	  was	  calculated	  as	  the	  concentration	  of	  the	  inhibitor	  resulting	  in	  a	  50%	  
decrease	  of	  the	  rate	  compared	  to	  the	  control.     
3.3.5 Plaque	  size	  reduction	  assay	  
Plaque	  reduction	  assays	  (PRA)	  in	  MDCK	  cells	  were	  performed	  by	  the	  addition	  of	  serial	  ten-­‐fold	  
dilutions	  of	  inhibitors	  in	  the	  overlay	  of	  serum-­‐free	  DMEM	  with	  0.6%	  molecular	  biology	  grade	  agarose	  
(Fisher,	  USA)	  containing	  1	  µg/mL	  of	  L-­‐1-­‐tosylamido-­‐2-­‐phenylethyl	  chloromethyl	  ketone	  (‘TPCK’)-­‐treated	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trypsin	  (Sigma,	  USA).	  The	  agarose	  overlays	  were	  removed	  after	  5	  days;	  cells	  were	  fixed	  with	  70%	  ethanol	  
and	  then	  stained	  with	  0.2%	  crystal	  violet.	  The	  IC50	  is	  the	  concentration	  of	  inhibitor	  causing	  a	  50%	  de-­‐
crease	  in	  plaque	  sizes.	  A	  range	  was	  used	  when	  the	  50%	  reduction	  in	  plaque	  size	  fell	  between	  two	  inhibi-­‐
tor	  concentrations.	  
3.4 Conclusion	  and	  future	  direction	  
In	  summary,	  we	  have	  designed	  and	  synthesized	  a	  panel	  of	  bivalent	  thiosialosides	  with	  C-­‐4	  modi-­‐
fications.	  By	  incorporating	  the	  robustness	  of	  S-­‐sialosides,	  increased	  intrinsic	  affinity	  of	  a	  single	  unit	  and	  
bivalency,	  we	  were	  able	  to	  demonstrate	  the	  inhibitory	  activity	  toward	  two	  different	  strains	  of	  influenza	  
virus	  using	  these	  compounds.	  The	  IC50	  values	  range	  from	  the	  low	  micromolar	  to	  a	  high	  nanomolar	  
ranges.	  In	  addition,	  we	  have	  identified	  the	  appropriate	  spacer	  resulted	  in	  higher	  inhibitory	  effect,	  which	  
is	  the	  carbon	  linker	  C6G	  and	  C12G.	  Finally,	  we	  note	  that	  these	  compounds	  are	  not	  as	  efficacious	  as	  
Zanamivir®	  or	  Oseltamivir®.	  	  As	  part	  of	  the	  future	  work,	  the	  Iyer	  group	  is	  currently	  making	  structural	  
modifications	  base	  on	  sialic	  acid,	  e.g.	  introducing	  a	  fluorine	  at	  the	  3	  position	  and	  tethering	  the	  molecules	  
polymeric/dendrimeric	  scaffold	  to	  develop	  second	  generation	  inhibitors.	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4 ELECTROCHEMICAL	  BIOSENSOR	  FOR	  DETECTION	  OF	  INFLUENZA	  VIRUSES	  
ABSTRACT	  
In	  this	  chapter,	  we	  report	  a	  novel	  electrochemical	  biosensor	  for	  the	  detection	  of	  influenza	  virus-­‐
es.	  Neuraminidase	  (NA)	  is	  one	  of	  the	  two	  abundant	  glycoproteins	  on	  the	  surface	  of	  influenza	  viruses.	  NA	  
functions	  an	  enzyme	  that	  hydrolyzes	  terminal	  sialic	  acid	  from	  glycans,	  glycoproteins	  or	  glycolipids.	  We	  
exploited	  the	  enzymatic	  property	  of	  NA	  to	  develop	  the	  biosensor.	  Specifically,	  we	  	  synthesized	  α-­‐2,	  6-­‐
sialylglucose,	  a	  substrate	  that	  can	  be	  recognized	  and	  hydrolyzed	  by	  viral	  NA.	  The	  hydrolysis	  product	  D-­‐
glucose	  can	  be	  detected	  electrochemically.	  	  
ABBREVIATION	  
Glassy	  carbon	  electrode,	  GCE;	  Cyclic	  voltammetry,	  CV;	  Deionized	  water,	  DI	  H2O;	  Nitric	  acid,	  
HNO3;	  Hydrochloric	  acid,	  HCl;	  Prussian	  blue,	  PB;	  Potassium	  ferricyanide,	  K3Fe(CN)6	  ;	  Potassium	  chloride,	  
KCl;	  Glucose	  oxidase,	  GOD;	  Chitosan,	  CS;	  Bismuth	  selenide,	  	  Bi2Se3;	  Bismuth	  nitrate,	  Bi(NO)3;	  Selenium	  







A	  summary	  of	  existing	  techniques	  for	  detection	  of	  influenza	  viruses	  was	  mentioned	  in	  chapter	  I.	  
One	  very	  well-­‐established	  technique	  that	  measures	  neuraminidase	  (NA)	  activity,	  thereby	  quantifying	  
influenza	  viruses	  is	  a	  fluorometric	  enzyme	  assay.(1)	  This	  assay	  utilizes	  a	  fluorogenic	  reagent	  2’-­‐(4-­‐
methylumberlliferyl)-­‐α-­‐D-­‐N-­‐acetylneuraminic	  acid	  (4-­‐MUNANA)	  as	  a	  NA	  substrate.	  The	  enzyme	  cleaves	  
the	  sialic	  acid	  from	  this	  substrate	  and	  releases	  the	  enzymatic	  hydrolysis	  product	  4-­‐
methylumberlliferone,	  which	  can	  be	  readily	  measured	  using	  by	  measuring	  the	  fluorescence	  intensity	  as	  
a	  function	  of	  time	  and	  concentration.The	  excitation	  and	  emission	  of	  4-­‐methylumberlliferone	  are	  365nm	  
and	  450nm	  respectively,	  which	  are	  significantly	  different	  compared	  to	  the	  excitation	  and	  emission	  of	  
MUNANA,	  which	  is	  	  315nm	  and	  374nm,	  respectively.	  Therefore,	  the	  fluorescent	  interference	  of	  MU-­‐
NANA	  can	  be	  ignored	  and	  the	  fluorescent	  intensity	  at	  450nm	  can	  be	  used	  to	  determine	  the	  concentra-­‐






















Figure	  4.1	  Cleavage	  of	  4-­‐MUNANA	  by	  neuraminidase	  
	  
While	  fluorescence	  can	  readily	  be	  measured	  in	  a	  laboratory	  setting,	  it	  is	  very	  difficult,	  if	  not	  im-­‐
possible,	  to	  use	  this	  compound	  in	  a	  primary	  care	  setting,	  where	  access	  to	  a	  flourometer	  	  might	  not	  be	  
feasible.	  Furthermore,	  optical	  detection	  can	  be	  subject	  to	  misinterpretation	  if	  not	  performed	  by	  trained	  
personnel	  and	  appropriate	  laboratory	  skills	  using	  instruments.	  Therefore,	  we	  decided	  to	  develop	  a	  novel	  
non-­‐optical	  method	  that	  could	  potentially	  be	  used	  to	  detect	  influenza	  viruses	  using	  the	  unique	  proper-­‐
ties	  of	  the	  hydrolase.	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We	  developed	  molecules,	  which	  could	  lead	  to	  a	  measurable	  electrical	  signal	  upon	  exposure	  to	  
influenza	  virus.	  The	  principle	  is	  that	  NA	  will	  cleave	  sialic	  acid	  from	  a	  “masked”	  sialic	  acid	  containing	  elec-­‐
trochemicallly	  inactive	  compound,	  releasing	  a	  molecule	  that	  can	  generate	  an	  electrochemical	  signal	  that	  
can	  easily	  be	  measured.	  	  Since	  we	  intend	  to	  use	  electrochemical	  detection	  as	  our	  technique	  of	  choice,	  a	  
brief	  primer	  of	  electrochemical	  biosensors	  is	  described	  in	  the	  following	  sections.	  	  
4.1.1 Electrochemical	  biosensor	  
Electrochemical	  biosensors	  offer	  several	  advantages,	  which	  make	  them	  attractive	  candidates	  for	  
real	  world	  applications,	  especially	  in	  low	  resource	  settings.	  Its	  a	  label	  free	  system,	  which	  greatly	  simpli-­‐
fies	  assay	  development,	  avoids	  possible	  change	  in	  target	  binding	  profile	  caused	  by	  labeling	  and	  elimi-­‐
nates	  variations	  in	  labeling	  efficiency.	  	  Sensitivity	  can	  be	  very	  high	  with	  small	  amount	  of	  analytes	  (2)	  
Electrochemical	  settings	  are	  easy	  to	  miniaturize	  and	  can	  be	  engineered	  into	  a	  portable	  device,	  .	  Unlike	  
fluorescent	  settings,	  turbid	  media	  can	  be	  used,	  thus	  eliminate	  the	  sample	  preparation	  step	  and	  there-­‐
fore,	  clinical	  samples	  including	  urine,	  saliva	  and	  blood	  can	  be	  tested	  directly.(3-­‐5)Integration	  of	  enzymes	  
to	  react	  with	  the	  released	  compound	  can	  greatly	  increase	  selectivity	  ,	  especially	  when	  the	  sample	  is	  very	  
complex	  and	  has	  multiple	  analytes.	  The	  response	  time	  of	  electrochemical	  biosensor	  is	  usually	  very	  short.	  
For	  example,	  seconds	  of	  wait	  time	  is	  sufficient	  using	  commercial	  glucose	  monitors.	  	  Low	  cost	  and	  long-­‐
term	  stability	  also	  make	  electrochemical	  biosensor	  are	  further	  advantages	  of	  an	  electrochemical	  biosen-­‐
sor.	  
The	  basic	  principle	  of	  electrochemical	  biosensor	  is	  utilizing	  chemical	  reaction	  between	  immobi-­‐
lized	  biomolecules,	  usually	  enzymes,	  or	  consumption	  of	  electrons	  to	  produce	  measurable	  electrical	  
property	  change,	  such	  as	  current,	  conductance,	  potential	  and	  ionic	  strength.	  A	  basic	  electrochemical	  
setting	  consists	  of	  three	  electrodes:	  working	  electrode,	  reference	  electrode	  and	  counter	  electrode	  (Fig-­‐
ure	  4.2).	  Typicalelectrodes	  are	  platinum,	  gold	  and	  carbon,	  since	  they	  are	  inert,	  biocompatible,	  highly	  
conductive	  and	  readily	  modified.	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Figure	  4.2	  Schematic	  of	  a	  three-­‐electrode	  system.	  The	  working	  electrode	  measures	  current	  
change	  produced	  by	  the	  interaction	  of	  immobilized	  enzymes	  and	  analytes.	  
	  
Electrochemical	  biosensors	  have	  broad	  applications	  in	  clinical	  diagnosis,	  covering	  a	  variety	  of	  
metabolites	  such	  as	  glucose,	  lactate,	  cholesterol	  and	  urea,	  etc.(4,	  6-­‐8)	  Other	  targets	  include	  antigens,	  
antibodies	  and	  cancer	  markers.(9-­‐11)In	  recent	  years,	  electrochemical	  sensing	  has	  been	  extended	  to	  
more	  complex	  targets:	  pathogens,	  e.g.,	  E.	  coli	  and	  HIV	  virus,	  by	  targeting	  at	  DNA	  or	  RNA.(12,	  13)	  Among	  
these	  applications,	  electrochemical	  sensing	  of	  glucose	  biosensor	  is	  the	  most	  successful	  example	  as	  it	  is	  
currently	  being	  used	  by	  pre-­‐diabetic	  and	  diabetic	  patients	  to	  monitor	  blood	  glucose	  concentration.	  In	  
the	  following	  sections,	  we	  describe	  the	  principles,	  methods	  and	  applications	  of	  electrochemical	  sensing	  
of	  glucose	  as	  our	  detection	  system	  as	  our	  novel	  assay	  is	  directly	  related	  to	  glucose	  sensing.	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4.1.2 Electrochemical	  sensing	  of	  glucose	  in	  diabetic	  patients.	  Principles,	  methods	  and	  applications	  	  
Diabetes	  is	  one	  of	  the	  most	  common	  threats	  of	  human	  health.	  	  According	  to	  American	  Diabetes	  
Association,	  there’re	  25.8	  million	  people	  who	  have	  diabetes	  in	  the	  United	  States,	  along	  with	  79	  million	  
people	  with	  pre-­‐diabetes.	  Blood	  glucose	  level	  is	  the	  indicator	  of	  diabetes	  and	  needs	  to	  be	  monitored	  
closely.	  If	  blood	  glucose	  is	  between	  70	  -­‐120	  mg/dl,	  patients	  are	  not	  diabetic.	  If	  the	  glucose	  level	  is	  above	  
126mg/dl	  from	  the	  fasting	  plasma	  glucose	  test,	  or	  200mg/dl	  from	  the	  oral	  glucose	  tolerance	  test,	  pa-­‐
tients	  are	  considered	  diabetic.(14) Therefore	  a	  lot	  of	  progress	  has	  been	  made	  towards	  the	  development	  
of	  a	  user	  friendly,	  portable	  glucose	  biosensor	  and	  these	  sensors	  are	  commercially	  available.	  The	  princi-­‐
ple	  of	  most	  glucose	  biosensors	  is	  that	  glucose	  oxidase	  (GOD)	  converts	  D-­‐glucose	  into	  D-­‐gluconic	  acid	  
with	  the	  presence	  of	  oxygen	  and	  also	  produces	  hydrogen	  peroxide,(15)	  as	  shown	  in	  the	  following	  reac-­‐
tion:	  




The	  enzyme	  provides	  the	  specificity	  needed	  for	  eliminating	  false	  positives	  or	  negatives.	  	  
While	  hydrogen	  peroxide	  can	  be	  readily	  detected	  using	  an	  electrochemical	  setup	  illustrated	  in	  
Figure	  4.2,	  the	  oxidation	  of	  hydrogen	  peroxide	  is	  usually	  over	  +600mV	  with	  standard	  electrodes,	  which	  is	  
high	  enough	  to	  oxidize	  many	  other	  electroactive	  compounds	  present	  in	  biological	  samples.	  Moreover,	  
the	  response	  of	  the	  biosensor	  is	  highly	  susceptible	  to	  oxygen	  concentration	  in	  the	  media	  thus	  affect	  the	  
reproducibility	  of	  the	  assays	  a	  great	  deal.(16)	  Therefore,	  redox	  mediators	  such	  as	  ferrocene,	  Prussian	  
blue	  (PB),	  potassium	  hexacyanoferrate	  are	  widely	  used	  due	  to	  the	  ability	  of	  significantly	  decreasing	  the	  
large	  overvoltage	  required	  for	  the	  oxidation	  or	  reduction	  of	  hydrogen	  peroxide.	  An	  alternative	  reaction	  







Where	  [Med]	  represents	  a	  mediator.	  Among	  several	  available	  mediators,	  ferrocene	  and	  its	  de-­‐
rivatives	  are	  the	  most	  widely	  used	  class	  of	  mediators	  in	  the	  development	  of	  chemically	  modified	  elec-­‐
trodes	  due	  to	  the	  following	  features:	  relatively	  low	  molecular	  mass,	  rapid	  responses	  to	  many	  electroac-­‐
tive	  substances,	  being	  pH-­‐independent,	  stability	  in	  both	  oxidized	  and	  reduced	  forms	  at	  low	  potential	  
and	  having	  fast	  electron	  transfer.(17)	  However,	  ferrocene	  usually	  has	  to	  be	  covalently	  linked	  to	  chitosan	  
in	  order	  to	  prevent	  leakage,	  a	  common	  problem	  seen	  in	  low	  molecular	  weight	  materials.	  
Ferrocene	  functions	  as	  artificial	  electron	  acceptor/donor	  or	  mediator	  by	  taking	  place	  of	  oxygen	  
in	  the	  enzymatic	  reaction.	  In	  the	  case	  of	  glucose	  oxidase,	  two	  electrons	  are	  first	  transferred	  from	  glu-­‐
cose	  to	  FAD	  to	  form	  FADH2,	  and	  then	  to	  ferrocene	  and	  convert	  it	  to	  the	  reduced	  form,	  which	  can	  be	  oxi-­‐
dized	  at	  the	  electrode	  surface	  and	  produce	  a	  current.	  The	  current	  is	  directly	  proportional	  to	  the	  glucose	  






GOD:	  Glucose	  oxidase;	  FAD:	  Flavin	  adenine	  dinucleotide;	  FADH2:	  reduced	  form	  of	  FAD;	  	  Fc:	  Fer-­‐
rocene.	  Fc+:	  oxidized	  form	  of	  ferrocene.	  
Prussian	  blue	  is	  also	  called	  “artificial	  peroxidase”,	  which	  can	  catalyze	  hydrogen	  peroxide	  electro-­‐
chemical	  reaction	  at	  lower	  potential,	  thus	  chosen	  as	  another	  candidate	  of	  mediators.	  The	  catalytic	  






-----Prussian-white-----------------------------------------Prussian-blue (2) 	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4.1.3 GOD	  immobilization	  
Since	  the	  first	  enzyme-­‐based	  commercial	  glucose	  biosensor	  came	  to	  the	  market	  (use	  reference	  
numbers),	  enormous	  effort	  has	  been	  devoted	  to	  develop	  enzyme	  immobilization	  technique.	  	  There’re	  
three	  major	  techniques	  including	  adsorption,	  covalently	  cross-­‐linking	  and	  entrapment.(20)	  Adsorption	  is	  
the	  simplest	  method	  but	  least	  stable	  due	  to	  the	  fast	  desorption	  of	  the	  enzyme.	  Cross-­‐linking	  enzyme	  to	  
a	  membrane	  or	  coating	  layer	  greatly	  increases	  stability	  but	  on	  the	  cost	  of	  possible	  enzymatic	  activity	  loss	  
due	  to	  the	  change	  of	  enzyme	  conformation.	  Moreover,	  when	  utilizing	  Shiff’s	  base	  formation,	  leaching	  of	  
enzyme	  can	  still	  occur	  due	  to	  reversibility	  of	  the	  reaction.(21)	  Entrapment	  using	  carbon	  paste	  or	  poly-­‐
mers	  increases	  the	  lifetime	  of	  enzyme-­‐modified	  electrode,	  however,	  utilization	  of	  the	  entrapped	  en-­‐
zyme	  is	  very	  limited.	  
We	  look	  for	  optimal	  enzyme	  immobilization	  method,	  which	  can	  be	  easily	  handled	  and	  also	  help	  
maintain	  enzyme	  activity	  in	  long	  term.	  Trough	  extensive	  literature	  survey	  and	  preliminary	  experiments	  
conducted	  in	  our	  laboratories,	  we	  found	  that	  sol-­‐gel	  coating	  technique	  is	  the	  best	  technique	  that	  can	  
readily	  produce	  the	  desired	  immobilization	  and	  coating	  of	  the	  electrodes..	  This	  coating	  technique	  utilizes	  
sol-­‐gel-­‐derived	  materials	  to	  embed	  enzyme	  onto	  electrodes,	  which	  possesses	  the	  following	  features:	  	  
physically	  rigid,	  chemically	  inert	  and	  thermally	  stable	  in	  both	  aqueous	  and	  organic	  solution.	  	  
For	  the	  polymer,	  we	  choose	  a	  complex	  polysaccharide,	  chitosan,	  comprising	  of	  repeating	  units	  
of	  	  	  randomly	  distributed	  β-­‐	  (1,4)-­‐linked	  D-­‐glucoseamine	  and	  N-­‐acetyl-­‐D-­‐glucoseamine.	  Chitosan	  is	  a	  
widely	  used	  material	  in	  enzyme	  immobilization	  due	  to	  its	  excellent	  film-­‐forming	  ability,	  biocompatibility,	  
well	  mechanical	  strength,	  cheapness	  and	  susceptibility	  to	  chemical	  modification.(22)	  Chitosan	  becomes	  
insoluble	  when	  the	  pH	  is	  above	  6.3,	  which	  greatly	  increases	  the	  stability	  of	  immobilized	  enzyme	  layer,	  
thus	  the	  assay	  for	  detecting	  glucose	  should	  be	  done	  under	  neutral	  or	  weak	  basic	  condition.	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4.1.4 Principle	  of	  detection	  of	  influenza	  virus	  by	  measuring	  glucose	  released	  by	  cleavage	  of	  sialic	  
acid-­‐glucose	  conjugates	  
The	  design	  of	  our	  probe	  for	  detecting	  influenza	  viruses	  shares	  similarity	  to	  the	  4-­‐MUNANA.	  The	  
a-­‐2,	  6-­‐sialylglucose	  contains	  terminal	  sialic	  acid,	  which	  can	  be	  recognized	  and	  hydrolyzed	  by	  neuramini-­‐
dase	  or	  intact	  influenza	  viruses.	  The	  intact	  probe	  itself	  will	  not	  result	  in	  electrochemical	  signal,	  however,	  
the	  hydrolysis	  product	  β-­‐D-­‐glucose	  can	  be	  detected	  electrochemically.	  The	  presence	  of	  absence	  of	  elec-­‐
trochemical	  signal	  indicates	  whether	  or	  not	  a	  unknown	  sample	  contains	  influenza	  viruses.	  Moreover,	  
when	  the	  glucose	  concentration	  in	  the	  hydrolysis	  sample	  falls	  in	  the	  linear	  range	  of	  detection,	  the	  
amount	  of	  glucose	  can	  be	  quantified.	  Thus,	  the	  NA	  unit,	  defined	  as	  the	  ability	  of	  hydrolyzing	  α-­‐2,	  6-­‐
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Figure	  4.3	  Cleavage	  of	  α-­‐2,	  6-­‐sialylglucose	  by	  neuraminidase	  or	  influenza	  viruses.	  
	  
4.1.5 Differences	  between	  commercial	  glucose	  biosensors	  and	  our	  assay	  
All	  commercial	  glucose	  sensors	  are	  designed	  to	  monitor	  human	  blood	  sugar	  range,	  which	  lies	  	  
between	  70-­‐180mg/dL	  or	  3.9-­‐10mM	  (non-­‐diabetics:	  70-­‐130mg/dL;	  diabetics:	  less	  than	  180mg/dL),	  Also,	  
glucose	  is	  already	  present	  in	  the	  blood	  for	  detection.	  In	  our	  system,	  we	  are	  interested	  in	  detecting	  influ-­‐
enza	  virus	  from	  nasal/throat	  swabs,	  which	  doesn’t	  has	  any	  glucose.	  Introduction	  of	  the	  substrate	  to	  a	  
sample	  containing	  the	  virus	  is	  expected	  to	  lead	  to	  the	  production	  of	  glucose;	  however,	  the	  concentra-­‐
tion	  of	  the	  glucose	  will	  be	  dependent	  on	  the	  amount	  of	  substrate,	  the	  concentration	  of	  the	  virus,	  the	  
nature	  and	  activity/catalytic	  turnover	  of	  the	  NA	  (	  eg.	  N1	  vs	  N2	  vs	  N7)	  present	  on	  the	  viral	  surface,	  etc.	  
Therefore,	  we	  need	  to	  develop	  glucose	  biosensors	  that	  have	  a	  wider	  range	  and	  potentially	  lower	  limit	  of	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detection	  than	  commercial	  systems.	  As	  a	  starting	  point,	  the	  conventional	  fluorescence	  based	  assay	  uti-­‐
lizing	  fluorogenic	  reagent	  2’-­‐(4-­‐methyllumbelliferyl)-­‐a-­‐D-­‐N-­‐acetylneuraminic	  acid	  (MUNANA)	  can	  detect	  
hydrolyzed	  substrate	  in	  the	  range	  of	  30-­‐1,000	  uM.	  Most	  clinical	  isolates	  that	  demonstrate	  normal	  to	  
high	  NA	  activity	  can	  be	  detected	  using	  this	  method.12	  Thus,	  we	  are	  seeking	  glucose-­‐sensing	  techniques	  
with	  the	  detection	  limit	  of	  micromolar	  level	  or	  lower.	  After	  an	  extensive	  literature	  survey,	  we	  decided	  to	  
follow	  a	  procedure	  that	  coelectrodeposits	  a	  PB/Bi2Se3	  hybrid	  film	  onto	  electrode	  surface	  and	  corporates	  
GOD	  by	  CS	  immobilization.	  The	  reported	  detection	  limit	  of	  glucose	  using	  this	  method	  was	  3.8	  μM.	  (	  ref-­‐
erence)	  Also,	  the	  modified	  surface	  was	  stable	  at	  mild	  acidic	  condition,	  which	  was	  required	  for	  maximum	  
activity	  of	  viral	  NA.	   
4.2 Experimental	  section	  
4.2.1 Synthesis	  of	  “masked”	  electrochemical	  substrates	  	  The	  synthesis	  was	  performed	  by	  Dr.	  
Abasaheb	  Dhawane,	  a	  postdoctoral	  fellow	  in	  our	  laboratories.	  
4.2.2 Fabrication	  of	  PB/Bi2Se3	  mediat	  ed	  glucose	  biosensor (22)	  
Glassy	  carbon	  electrode	  (GCE)	  was	  polished	  and	  cleaned	  thoroughly	  prior	  to	  the	  modification	  
following	  standard	  procedures.	  Briefly,	  GCE	  was	  polished	  on	  a	  nylon-­‐polishing	  pad	  using	  alumina	  mi-­‐
cropolish	  powder	  of	  different	  particle	  size,	  following	  the	  sequence	  of	  1.0	  μm,	  0.3	  μm	  and	  0.05	  μm	  with	  
rinses	  in	  between.	  The	  polished	  GCE	  then	  was	  washed	  ultrasonically	  in	  HNO3	  (50%	  in	  H2O),	  ethanol	  (50%	  
in	  H2O)	  and	  DI	  H2O.	  The	  clean	  surface	  of	  GCE	  was	  dried	  under	  continuous	  airflow.	  
PB	  solution	  was	  prepared	  by	  dissolving	  K3Fe(CN)6	  	  and	  FeCl3	  in	  10mM	  HCl	  containing	  0.1M	  KCl,	  
reaching	  a	  final	  concentration	  of	  2mM.	  Electrodepositing	  Bi2Se3	  solution	  was	  a	  mixture	  of	  2mM	  Bi(NO)3	  
and	  3mM	  SeO2	  in	  diluted	  nitric	  acid	  (14%	  in	  H2O).	  Co-­‐electrodepositing	  solution	  was	  obtained	  by	  mixing	  
PB	  solution	  and	  Bi2Se3	  solution	  in	  the	  ratio	  of	  2:1.	  Activation	  solution	  was	  0.1M	  KCl	  in	  10mM	  HCl.	  0.5%	  
CS	  solution	  was	  prepared	  by	  dissolving	  50mg	  CS	  in	  10ml	  of	  2%	  acetic	  acid	  with	  sonication.	  2mg	  of	  Glu-­‐
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cose	  oxidase	  was	  mixed	  with	  50ul	  of	  CS	  solution	  and	  pipetted	  gently	  to	  obtain	  a	  homogenous	  mixture.	  
All	  solutions	  were	  prepared	  fresh	  daily.	  	  
The	  hybrid	  film	  of	  PB/Bi2Se3	  was	  electrodeposited	  on	  the	  GCE	  surface	  by	  cyclic	  voltammetry	  (CV)	  
with	  a	  scan	  range	  of	  -­‐0.2V	  to	  +0.6V	  and	  scan	  rate	  of	  20mV/s	  for	  30	  cycles.	  The	  modified	  electrode	  was	  
rinsed	  with	  DI	  H2O	  and	  activated	  in	  activation	  solution	  by	  CV	  with	  a	  scan	  range	  of	  	  -­‐0.05V	  to	  +0.35V	  and	  
scan	  rate	  of	  50mV/s	  for	  30	  cycles,	  followed	  by	  rinse	  and	  air-­‐dry	  procedure.	  The	  electrode	  was	  further	  
modified	  with	  glucose	  oxidase	  by	  dropping	  10μl	  of	  GOD-­‐CS	  mixture	  onto	  the	  electrode	  surface	  and	  then	  
dried	  with	  airflow.	  Modified	  electrode	  was	  soaked	  in	  PBS	  buffer	  (pH=6.86)	  and	  stored	  at	  4oC	  when	  not	  in	  
use.	  
4.2.3 Amperometric	  measurement	  of	  glucose	  standard	  solution	  
A	  serial	  2-­‐fold	  dilution	  of	  D-­‐(+)-­‐glucose	  solution	  in	  25mM	  PBS	  containing	  0.1M	  KCl	  (pH=6.8),	  
from	  800	  μM	  to	  6.25	  μM,	  was	  prepared	  to	  determine	  the	  linear	  measurement	  range	  of	  GOD	  modified	  
PB/Bi2Se3/GCE.	  Current	  was	  measured	  continuously	  in	  200	  seconds	  with	  applied	  potential	  of	  0.0V.	  The	  
end	  point	  current	  was	  recorded	  to	  establish	  the	  standard	  curve.	  	  
4.2.4 Hydrolysis	  of	  sialylglucose	  by	  recombinant	  NA	  or	  intact	  influenza	  virus	  
A	  10mM	  sialylglucose	  stock	  solution	  was	  diluted	  in	  10mM	  of	  NH4OAc	  buffer	  (pH=5.68)	  and	  re-­‐
combinant	  NA	  or	  live	  influenza	  virus	  suspension	  was	  added.	  The	  final	  concentration	  of	  sialylglucose	  was	  
adjusted	  to	  1mM.	  The	  substrate/NA	  or	  virus	  mixture	  was	  incubated	  at	  37oC.	  NA	  or	  influenza	  virus	  was	  
removed	  by	  filtration	  using	  Amicon-­‐ultra	  centrifugal	  filter	  with	  a	  300K	  cut-­‐off	  membrane.	  The	  glucose	  
concentration	  then	  was	  measured	  amperometrically	  following	  the	  same	  procedure	  as	  the	  glucose	  
standard	  solution.	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4.3 Results	  and	  discussion	  
4.3.1 Co-­‐electrodeposition	  of	  PB/Bi2Se3	  hybrid	  film	  by	  cyclic	  voltammograms	  (CV)	  
The	  method	  of	  employing	  cyclic	  voltammograms	  to	  obtain	  stable	  PB/Bi2Se3	  hybrid	  film	  was	  re-­‐
ported	  by	  Wu	  et	  al.	  In	  comparison	  to	  pure	  PB	  film,	  the	  nanostructure	  of	  PB	  particles	  that	  are	  co-­‐
deposited	  on	  the	  electrode	  surface	  was	  more	  compact	  and	  smaller	  in	  size.	  Under	  scanning	  electron	  mi-­‐
croscope	  (SEM),	  the	  pure	  PB	  film	  showed	  serious	  aggregation,	  which	  enlarged	  the	  effective	  particle	  size	  
furthermore;	  on	  the	  contrary,	  a	  much	  smoother	  surface	  without	  obvious	  defect	  was	  observed	  when	  PB	  
was	  co-­‐electrodeposited.	  In	  addition,	  the	  alkaline-­‐resistant	  Bi2Se3	  particles	  can	  prevent	  PB	  from	  leaching	  
under	  mild	  basic	  condition,	  thus	  expand	  the	  pH	  range	  of	  running	  assays.	  The	  CV	  technique	  allows	  disso-­‐
lution	  and	  electrodeposition	  film	  occur	  alternatively	  during	  the	  oxidation	  and	  reduction	  process,	  as	  a	  
result,	  the	  deposited	  film	  is	  compact	  and	  can	  firmly	  adherent	  to	  the	  electrode	  surface.	  
The	  cyclic	  voltammograms	  of	  PB/Bi2Se3	  hybrid	  film	  co-­‐depostion	  are	  shown	  in	  figure	  4.4	  (A).	  Two	  
pairs	  of	  redox	  peaks	  and	  one	  irreversible	  peak	  are	  observed,	  in	  accordance	  with	  the	  previous	  report.	  The	  
redox	  pair	  at	  around	  +0.21V	  correspond	  to	  PB	  while	  the	  pair	  at	  0.40V	  may	  be	  attributed	  to	  nitric	  acid	  in	  
the	  coating	  solution.	  The	  peak	  at	  -­‐0.11V	  is	  attributed	  to	  the	  formation	  of	  Bi2Se3,	  resulting	  from	  reduction	  
of	  H2SeO3.	  The	  reaction	  equation	  is	  shown	  below.	  	  
3H2SeO3	  +	  2Bi3+	  +	  12H+	  +	  18e-­‐	  	  =	  Bi2Se3	  +	  9H2O	  
The	  PB	  redox	  peak	  pair	  increases	  gradually	  as	  the	  cycle	  of	  scan	  increases,	  indicating	  the	  continu-­‐
ous	  growth	  of	  PB	  layer.	  30	  cycles	  of	  scan	  has	  been	  found	  to	  be	  optimal,	  resulting	  in	  a	  PB	  layer	  with	  opti-­‐
mal	  thickness	  that	  provides	  sufficient	  stability	  as	  well	  as	  sensitivity.	  50	  cycles	  or	  more	  of	  scan	  (data	  not	  
shown)	  lead	  to	  a	  much	  thicker	  PB	  layer	  but	  greatly	  reduce	  the	  sensitivity	  in	  detecting	  hydrogen	  perox-­‐
ide.	  The	  scan	  rate	  is	  also	  a	  key	  factor	  in	  the	  co-­‐electrodeposition	  process.	  Although	  a	  higher	  scan	  rate	  
accelerates	  the	  coating	  process,	  the	  resulting	  deposited	  PB	  layer	  is	  less	  compact	  and	  unstable.	  The	  PB	  
layer	  formed	  at	  a	  scan	  rate	  of	  100mV/s	  decomposes	  with	  only	  a	  few	  assays	  in	  KCl	  solution.	  On	  the	  con-­‐
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trary,	  a	  scan	  rate	  of	  20mV/s	  results	  in	  a	  much	  more	  stable	  PB	  layer,	  which	  lasts	  for	  more	  than	  30	  assays.	  
The	  activation	  step	  helps	  stabilize	  the	  current	  in	  cyclic	  voltammotric	  run	  in	  KCl	  solution.	  The	  cyclic	  volt-­‐
ammogram	  is	  shown	  in	  figure	  4.4B.	  	  
	  
Figure	  4.4	  (A)	  Cyclic	  voltammograms	  of	  PB/Bi2Se3	  coating	  on	  GCE:	  30	  cycles	  in	  a	  range	  of	  -­‐0.2V	  to	  
+0.6V	  at	  a	  scan	  rate	  of	  20mV/s.	  (B)	  Cyclic	  voltammograms	  of	  PB/Bi2Se3	  coated	  GCE	  in	  activation	  buffer:	  
30	  cycles	  in	  a	  range	  of	  -­‐0.05V	  to	  +0.35V	  at	  a	  scan	  rate	  of	  50mV/s.	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4.3.2 Amperometric	  detection	  of	  glucose	  
GODs	  from	  different	  sources	  have	  various	  optimal	  pH	  ranges.	  Generally,	  GOD	  from	  fungi	  and	  
yeast,	  such	  as	  Aspergillus	  niger	  GOD	  which	  was	  used	  in	  fabricating	  our	  glucose	  biosensor,	  requires	  acidic	  
to	  neutral	  pH	  range.13	  On	  the	  other	  hand,	  CS	  stays	  insoluble	  when	  pH	  is	  above	  6.3,	  which	  is	  crucial	  to	  the	  
stability	  of	  the	  glucose	  biosensor.	  Considering	  both	  factors,	  a	  buffer	  with	  the	  pH	  of	  6.9	  was	  chosen.	  The	  
amperometric	  response	  of	  PB/Bi2Se3	  coated	  GCE	  at	  different	  concentration	  of	  glucose	  is	  shown	  in	  figure	  
4.5A.	  Excellent	  linear	  response	  with	  a	  correlation	  coefficient	  of	  0.998	  is	  observed	  in	  the	  range	  of	  12.5	  
μM	  to	  800	  μM.	  The	  detection	  limit	  is	  sufficient	  for	  our	  application	  of	  detecting	  glucose	  from	  influenza	  
virus	  hydrolysis	  samples.	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Figure	  4.5	  (A)	  Amperometric	  response	  of	  PB/Bi2Se3	  coated	  GCE	  at	  different	  concentration	  of	  D-­‐
(+)-­‐glucose.	  Applied	  potential:	  0.00V.	  (B)	  Standard	  curve	  generated	  by	  linear	  regression.	  The	  insert	  is	  a	  
zoomed	  region	  from	  0-­‐100uM.	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4.3.3 Hydrolysis	  of	  sialylglucose	  by	  recombinant	  NA	  or	  influenza	  viruses	  
Influenza	  neuraminidases	  are	  enzymes	  that	  can	  hydrolyze	  terminal	  sialic	  acid	  from	  glycoproteins	  
or	  glycolipids.	  In	  the	  previous	  chapter,	  we	  have	  shown	  that	  influenza	  NA	  hydrolyzes α-­‐2,3-­‐sialyllactose	  
faster	  than	  α-­‐2,6-­‐sialyllactose.	  However,	  to	  the	  best	  of	  our	  knowledge,	  no	  study	  has	  been	  done	  to	  de-­‐
termine	  the	  hydrolysis	  of	  α-­‐sialylglucose	  by	  NA.	  We	  first	  examined	  if	  our	  novel	  synthetic	  substrate	  α-­‐
2,6-­‐sialylglucose	  could	  be	  hydrolyzed	  by	  influenza	  NA	  by	  mass	  spectroscopy.	  To	  ensure	  a	  complete	  hy-­‐
drolysis,	  the	  substrate	  was	  incubated	  with	  NA	  overnight.	  At	  a	  physiological	  pH	  7.40	  and	  room	  tempera-­‐
ture	  at	  overnight	  incubation	  ,	  both	  substrate	  peak	  and	  hydrolysis	  product	  sialic	  acid	  peak	  could	  be	  seen,	  
indicating	  an	  incomplete	  hydrolysis	  (Figure	  4.6A).	  However,	  when	  the	  pH	  was	  adjusted	  to	  5.68	  and	  tem-­‐
perature	  was	  increased	  to	  37	  oC	  which	  was	  optimal	  for	  NA,	  the	  substrate	  peak	  could	  no	  longer	  be	  ob-­‐
served	  (Figure	  4.6B).	  The	  same	  condition	  was	  applied	  for	  intact	  influenza	  virus	  hydrolysis	  and	  the	  mass	  
spectrum	  showed	  complete	  hydrolysis	  for	  both	  H1N1	  and	  H3N2	  viruses	  (Figure	  4.6C	  and	  D).	  	  	  
The	  molecular	  ion	  peak	  of	  both	  α-­‐2,6-­‐sialylglucose	  and	  sialic	  acid	  could	  be	  clearly	  seen	  in	  the	  
mass	  spectrum,	  however,	  the	  glucose	  peak	  was	  hardly	  observed.	  The	  reason	  is	  that	  glucose	  lacks	  func-­‐
tional	  groups	  such	  as	  carboxyl	  group	  or	  amine	  group,	  which	  can	  be	  easily	  ionized.	  The	  mass	  spectrum	  
obtained	  from	  a	  sample	  containing	  equal	  amount	  of	  sialic	  acid	  and	  glucose	  showed	  strong	  peak	  of	  sialic	  
acid	  but	  very	  tiny	  peak	  of	  glucose	  (data	  not	  shown).	  In	  our	  study,	  we	  use	  the	  sialic	  acid	  peak	  and	  the	  dis-­‐





Figure	  4.6	  Mass	  spectrums	  of	  α-­‐2,6-­‐sialylglucose	  samples	  after	  hydrolysis	  by	  recombinant	  NA	  or	  
influenza	  viruses.	  (A)	  Hydrolysis	  of	  α-­‐2,6-­‐sialylglucose	  by	  H5N1	  NA	  at	  pH	  7.40	  and	  room	  temperature.	  (B)	  
Hydrolysis	  of	  α-­‐2,6-­‐sialylglucose	  by	  H3N2	  NA	  at	  pH	  5.68	  and	  37oC.	  (C)	  Hydrolysis	  of	  α-­‐2,6-­‐sialylglucose	  
by	  influenza	  virus	  A/Solomon	  Island/59/07	  (H1N1)	  at	  pH	  5.68	  and	  37oC.	  (D)	  Hydrolysis	  of	  α-­‐2,6-­‐
sialylglucose	  by	  influenza	  virus	  A/Honkong/8/68	  at	  pH	  5.68	  and	  37oC.	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4.3.4 Electrochemical	  sensing	  of	  glucose	  in	  NA	  or	  influenza	  virus	  hydrolysis	  samples	  
The	  concentration	  of	  glucose	  from	  the	  hydrolysis	  of	  α-­‐2,6-­‐sialylglucose	  by	  recombinant	  NA	  or	  in-­‐
tact	  influenza	  viruses	  were	  measured	  amperometrically.	  The	  hydrolysis	  reaction	  was	  carried	  out	  in	  
10mM	  NH4OAc	  buffer	  with	  a	  pH	  of	  5.68	  and	  the	  reaction	  mixture	  then	  was	  diluted	  in	  PBS	  buffer	  contain-­‐
ing	  0.1	  KCl	  as	  support	  electrolyte	  for	  electrochemical	  sensing	  using	  1	  mM	  of	  the	  substrate.	  Amperomet-­‐
ric	  responses	  of	  overnight	  hydrolysis	  samples	  by	  NA	  or	  influenza	  viruses	  are	  	  shown	  in	  figure	  4.7A..	  The	  
concentrations	  of	  glucose	  in	  these	  hydrolysis	  samples	  were	  calculated	  by	  applying	  the	  current	  value	  into	  
the	  linear	  regression	  equation	  obtained	  from	  the	  glucose	  standard	  curve..	  We	  also	  performed	  a	  time	  
course	  of	  the	  reaction.	  The	  hydrolysis	  of	  α-­‐2,6-­‐sialylglucose	  by	  H1N1	  virus	  was	  stopped	  at	  1h,	  5h	  and	  
overnight	  respectively	  and	  the	  current	  was	  recorded.	  The	  1h	  and	  5h	  samples	  showed	  currents	  compara-­‐
ble	  to	  the	  100	  μM	  glucose	  standard	  solution	  while	  the	  overnight	  sample	  showed	  significantly	  lower	  cur-­‐
rent.	  This	  result	  indicated	  that	  the	  hydrolysis	  reaction	  was	  completed	  in	  1h,	  however,	  elongation	  of	  in-­‐
cubation	  time	  decreased	  the	  glucose	  concentration,	  presumably	  because	  the	  released	  glucose	  is	  con-­‐
sumed	  by	  the	  virus	  or	  is	  degraded	  by	  an	  unknown	  mechanism	  if	  left	  overnight.	  Summary	  of	  current	  and	  
calculated	  glucose	  concentration	  in	  all	  hydrolysis	  samples	  is	  shown	  in	  table	  4.1.	  Include	  one	  more	  col-­‐
umn	  where	  the	  %	  of	  glucose	  released	  in	  given.	  Is	  it	  100%,	  or	  50%.	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Figure	  4.7	  (A)	  Amperometric	  response	  of	  overnight	  hydrolysis	  samples	  by	  NA	  or	  influenza	  virus-­‐
es.	  Applied	  potential:	  0.00V.	  (B)	  Amperometric	  response	  of	  hydrolysis	  samples	  by	  H1N1	  virus	  for	  differ-­‐




Sample	   Current(A)	   Calculated	  conc.	  of	  glucose(μM)	  
H1N1	  virus	  1h	   1.262E-­‐07	   116.2	  
H1N1	  virus	  5h	   1.366E-­‐07	   126.6	  
H1N1	  virus	  overnight	   6.066E-­‐08	   50.66	  
H3N2	  NA	  overnight	   1.123E-­‐07	   102.3	  
H5N1	  NA	  overnight	   7.647E-­‐08	   66.47	  
H3N2	  virus	  overnight	   8.609E-­‐08	   76.09	  
	  
Table	  4.1	  Summary	  of	  amperometric	  current	  and	  calculated	  concentration	  of	  glucose	  in	  sialyl-­‐
glucose	  hydrolysis	  samples	  by	  NA	  or	  influenza	  viruses.	  
	  
4.4 Conclusion	  and	  future	  direction	  
In	  this	  chapter,	  we	  established	  proof	  of	  concept	  of	  detecting	  influenza	  viruses	  using	  a	  novel	  
compound	  α-­‐2,	  6-­‐sialylglucose	  as	  substrate.	  The	  mass	  spectrums	  clearly	  showed	  that	  α-­‐2,	  6-­‐sialylglucose	  
was	  hydrolyzed	  by	  both	  recombinant	  NA	  and	  intact	  influenza	  viruses.	  The	  hydrolysis	  product	  β-­‐D-­‐
glucose	  can	  be	  detected	  quantified	  using	  electrochemical	  methods,.	  The	  next	  steps	  to	  further	  develop	  
this	  novel	  method	  to	  a	  commercial	  biosensor,	  we	  have	  to	  optimize	  conditions	  and	  test	  clinical	  samples.	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